Oncolytic viral delivery of therapeutic polypeptides

ABSTRACT

Described herein are pseudotyped oncolytic viruses comprising nucleic acids encoding an engager molecule. In some embodiments, the pseudotyped oncolytic viruses comprises nucleic acids encoding an engager molecule and one or more therapeutic molecules. Pharmaceutical compositions containing the pseudotyped oncolytic virus and methods of treating cancer using the pseudotyped oncolytic viruses are further provided herein.

REFERENCE TO RELATED APPLICATIONS

This is a continuation application of U.S. patent application Ser. No.16/170,764, filed Oct. 25, 2018, which is a continuation of U.S. patentapplication Ser. No. 15/720,696, filed Sep. 29, 2017, which is acontinuation of and claims priority under 35 U.S.C. 111(a) toInternational PCT Application No. PCT/US2017/040354, filed Jun. 30,2017, which claims priority to U.S. Provisional Application No.62/357,195, filed Jun. 30, 2016, each of which are incorporated hereinby reference in their entireties.

DESCRIPTION OF THE TEXT FILED SUBMITTED ELECTRONICALLY

The contents of the text filed submitted electronically herewith areincorporated herein by reference in their entirety: A computer readableformat copy of the Sequence Listing (file name: ONCR_004_05US_ST25.txt;date recorded: Jan. 28, 2020; file size: 193 kilobytes).

BACKGROUND OF THE INVENTION

Patients with certain hematologic and solid tumors remain in need of newtherapies. The use of bispecific antibodies to direct cytotoxic T cellsto tumor cells, and chimeric antigen receptors (CARs) to engineerantigen specificity onto an immune effector cell are being demonstratedto provide a therapeutic benefit. Also, oncolytic virus technologies areuseful additions to the current standard of care of solid tumors,expected to have a safety profile and the ability to infect, replicatein, and lyse tumor cells. However, the antitumor efficacy of thebispecific antibodies, CARs and oncolytic virus are suboptimal,demonstrating the continued need for further advances of oncology,antibodies, and oncolytic virus therapy.

SUMMARY OF THE INVENTION

In some embodiments, the present invention provides a pseudotypedoncolytic virus comprising a recombinant nucleic acid comprising (i) afirst nucleic acid sequence encoding an engager polypeptide, wherein theengager polypeptide comprises an activation domain specific for anantigen expressed on an effector cell and an antigen recognition domainspecific for a cell-surface antigen expressed on a target cell. In someembodiments, the antigen recognition domain specifically binds to atumor antigen. In some embodiments, tumor antigen is selected from Table2.

In some embodiments, the present invention provides a pseudotypedoncolytic virus comprising a recombinant nucleic acid comprising (i) afirst nucleic acid sequence encoding an engager polypeptide, wherein theengager polypeptide comprises an activation domain specific for anantigen expressed on an effector cell and a therapeutic molecule domainthat binds to an inhibitory antigen expressed on a cell surface. In someembodiments, the therapeutic molecule domain specifically binds to PD1,PDL1, or CD47. In some embodiments, the recombinant nucleic acid furthercomprises a second nucleic acid sequence encoding a therapeuticpolypeptide. In some embodiments, the therapeutic polypeptide is animmune modulator polypeptide. In some embodiments, the immune modulatorpolypeptide is selected from a cytokine, a costimulatory molecule, animmune checkpoint polypeptide, an anti-angiogenesis factor, a matrixmetalloprotease (MMP), or a nucleic acid.

In some embodiments, the immune checkpoint polypeptide comprises (i) aninhibitor of PD-1, PDL-1, CTLA-4, LAG3, TIM3, neuropilin, or CCR4; (ii)an agonist of GITR, OX-40, or CD28; or (iii) a combination of (i) and(ii). In some embodiments, the immune checkpoint polypeptide comprisesan MMP, wherein the MMP is MMP9. In some embodiments, the immunecheckpoint polypeptide comprises a cytokine, wherein the cytokine isselected from IL-15, IL-12, and CXCL10.

In some embodiments, the effector cell engaged by the engager moleculesherein is a T cell, an NKT cell, an NK cell, or a macrophage. In someembodiments, the activation domain of the effector molecule specificallybinds to CD3, CD4, CD5, CD8, CD16, CD28, CD40, CD134, CD137, or NKG2D.

In some embodiments, the recombinant nucleic acid provides herein aremulticistronic sequences. In some embodiments, the multicistronicsequence is a bicistronic sequence or a tricistronic sequence. In someembodiments, the multicistronic sequence comprises apicornavirus-2a-like sequence, and wherein the first and second nucleicacid sequences are expressed from a single promoter sequence present inthe recombinant nucleic acid.

In some embodiments, the present invention provides a pseudotypedoncolytic virus comprising a recombinant nucleic acid sequencecomprising (i) a first nucleic acid sequence encoding an engagerpolypeptide, wherein the engager polypeptide comprises an activationdomain specific for an antigen expressed on an effector cell and anantigen recognition domain specific for a tumor cell antigen expressedon a target cell, wherein the antigen expressed on the effector cell isCD3, and wherein the tumor cell antigen is CD19. In some embodiments,the recombinant nucleic acid sequence encodes a polypeptide sequencethat is at least 90% identical to SEQ ID NO: 44. In some embodiments,the recombinant nucleic acid sequence comprises SEQ ID NO: 43. In someembodiments, the recombinant nucleic acid sequence further comprises(ii) a second nucleic acid sequence encoding a therapeutic molecule,wherein the therapeutic molecule is IL-12. In such embodiments, therecombinant nucleic acid sequence encodes a polypeptide sequence that isat least 90% identical to SEQ ID NO: 54. In some embodiments, therecombinant nucleic acid sequence further comprises (ii) a secondnucleic acid sequence encoding a therapeutic molecule, wherein thetherapeutic molecule is IL-15. In such embodiments, the recombinantnucleic acid sequence encodes a polypeptide sequence that is at least90% identical to SEQ ID NO: 53. In some embodiments, the recombinantnucleic acid sequence further comprises (ii) a second nucleic acidsequence encoding a therapeutic molecule, wherein the therapeuticmolecule is CXCL10. In such embodiments, the recombinant nucleic acidsequence encodes a polypeptide sequence that is at least 90% identicalto SEQ ID NO: 55. In some embodiments, the recombinant nucleic acidsequence further comprises (ii) a second nucleic acid sequence encodinga therapeutic molecule, wherein the therapeutic molecule is MMP9.

In some embodiments, the present invention provides a pseudotypedoncolytic virus comprising a recombinant nucleic acid sequencecomprising (i) a first nucleic acid sequence encoding an engagerpolypeptide, wherein the engager polypeptide comprises an activationdomain specific for an antigen expressed on an effector cell and antherapeutic molecule domain specific for an inhibitory antigen, whereinthe antigen expressed on the effector cell is CD3, and wherein theinhibitory antigen is PDL1. In some embodiments, the recombinant nucleicacid sequence comprises a nucleic acid sequence encoding a polypeptidesequence that is at least 90% identical to SEQ ID NO: 50. In someembodiments, the recombinant nucleic acid sequence comprises SEQ ID NO:49. In some embodiments, the recombinant nucleic acid sequence furthercomprises (ii) a second nucleic acid sequence encoding a therapeuticmolecule, wherein the therapeutic molecule is IL-12. In someembodiments, the recombinant nucleic acid sequence encodes a polypeptidesequence that is at least 90% identical to SEQ ID NO: 63. In someembodiments, the recombinant nucleic acid sequence further comprises(ii) a second nucleic acid sequence encoding a therapeutic molecule,wherein the therapeutic molecule is IL-15. In some embodiments, therecombinant nucleic acid sequence encodes a polypeptide sequence that isat least 90% identical to SEQ ID NO: 62. In some embodiments, therecombinant nucleic acid sequence further comprises (ii) a secondnucleic acid sequence encoding a therapeutic molecule, wherein thetherapeutic molecule is CXCL10. In some embodiments, the recombinantnucleic acid sequence encodes a polypeptide sequence that is at least90% identical to SEQ ID NO: 64. In some embodiments, the recombinantnucleic acid sequence further comprises (ii) a second nucleic acidsequence encoding a therapeutic molecule, wherein the therapeuticmolecule is MMP9. In some embodiments, the engager molecule furthercomprises a third binding domain. In some embodiments, the third bindingdomain comprises an immunoglobulin Fc domain. In some embodiments, therecombinant nucleic acid sequence encodes a polypeptide sequence that isat least 90% identical to SEQ ID NO: 52. In some embodiments, therecombinant nucleic acid sequence comprises SEQ ID NO: 51.

In some embodiments, the present invention provides a pseudotypedoncolytic virus comprising a recombinant nucleic acid sequencecomprising (i) a first nucleic acid sequence encoding an engagerpolypeptide, wherein the engager polypeptide comprises an activationdomain specific for an antigen expressed on an effector cell and antherapeutic molecule domain specific for an inhibitory antigen, whereinthe antigen expressed on the effector cell is CD3, and wherein theinhibitory antigen is SIRP1α. In some embodiments, the recombinantnucleic acid sequence comprises a nucleic acid sequence encoding apolypeptide sequence that is at least 90% identical to SEQ ID NO: 46 or48. In some embodiments, the recombinant nucleic acid sequence comprisesSEQ ID NO: 45 or 47. In some embodiments, the recombinant nucleic acidsequence further comprises (ii) a second nucleic acid sequence encodinga therapeutic molecule, wherein the therapeutic molecule is IL-12. Insome embodiments, the recombinant nucleic acid sequence encodes apolypeptide sequence that is at least 90% identical to SEQ ID NO: 58 or59. In some embodiments, the recombinant nucleic acid sequence furthercomprises (ii) a second nucleic acid sequence encoding a therapeuticmolecule, wherein the therapeutic molecule is IL-15. In someembodiments, the recombinant nucleic acid sequence encodes a polypeptidesequence that is at least 90% identical to SEQ ID NO: 56 or 57. In someembodiments, the recombinant nucleic acid sequence further comprises(ii) a second nucleic acid sequence encoding a therapeutic molecule,wherein the therapeutic molecule is CXCL10. In some embodiments, therecombinant nucleic acid sequence encodes a polypeptide sequence that isat least 90% identical to SEQ ID NO: 60 or 61. In some embodiments, therecombinant nucleic acid sequence further comprises (ii) a secondnucleic acid sequence encoding a therapeutic molecule, wherein thetherapeutic molecule is MMP9. In some embodiments, the recombinantnucleic acid sequence encodes a polypeptide sequence that is at least90% identical to SEQ ID NO: 65 or 66. In some embodiments, therecombinant nucleic acid sequence further comprises (ii) a secondnucleic acid sequence encoding a therapeutic molecule, wherein thetherapeutic molecule is an anti-PDL1 scFv linked to an IgG1 Fc domain.In some embodiments, the recombinant nucleic acid sequence encodes apolypeptide sequence that is at least 90% identical to SEQ ID NO: 68 or70. In some embodiments, the recombinant nucleic acid sequence comprisesSEQ ID NO: 67 or 69.

In some embodiments, the pseudotyped oncolytic viruses of the presentinvention are selected from adenovirus, herpes simplex virus 1 (HSV1),myxoma virus, reovirus, poliovirus, vesicular stomatitis virus (VSV),measles virus (MV), lassa virus (LASV), or Newcastle disease virus(NDV). In some embodiments, the pseudotyped oncolytic virus comprises areduced neurotropism activity and/or neurotoxicity activity in a humansubject as compared to a reference virus. In some embodiments, thereference virus is i) a non-pseudotyped oncolytic virus, or ii) avaccinia virus. In some embodiments, the pseudotyped oncolytic virus isan attenuated oncolytic virus. In some embodiments, the virus is not avaccinia virus.

In some embodiments, the pseudotyped oncolytic viruses of the presentinvention comprise a single recombinant nucleic acid. In someembodiments, the pseudotyped oncolytic viruses comprise a plurality ofrecombinant nucleic acids. In some embodiments, the oncolytic virusselectively infects a target cell. In some embodiments, the target cellis a tumor cell and wherein the oncolytic virus is capable ofselectively replicating within the tumor cell.

In some embodiments, the engager polypeptide is a bipartite polypeptideand is comprised of an antibody, an antibody domain, a humanimmunoglobulin heavy chain variable domain, a dual-variable-domainantibody (DVD-Ig), a Tandab, a diabody, a flexibody, a dock-and-lockantibody, a Scorpion polypeptide, a single chain variable fragment(scFv), a BiTE, a DuoBody, an Fc-engineered IgG, an Fcab, a Mab2, orDART polypeptide.

In some embodiments, the present invention provides a pharmaceuticalcomposition comprising any of the pseudotyped oncolytic virusesdescribed herein. In some embodiments, the pseudotyped oncolytic virusinduces an immune response. In some embodiments, immune response isselectively cytotoxic to a target cell. In some embodiments, the targetcell is a solid tumor cell or a hematologic cancer cell. In someembodiments, the target cell expresses one or more tumor antigens. Insome embodiments, the one or more tumor antigens are selected from Table2.

In some embodiments, the present invention provides a method of treatinga cancer in a subject in need thereof, comprising administering atherapeutically effective amount of an oncolytic virus described hereinor a pharmaceutical composition described herein. In some embodiments,the method further comprises administering one or more additionaltherapies to the subject in need thereof. In some embodiments, the oneor more additional therapies comprise surgery, radiation, chemotherapy,immunotherapy, hormone therapy, or a combination thereof.

In some embodiments, the present invention provides a method of treatingone or more tumors in a subject in need thereof comprising administeringa therapeutically effective amount of an oncolytic virus describedherein or a pharmaceutical composition described herein to a patient,wherein the one or more tumors express a tumor antigen.

In some embodiments, the present invention provides a method ofselecting a patient for treatment comprising (a) determining theexpression of a tumor antigen on one or more tumor cells derived fromthe patient; and (b) administering an oncolytic virus described hereinor a pharmaceutical composition described herein if the tumor cellsobtained from the patient express the one or more tumor antigens. Insome embodiments, the one or more tumor antigens are selected from Table2. In some embodiments, the present invention provides a method ofdelivering an engager polypeptide and a therapeutic polypeptide to atumor site comprising administering to a patient in need thereof anoncolytic virus described herein or a pharmaceutical compositiondescribed herein.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 illustrates an amino acid sequence of a CD19-CD3 bipartitepolypeptide comprising a first single chain variable fragment (scFv)directed against CD19 linked to a second scFv directed against CD3.

FIG. 2 illustrates an amino acid sequence of a CD19-CD3-IL15 constructencoded by a bicistronic gene. The first gene encodes a bipartitepolypeptide comprising a first scFv directed against CD19 linked to asecond scFv directed against CD3. A second gene encoding IL-15 is linkedto the bipartite gene sequence by a T2A self-cleaving polypeptidelinker.

FIG. 3 illustrates an amino acid sequence of a CD19-CD3-IL12 constructencoded by a multicistronic gene. The first gene encodes a bipartitepolypeptide comprising a first scFv directed against CD19 linked to asecond scFv directed against CD3. A second gene encoding the p35 subunitof IL-12 is linked to the bipartite gene sequence by a T2A self-cleavingpolypeptide linker and a third gene encoding the p40 subunit of IL-12 islinked by a T2A self-cleaving polypeptide linker.

FIG. 4 illustrates an amino acid sequence of a CD19-CD3-CXCL10 constructencoded by a bicistronic gene. The first gene encodes a bipartitepolypeptide comprising a first scFv directed against CD19 linked to asecond scFv directed against CD3. A second gene encoding CXCL10 islinked to the bipartite gene sequence by a T2A self-cleaving polypeptidelinker.

FIG. 5 illustrates an amino acid sequence of a SIRP1α-CD3 bipartitepolypeptide comprising a first protein comprising the first 120 aminoacids of SIRP1α linked by a single amino acid linker to an scFv directedagainst CD3.

FIG. 6 illustrates an amino acid sequence of a SIRP1α-CD3-LL bipartitepolypeptide comprising a first protein comprising the first 120 aminoacids of SIRP1α linked by a G4S motif linker to an scFv directed againstCD3.

FIG. 7 illustrates an amino acid sequence of a SIRP1α-CD3-IL15 constructencoded by a bicistronic gene. The first gene encodes a bipartitepolypeptide comprising the first 120 amino acids of SIRP1α linked by asingle amino acid linker to an scFv directed against CD3. A second geneencoding IL-15 is linked to the bipartite gene sequence by a T2Aself-cleaving polypeptide linker.

FIG. 8 illustrates an amino acid sequence of a SIRP1α-CD3-IL15-LLconstruct encoded by a bicistronic gene. The first gene encodes abipartite polypeptide comprising the first 120 amino acids of SIRP1αlinked by a G4S motif linker to an scFv directed against CD3. A secondgene encoding IL-15 is linked to the bipartite gene sequence by a T2Aself-cleaving polypeptide linker.

FIG. 9 illustrates an amino acid sequence of a SIRP1α-CD3-IL12 constructencoded by a multicistronic gene. The first gene encodes a bipartitepolypeptide comprising the first 120 amino acids of SIRP1α linked by asingle amino acid linker to an scFv directed against CD3. A second geneencoding the p35 subunit of IL-12 is linked to the bipartite genesequence by a T2A self-cleaving polypeptide linker and a third geneencoding the p40 subunit of IL-12 is linked by a T2A self-cleavingpolypeptide linker.

FIG. 10 illustrates an amino acid sequence of a SIRP1α-CD3-IL12-LLconstruct encoded by a multicistronic gene. The first gene encodes abipartite polypeptide comprising the first 120 amino acids of SIRP1αlinked by a G4S motif linker to an scFv directed against CD3. A secondgene encoding the p35 subunit of IL-12 is linked to the bipartite genesequence by a T2A self-cleaving polypeptide linker and a third geneencoding the p40 subunit of IL-12 is linked by a T2A self-cleavingpolypeptide linker.

FIG. 11 illustrates an amino acid sequence of a SIRP1α-CD3-CXCL10construct encoded by a bicistronic gene. The first gene encodes abipartite polypeptide comprising the first 120 amino acids of SIRP1αlinked by a single amino acid linker to an scFv directed against CD3. Asecond gene encoding CXCL10 is linked to the bipartite gene sequence bya T2A self-cleaving polypeptide linker.

FIG. 12 illustrates an amino acid sequence of a SIRP1α-CD3-CXCL10-LLconstruct encoded by a bicistronic gene. The first gene encodes abipartite polypeptide comprising the first 120 amino acids of SIRP1αlinked by a G4S motif linker to an scFv directed against CD3. A secondgene encoding CXCL10 is linked to the bipartite gene sequence by a T2Aself-cleaving polypeptide linker.

FIG. 13 illustrates an amino acid sequence of a PDL1-CD3 bipartitepolypeptide comprising a first scFv directed against PDL1 linked to asecond scFv directed against CD3.

FIG. 14 illustrates an amino acid sequence of a PDL1-CD3-IL15 constructencoded by a bicistronic gene. The first gene encodes a bipartitepolypeptide comprising a first scFv directed against PDL1 linked to asecond scFv directed against CD3. A second gene encoding IL-15 is linkedto the bipartite gene sequence by a T2A self-cleaving polypeptidelinker.

FIG. 15 illustrates an amino acid sequence of a PDL1-CD3-IL12 constructencoded by a multicistronic gene. The first gene encodes a bipartitepolypeptide comprising a first scFv directed against PDL1 linked to asecond scFv directed against CD3. A second gene encoding the p35 subunitof IL-12 is linked to the bipartite gene sequence by a T2A self-cleavingpolypeptide linker and a third gene encoding the p40 subunit of IL-12 islinked by a T2A self-cleaving polypeptide linker.

FIG. 16 illustrates an amino acid sequence of a PDL1-CD3-CXCL10construct encoded by a bicistronic gene. The first gene encodes abipartite polypeptide comprising a first scFv directed against PDL1linked to a second scFv directed against CD3. A second gene encodingCXCL10 is linked to the bipartite gene sequence by a T2A self-cleavingpolypeptide linker.

FIG. 17 illustrates an amino acid sequence of a PDL1-CD3-Fc tripartitepolypeptide comprising a first scFv directed against CD3, linked by aG4S motif linker to a second scFv directed against PDL1, which is inturn linked to the CH2-CH3 domain of human IgG1 by an IgG1 hinge.

FIG. 18A-FIG. 18B illustrate an amino acid sequence of aSIRP1α-CD3-MMP9-SL construct encoded by a bicistronic gene (FIG. 18A)and an amino acid sequence of a SIRP1α-CD3-MMP9-LL construct encoded bya bicistronic gene (FIG. 18B).

FIG. 19A-19C illustrate the binding of CD19-CD3 BiTE constructs (FIG.19A), SIRP1α-CD3 BiTE constructs (FIG. 19B), and PDL1-CD3-Fc tripartiteT cell engagers (FIG. 19C) CD3⁺ T cells.

FIG. 20 illustrates the quantification of the T cell engager constructbinding shown in FIG. 19.

FIG. 21A-FIG. 21C illustrate the CD3-specific binding of CD19-CD3 BiTEconstructs (FIG. 21A), SIRP1α-CD3 BiTE constructs (FIG. 21B), andPDL1-CD3-Fc tripartite T cell engagers (FIG. 21C) through the use of ananti-CD3 antibody, OKT3.

FIG. 22 illustrates the specificity of the CD47-binding SIRP1α arm of aSIRP1α-CD3 BiTE construct.

FIG. 23A-FIG. 23B illustrate the binding of CD19-CD3 and SIRP1α-CD3 BiTEconstructs (FIG. 23A) to Raji cells (CD19⁺CD47⁺). % binding isquantified in FIG. 23B.

FIG. 24A-FIG. 24B illustrate the binding of CD19-CD3 and SIRP1α-CD3 BiTEconstructs (FIG. 24A) to U2OS cells (CD19⁻CD47⁺). % binding isquantified in FIG. 24B.

FIG. 25A-FIG. 25B illustrate the binding of CD19-CD3 and SIRP1α-CD3 BiTEconstructs (FIG. 25A) to GBM30-luc cells (CD19⁻CD47⁺). % binding isquantified in FIG. 25B.

FIG. 26A-FIG. 26B illustrate the binding of CD19-CD3 and SIRP1α-CD3 BiTEconstructs (FIG. 26A) to U251 cells (CD19⁻CD47⁺). % binding isquantified in FIG. 26B.

FIG. 27A-FIG. 27C illustrate the binding of PDL1-Fc-CD3 tripartite Tcell engagers to U251 cells. The binding of the PDL1-Fc-CD3 constructs(FIG. 27B) is compared to the binding of an anti-PDL1 antibody (FIG.27A). Binding was not mediated by FcγRs, as U251 cells do not expressFcγRI, FcγRII, or FcγRIII (FIG. 27C).

FIG. 28 illustrates CD19-CD3 BiTE, SIRP1α-CD3 BiTE, and PDL1-CD3-Fctripartite T cell engager-mediated T cell-dependent cytotoxicity (TDCC)of Raji cells.

FIG. 29 illustrates CD19-CD3 BiTE and PDL1-CD3-Fc tripartite T cellengager-mediated TDCC of THP1 cells.

FIG. 30 illustrates CD19-CD3 BiTE and PDL1-CD3-Fc tripartite T cellengager-mediated TDCC of U251 cells.

FIG. 31 illustrates SIRP1α-CD3 BiTE-mediated TDCC of 293F cells comparedto an osteopontin-fusion control construct.

FIG. 32 illustrates expression of SIRP1α-CD3 BiTE constructs fromoncolytic-HSV vectors. Expression of SIRP1α-CD3 BiTE constructs withshort linkers (Lanes 1-4 and ONCR085 in lanes 5-6, shown in FIG. 5) andSIRP1α-CD3 BiTE constructs with long linkers (ONCR087 in lanes 7-8,shown in FIG. 6) are shown.

FIG. 33 illustrates expression of PDL1-CD3-Fc BiTE constructs fromoncolytic-HSV vectors. Purified PDL1-CD3-Fc BiTE protein is shown inlanes 1-4. Concentrated viral supernatants are shown in lanes 5-6.

FIG. 34A-FIG. 34B illustrate TDCC of U251 cells by virally producedSIRP1α-CD3, SIRP1α-CD3-LL, and PDL1-CD3-Fc BiTE constructs. Photographsof U251 cell cultures after incubation with the indicated BiTEconstructs and CD8+ T cells are shown in FIG. 34A. Activity of virallyproduced BiTE constructs, measured by % of cell killing and quantifiedby flow cytometry, is shown in FIG. 34B.

FIG. 35 illustrates that Amicon ultrafiltration effectively removesvirus from samples, as determined by Western blotting with polyclonalanti-HSV antibody, and indicated that BiTE-killing is due to the BiTEand not viral infection.

FIG. 36 illustrates a cartoon representation of the production of apseudotyped oncolytic virus and a recombinant oncolytic virus andinfection of a target cell by the respective pseudotyped oncolytic virusand the recombinant oncolytic virus.

FIG. 37 illustrates an amino acid sequence of a SIRP1α-CD3-PDL1-Fc (SL)construct encoded by a bicistronic gene wherein the first gene encodesan anti-PDL1 scFv linked to an IgG1 Fc domain and the second geneencodes a bipartite polypeptide comprising the first 120 amino acids ofSIRP1α linked by a single amino acid linker to an scFv directed againstCD3.

FIG. 38 illustrates an amino acid sequence of a SIRP1α-CD3-PDL1-Fc (LL)construct encoded by a bicistronic gene wherein the first gene encodesan anti-PDL1 scFv linked to an IgG1 Fc domain and the second geneencodes a bipartite polypeptide comprising the first 120 amino acids ofSIRP1α linked by a G4S motif linker to an scFv directed against CD3.

FIG. 39 illustrates a schematic of a SIRP1α-CD3-PDL1-Fc expressionplasmid. Two plasmid constructs, one for SIRP1α-CD3-PDL1-Fc (SL) and onefor SIRP1α-CD3-PDL1-Fc (LL) were generated.

FIG. 40A-FIG. 40B illustrate purification of the SIRP1α-CD3 BiTE (SL),SIRP1α-CD3 BiTE (LL), and the anti-PDL1-Fc compounds from supernatantsof transfected 293 T cells. FIG. 40A shows purification of anti-PDL1-Fccompounds assessed by Coomassie. FIG. 40B illustrates purification ofSIRP1α-CD3 BiTE compounds as assessed by Western Blot using an anti-Hisdetection antibody.

FIG. 41A-FIG. 41C show results of a PD1/PDL1 blockade assay. A schematicof the assay is shown in FIG. 41A-FIG. 41B. The results of the PD1/PDL1blockade assay using the anti-PDL1-Fc compound produced from 293 cellstransfected are shown in FIG. 41C.

DETAILED DESCRIPTION OF THE INVENTION

The present disclosure provides novel engineered oncolytic viruses, inparticular pseudotyped oncolytic viruses that produce multipartitepolypeptides and/or other therapeutic polypeptides for the treatment ofcancer including solid tumors (e.g., advanced solid tumors) andhematologic malignancies. In some embodiments, the oncolytic virus isengineered by pseudotyping or other recombinant technology in order tomodulate the tropism of the virus to result in a viral infectionspecific for tumor cells and/or surrounding tumor stroma and/or forother beneficial purposes as provided herein. In some embodiments, themultipartite and/or therapeutic polypeptides produced by the oncolyticviruses described herein mediate or enhance the anti-tumor effects ofthe oncolytic viruses, such as by effector-cell mediated lysis of targetcells (e.g., tumor cells). The oncolytic viruses described herein mayhave multiple (e.g. dual) modes of action, including effectorcell-mediated cytolysis of target cells as a result of the expression ofmultipartite polypeptides, and viral-mediated destruction of targetcells. The present disclosure further provides therapeutic compositionscomprising the engineered oncolytic viruses and methods of use in thetreatment of solid tumors and hematologic malignancies.

Overview

In some embodiments, the present invention provides pseudotypedoncolytic viruses, compositions thereof, and methods of use for thetreatment of cancer. The pseudotyped oncolytic viruses provided hereincomprise recombinant nucleic acids that encode engager polypeptidesand/or other therapeutic molecules (e.g., therapeutic polypeptides).Typically, the engager polypeptides function as effector cell engagersand generally comprise a first domain directed against an activationmolecule expressed on an effector cell (e.g., an activation domain or anengager domain) and a second domain directed against a target cellantigen (e.g., an antigen recognition domain) or other cell-surfacemolecule (e.g., a therapeutic molecule domain). Also provided arebipartite, tripartite or multipartite polypeptides (e.g., comprising oneor multiple engager domains, one or multiple antigen recognitiondomains, or one or multiple therapeutic molecule domains, and optionallyone or multiple other functional domains).

Also provided are methods of treating cancer, comprising the step ofdelivering to human subject in need thereof a therapeutically effectiveamount of the oncolytic viruses or pharmaceutical compositions thereofprovided herein. Such methods optionally include the step of deliveringto the human subject an additional cancer therapy, such as surgery,radiation, chemotherapy, immunotherapy, hormone therapy, or acombination thereof.

Definitions

As used herein, the singular forms “a,” “an,” or “the” include pluralreferences unless the context clearly dictates otherwise.

Throughout this specification, unless the context requires otherwise,the word “comprise”, or variations such as “comprises” or “comprising”,will be understood to imply the inclusion of a stated element or integeror group of elements or integers but not the exclusion of any otherelement or integer or group of elements or integers.

As used in this application, the terms “about” and “approximately” areused as equivalents. Any numerals used in this application with orwithout about/approximately are meant to cover any normal fluctuationsappreciated by one of ordinary skill in the relevant art. In certainembodiments, the term “approximately” or “about” refers to a range ofvalues that fall within 30%, 25%, 20%, 19%, 18%, 17%, 16%, 15%, 14%,13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, or less ineither direction (greater than or less than) of the stated referencevalue unless otherwise stated or otherwise evident from the context(except where such number would exceed 100% of a possible value).

As used herein the specification, “subject” or “subjects” or“individuals” include, but are not limited to, mammals such as humans ornon-human mammals, including domesticated, agricultural or wild,animals, as well as birds, and aquatic animals. In some embodiments,subjects are livestock such as cattle, sheep, goats, cows, swine, andthe like; poultry such as chickens, ducks, geese, turkeys, and the like;and domesticated animals such as dogs and cats. In some embodiments(e.g., particularly in research contexts) subjects are rodents (e.g.,mice, rats, hamsters), rabbits, primates, or swine such as inbred pigsand the like. In particular embodiments, the subject is a human.“Patients” are subjects suffering from or at risk of developing adisease, disorder, or condition or otherwise in need of the compositionsand methods provided herein. None of the terms require or are limited tosituations characterized by the supervision (e.g. constant orintermittent) of a health care worker (e.g. a doctor, a registerednurse, a nurse practitioner, a physician's assistant, an orderly or ahospice worker).

As used herein, “treating” or “treatment” refers to any indicia ofsuccess in the treatment or amelioration of a disease or condition,particularly cancer. Treating or treatment may be performed in vitroand/or in vivo, and may comprise delivering an oncolytic virus, orcomposition thereof, described herein to a patient or subject in needthereof. In some embodiments, treating includes, for example, reducing,delaying or alleviating the severity of one or more symptoms of thedisease or condition, and/or reducing the frequency with which symptomsof a disease, defect, disorder, or adverse condition are experienced bya subject or patient. Herein, “treat or prevent” is used herein to referto a method that results in some level of treatment or amelioration ofthe disease or condition, and contemplates a range of results directedto that end, including but not restricted to prevention of the conditionentirely.

As used herein, “preventing” refers to the prevention of a disease orcondition, e.g., tumor formation, in a patient or subject and may alsobe referred to as “prophylactic treatment.” Prevention of diseasedevelopment can refer to complete prevention of the symptoms of disease,a delay in disease onset, or a lessening of the severity of the symptomsin a subsequently developed disease. As a non-limiting illustrativeexample, if an individual at risk of developing a tumor or other form ofcancer is treated with the methods of the present invention and does notlater develop the tumor or other form of cancer, then the disease hasbeen prevented, at least over a period of time, in that individual.

The terms “therapeutically effective amount” and “therapeuticallyeffective dose” are used interchangeably herein and refer to the amountof an oncolytic virus or composition thereof that is sufficient toprovide a beneficial effect or to otherwise reduce a detrimentalnon-beneficial event (e.g. an amount or dose sufficient to treat adisease). The exact amount or dose of an oncolytic virus comprisedwithin a therapeutically effective amount or therapeutically effectivedose will depend on variety of factors including: the purpose of thetreatment; the weight, sex, age, and general health of the subject orpatient; the route of administration; the timing of administrations; andthe nature of the disease to be treated. The therapeutically effectiveamount for a given subject or patient is ascertainable by one skilled inthe art using known techniques (see, e.g. Lieberman, PharmaceuticalDosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technologyof Pharmaceutical Compounding (1999); and Pickar, Dosage Calculations(1999)).

“Pseudotype” refers to a virus particle, wherein a portion of the virusparticle (e.g., the envelope or capsid) comprises heterologous proteins,such as viral proteins derived from a heterologous virus or non-viralproteins. Non-viral proteins may include antibodies and antigen-bindingfragments thereof. Preferably, a pseudotyped virus is capable of i)altered tropism relative to non-pseudotyped virus, and/or ii) reductionor elimination of a non-beneficial effect. For example, in someembodiments a pseudotyped virus demonstrates reduced toxicity or reducedinfection of non-tumor cells or non-tumor tissue as compared to anon-pseudotyped virus.

The term “targeting moiety” refers herein to a heterologous proteinlinked to a virus particle that is capable of binding to a protein onthe cell surface of a selected cell type in order to direct interactionbetween the virus particle and the selected cell type. The targetingmoiety may be covalently or non-covalently linked and is generallylinked to an envelope protein, e.g., E1, E2, or E3. Representativetargeting moieties include antibodies, antigen binding fragmentsthereof, and receptor ligands. A viral “envelope” protein, or “Env”protein, refers to any polypeptide sequence that resides on the surfacelipid bilayer of a virion and whose function is to mediate theadsorption to and the penetration of host cells susceptible toinfection.

The term “vector” is used herein to refer to a nucleic acid moleculecapable transferring or transporting another nucleic acid molecule. Thetransferred nucleic acid is generally linked to, e.g., inserted into,the vector nucleic acid molecule. A vector may include sequences thatdirect autonomous replication in a cell, or may include sequencessufficient to allow integration into host cell DNA. In some embodiments,the vector is a virus (i.e., a viral vector or oncolytic viral vector)and the transferred nucleic acid sequence is a recombinant nucleic acidsequence encoding an engager molecule and/or a therapeutic molecule. Aviral vector may sometimes be referred to as a “recombinant virus” or a“virus.” The terms “oncolytic virus” and “oncolytic vector” are usedinterchangeably herein.

“Nucleic acid genome” or “viral genome” refers to the nucleic acidcomponent of a virus particle, which encodes the genome of the virusparticle including any proteins required for replication and/orintegration of the genome. In some embodiments, a viral genome acts as aviral vector and may comprise a heterologous gene operably linked to apromoter. The promoter may be either native or heterologous to the geneand may be viral or non-viral in origin. The viral genomes describedherein may be based on any virus, may be an RNA or DNA genome, and maybe either single stranded or double stranded. Preferably, the nucleicacid genome is from the family Rhabdoviridae.

“Retroviral vectors,” as used herein, refer to viral vectors based onviruses of the Retroviridae family. In their wild-type (WT) form,retroviral vectors typically contain a nucleic acid genome. Providedherein are pseudotyped retroviral vectors that also comprise aheterologous gene, such as a recombinant nucleic acid sequence describedherein.

The term “antibody fragment or derivative thereof” includes polypeptidesequences containing at least one CDR and capable of specificallybinding to a target antigen. The term further relates to single chainantibodies, or fragments thereof, synthetic antibodies, antibodyfragments, such as a Camel Ig, Ig NAR, Fab fragments, Fab′ fragments,F(ab)′2 fragments, F(ab)′3 fragments, Fv, single chain Fv antibody(“scFv”), bis-scFv, (scFv)2, minibody, diabody, triabody, tetrabody,disulfide stabilized Fv protein (“dsFv”), and single-domain antibody(sdAb, nanobody), etc., or a chemically modified derivative of any ofthese. In some embodiments, antibodies or their correspondingimmunoglobulin chain(s) are further modified by using, for example,amino acid deletion(s), insertion(s), substitution(s), addition(s),and/or recombination(s) and/or any other modification(s) (e.g.posttranslational and chemical modifications, such as glycosylation andphosphorylation), either alone or in combination. Methods forintroducing such modifications in the DNA sequence underlying the aminoacid sequence of an immunoglobulin chain are well known to the personskilled in the art.

The term “single-chain” as used in accordance with the presentdisclosure refers to the covalent linkage of two or more polypeptidesequences, preferably in the form of a co-linear amino acid sequenceencoded by a single nucleic acid molecule.

The terms “binding to” and “interacting with” are used interchangeablyherein and refer to the interaction of at least two“antigen-interaction-sites” with each other. An“antigen-interaction-site” refers to a motif of a polypeptide (e.g., anantibody or antigen binding fragment thereof) capable of specificinteraction with an antigen or a group of antigens. Thebinding/interaction is also understood to define a “specificinteraction” or “specific binding.”

The terms “specific binding” or “specific interaction” refer to anantigen-interaction-site that is capable of specifically interactingwith and/or binding to at least two amino acids of a target molecule asdefined herein. The term relates to the ability of theantigen-interaction-site to discriminate between the specific regions(e.g. epitopes) of the target molecules defined herein such that it doesnot, or essentially does not, cross-react with polypeptides of similarstructures. In some embodiments, the epitopes are linear. In someembodiments, the epitopes are conformational epitopes, a structuralepitope, or a discontinuous epitope consisting of two regions of thehuman target molecules or parts thereof. In context of this disclosure,a conformational epitope is defined by two or more discrete amino acidsequences separated in the primary sequence which come together on thesurface of the folded protein. Specificity and/or cross-reactivity of apanel of antigen bindings construct under investigation can be tested,for example, by assessing binding of the panel of the constructs to thepolypeptide of interest as well as to a number of more or less(structurally and/or functionally) closely related polypeptides underconventional conditions (see, e.g., Harlow and Lane, Antibodies: ALaboratory Manual, Cold Spring Harbor Laboratory Press, 1988 and UsingAntibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press,1999). Only those constructs that bind to the polypeptide/protein ofinterest and do not, or essentially do not, bind to any of the otherpolypeptides are considered specific for the polypeptide/protein ofinterest. Examples of specific interactions of anantigen-interaction-site with a specific antigen include the interactionof ligands which induce a signal upon binding to its specific receptor,the specificity of a ligand for its receptor, such as cytokines thatbind to specific cytokine receptors, and the binding of an antigenbinding site of an antibody to an antigenic epitope, among others.

In some instances, the specific interaction of theantigen-interaction-site with a specific antigen results in theinitiation of a signal, e.g. due to the induction of a change of theconformation of the antigen, oligomerization of the antigen, etc. Insome embodiments, specific binding encompasses a “key-lock-principle.”Therefore in some embodiments, specific motifs in the amino acidsequence of the antigen-interaction-site interact with specific motifsin the antigen and bind to each other as a result of their primary,secondary or tertiary structure, or as the result of secondarymodifications of said structure. In some embodiments, the specificinteraction of the antigen-interaction-site with its specific antigenresults in a simple binding of the site to the antigen.

Oncolytic Viruses

Oncolytic viruses are able to infect, replicate in, and lyse tumorcells, and are further capable of spreading to other tumor cells insuccessive rounds of replication. While past oncolytic virus therapy hasshown promise in preclinical models and clinical studies, anti-tumorefficacy of these oncolytic virus, such as vaccinia, has beensuboptimal. For example, these viruses demonstrated limited viral spreadthroughout the tumor and/or limited activation of anti-tumor T cellresponses within the tumor. Therefore, the present disclosure providesan oncolytic virus that 1) facilitates tumor infiltration and activationof effector cells (e.g., T cells), and 2) effectively lyses tumor cellsthat are not infected the virus (also known as by-stander killing).

In some embodiments, provided are viral vectors which have advantagesincluding one or more of the following properties:

(a) (i) the vectors are oncolytic and have a particularly high oncolyticactivity compared to other previously described oncolytic viral vectors;

(b) (ii) the vectors replicate preferentially in tumor cells and have aparticularly high replication capability compared to other oncolyticviral vectors;

(c) (iii) the vectors infect actively dividing cells as well as restingcells;

(d) (iv) the vectors induce a strong innate, humoral, and cellularimmune response;

(e) (v) the vectors replicate purely cytoplasmatically, i.e., as RNAviruses they cannot integrate into the host cell genome or recombineinto replication-competent viruses;

(f) (vi) the vectors are easy to package; and/or

(g) (vii) the native viral glycoprotein is interchangeable with aforeign envelope protein.

Some embodiments of the invention relate to recombinant vesicularstomatitis viruses (VSV) and VSV vectors. The VSV genome includes fivegenes, l, m, n, p and g, which encode the proteins L, M, N, P and G andare essential for the reproduction of the virus. N is a nucleoproteinwhich packages the VSV genomic RNA. The VSV genome is replicated asRNA-protein complex and L and P together form a polymerase complex whichreplicates the VSV genome and transcribes the VSV mRNA. M is a matrixprotein which provides structural support between the lipid envelope andnucleocapsid and is important for particle sprouting at the cellmembrane. G is the envelope protein which is incorporated in the viralenvelope and is essential for the infectivity and tropism of the virus.

Pseudotyped Oncolytic Viruses

In some embodiments, the present invention provides oncolytic virusesthat are capable of being pseudotyped or otherwise engineered.“Pseudotyped viruses” refer to viruses in which one or more of the viralcoat proteins (e.g., envelope proteins) have been replaced or modified.In some embodiments, a pseudotyped virus is capable of infecting a cellor tissue type that the corresponding non-pseudotyped virus is notcapable of infecting. In some embodiments, a pseudotyped virus iscapable of preferentially infecting a cell or tissue type compared to anon-pseudotyped virus.

In general, viruses have natural host cell populations that they infectmost efficiently. For example, retroviruses have limited natural hostcell ranges, while adenoviruses and adeno-associated viruses are able toefficiently infect a relatively broader range of host cells, althoughsome cell types are refractory to infection by these viruses. Theproteins on the surface of a virus (e.g., envelope proteins or capsidproteins) meditate attachment to and entry into a susceptible host celland thereby determine the tropism of the virus, i.e., the ability of aparticular virus to infect a particular cell or tissue type. In someembodiments, the oncolytic viruses described herein comprise a singletypes of protein on the surface of the virus. For example, retrovirusesand adeno-associated viruses have a single protein coating theirmembrane. In some embodiments, the oncolytic viruses described hereincomprise more than one type of protein on the surface of the virus. Forexample, adenoviruses are coated with both an envelope protein andfibers that extend away from the surface of the virus.

The proteins on the surface of the virus can bind to cell-surfacemolecules such as heparin sulfate, thereby localizing the virus to thesurface of the potential host cell. The proteins on the surface of thevirus can also mediate interactions between the virus and specificprotein receptors expressed on a host cell that induce structuralchanges in the viral protein in order to mediate viral entry.Alternatively, interactions between the proteins on the surface of thevirus and cell receptors can facilitate viral internalization intoendosomes, wherein acidification of the endosomal lumen inducesrefolding of the viral coat. In either case, viral entry into potentialhost cells requires a favorable interaction between at least onemolecule on the surface of the virus and at least one molecule on thesurface of the cell.

In some embodiments, the oncolytic viruses described herein comprise aviral coat (e.g., a viral envelop or viral capsid), wherein the proteinspresent on the surface of the viral coat (e.g., viral envelop proteinsor viral capsid proteins) modulate recognition of a potential targetcell for viral entry. In some instances, this process of determining apotential target cell for entry by a virus is referred to as hosttropism. In some embodiments, the host tropism is cellular tropism,wherein viral recognition of a receptor occurs at a cellular level, ortissue tropism, wherein viral recognition of cellular receptors occursat a tissue level. In some instances, the viral coat of a virusrecognizes receptors present on a single type of cell. In otherinstances, the viral coat of a virus recognizes receptors present onmultiple cell types (e.g., 2, 3, 4, 5, 6 or more different cell types).In some instances, the viral coat of a virus recognizes cellularreceptors present on a single type of tissue. In other instances, theviral coat of a virus recognizes cellular receptors present on multipletissue types (e.g., 2, 3, 4, 5, 6 or more different tissue types).

In some embodiments, the oncolytic viruses described herein comprise aviral coat that has been modified to incorporate surface proteins from adifferent virus in order to facilitate viral entry to a particular cellor tissue type. Such oncolytic viruses are referred to herein aspseudotyped oncolytic viruses. In some embodiments, a pseudotypedoncolytic viruses comprises a viral coat wherein the viral coat of afirst virus is exchanged with a viral coat of second, wherein the viralcoat of the second virus is allows the pseudotyped oncolytic virus toinfect a particular cell or tissue type. In some embodiments, the viralcoat comprises a viral envelope. In some instances, the viral envelopecomprises a phospholipid bilayer and proteins such as proteins obtainedfrom a host membrane. In some embodiments, the viral envelope furthercomprises glycoproteins for recognition and attachment to a receptorexpressed by a host cell. In some embodiments, the viral coat comprisesa capsid. In some instances, the capsid is assembled from oligomericprotein subunits termed protomers. In some embodiments, the capsid isassembled from one type of protomer or protein, or is assembled fromtwo, three, four, or more types of protomers or proteins.

In some embodiments, it is advantageous to limit or expand the range ofcells susceptible to transduction by an oncolytic virus for the purposeof oncolytic therapy. To this end, many viruses have been developed inwhich the endogenous viral coat proteins (e.g., viral envelope or capsidproteins) proteins have been replaced by viral coat proteins from otherviruses or by chimeric proteins. In some embodiments, the chimericproteins are comprised of parts of a viral protein necessary forincorporation into the virion, as well proteins or nucleic acidsdesigned to interact with specific host cell proteins, such as atargeting moiety.

In some embodiments, the pseudotyped oncolytic viruses described hereinare pseudotyped in order to limit or control the viral tropism (i.e., toreduce the number of cell or tissue types that the pseudotyped oncolyticvirus is capable of infecting). Most strategies adopted to limit tropismhave used chimeric viral coat proteins (e.g., envelope proteins) linkedantibody fragments. These viruses show great promise for the developmentof oncolytic therapies. In some embodiments, the pseudotyped oncolyticviruses described herein are pseudotyped in order to expand the viraltropism (i.e., to increase the number of cell or tissue types that thepseudotyped oncolytic virus is capable of infecting). One mechanism forexpanding the cellular tropism of viruses (e.g., enveloped viruses) isthrough the formation of phenotypically mixed particles or pseudotypes,a process that commonly occurs during viral assembly in cells infectedwith two or more viruses. For example, human immunodeficiency virus type1 (HIV-1). HIV1 infects cells that express CCR4 with an appropriateco-receptor. However, HIV1 forms pseudotypes by the incorporation ofheterologous glycoproteins (GPs) through phenotypic mixing, such thatthe virus can infect cells that do not express the CD4 receptor and/oran appropriate co-receptor, thereby expanding the tropism of the virus.Several studies have demonstrated that wild type HIV-1 produced in cellsinfected with xenotropic murine leukemia virus (MLV), amphotropic MLV,or herpes simplex virus gives rise to phenotypically mixed virions withan expanded host range, indicating that pseudotyped virions had beenproduced. Phenotypic mixing of viral GPs has also been shown to occurbetween HIV-1 and VSV in coinfected cell cultures. These earlyobservations were key to the subsequent design of HIV-1-based lentiviralvectors bearing heterologous GPs.

There is an ever-growing list of alternative GPs for pseudotypinglentiviruses, each with specific advantages and disadvantages. Thewidespread use of VSV G-proteins (VSV-G) to pseudotype lentiviruses hasmade this GP in effect the standard against which the usefulness ofother viral GPs to form pseudotypes are compared. Additionalnon-limiting examples of lentivirus pseudotypes include pseudotypesbearing lyssavirus-derived GPs, pseudotyped lentiviruses bearinglymphocytic choriomeningitis virus GPs, lentivirus pseudotypes bearingalphavirus GPs (e.g., lentiviral vectors pseudotyped with the RRV andSFV GPs, lentiviral vectors pseudotyped with sindbis virus GPs),pseudotypes bearing filovirus GPs, and lentiviral vector pseudotypescontaining the baculovirus GP64.

In some embodiments, the engineered (e.g., pseudotyped) viruses arecapable of binding to a tumor and/or tumor cell, typically by binding toa protein, lipid, or carbohydrate expressed on a tumor cell. In suchembodiments, the engineered viruses described herein may comprise atargeting moiety that directs the virus to a particular host cell. Insome instances, any cell surface biological material known in the art oryet to be identified that is differentially expressed or otherwisepresent on a particular cell or tissue type (e.g., a tumor or tumorcell, or tumor associated stroma or stromal cell) may be used as apotential target for the oncolytic viruses the present invention. Inparticular embodiments, the cell surface material is a protein. In someembodiments, the targeting moiety binds cell surface antigens indicativeof a disease, such as a cancer (e.g., breast, lung, ovarian, prostate,colon, lymphoma, leukemia, melanoma, and others); an autoimmune disease(e.g. myasthenia gravis, multiple sclerosis, systemic lupuserythymatosis, rheumatoid arthritis, diabetes mellitus, and others); aninfectious disease, including infection by HIV, HCV, HBV, CMV, and HPV;and a genetic disease including sickle cell anemia, cystic fibrosis,Tay-Sachs, J3-thalassemia, neurofibromatosis, polycystic kidney disease,hemophilia, etc. In certain embodiments, the targeting moiety targets acell surface antigen specific to a particular cell or tissue type, e.g.,cell-surface antigens present in neural, lung, kidney, muscle, vascular,thyroid, ocular, breast, ovarian, testis, or prostate tissue.

Exemplary antigens and cell surface molecules for targeting include,e.g. P-glycoprotein, Her2/Neu, erythropoietin (EPO), epidermal growthfactor receptor (EGFR), vascular endothelial growth factor receptor(VEGF-R), cadherin, carcinoembryonic antigen (CEA), CD4. CD8, CD19.CD20, CD33, CD34, CD45, CD117 (c-kit), CD133, HLA-A. HLA-B, HLA-C,chemokine receptor 5 (CCR5), stem cell marker ABCG2 transporter, ovariancancer antigen CA125, immunoglobulins, integrins, prostate specificantigen (PSA), prostate stem cell antigen (PSCA), dendriticcell-specific intercellular adhesion molecule 3-grabbing nonintegrin(DC-SIGN), thyroglobulin, granulocyte-macrophage colony stimulatingfactor (GM-CSF), myogenic differentiation promoting factor-1 (MyoD-1),Leu-7 (CD57), LeuM-1, cell proliferation-associated human nuclearantigen defined by the monoclonal antibody Ki-67 (Ki-67), viral envelopeproteins, HIV gp120, transferrin receptor, etc. Additional antigens andcell surface molecules for targeting are shown in Table 2.

In some embodiments, the pseudotyped oncolytic viruses provided hereinare capable of selectively entering, replicating in, and/or lysing tumorcells. Such an embodiment is illustrated in FIG. 36, wherein thepseudotyped oncolytic virus gains entry to the target cell due to theincorporation of viral glycoproteins derived from a different (i.e.,heterologous) virus that allow for entry of the pseudotyped oncolyticvirus into the target cell. In contrast, the non-pseudotyped oncolyticvirus is unable to gain entry into the target cell due to thenon-permissive nature of the envelope proteins. In some instances, theability of a pseudotyped oncolytic virus to selectively enter, replicatein, and/or lyse a tumor cells is due to a reduced or otherwiseineffective cellular interferon (IFN) response. In some embodiments, thepseudotyped oncolytic viruses produce an engager molecule and/or atherapeutic molecule, such as an immune modulating polypeptide, thatinterferes or impairs the cellular IFN response, thereby enhancing thereplication of the pseudotyped or engineered virus.

The pseudotyped oncolytic viruses described herein may be derived from avariety of viruses, non-limiting examples of which include vacciniavirus, adenovirus, herpes simplex virus 1 (HSV1), myxoma virus,reovirus, poliovirus, vesicular stomatitis virus (VSV), measles virus(MV), lassa virus (LASV) and Newcastle disease virus (NDV). In someembodiments, the pseudotyped oncolytic viruses described herein caninfect substantially any cell type. An exemplary lentivirus for use inoncolytic therapy is Simian immunodeficiency virus coated with theenvelope proteins, G-protein (GP), from VSV. In some instances, thisvirus is referred to as VSV G-pseudotyped lentivirus, and is known toinfect an almost universal set of cells.

In some embodiments, the pseudotyped oncolytic viruses of the presentinvention are VSV viruses pseudotyped against healthy brain cells, i.e.,neurons and exhibit considerably reduced toxicity. Since neurotropism isa dose-limiting factor in all applications of oncolytic VSV, the use ofthe vector according to some embodiments of the present invention isthat they are used for all tumors types of solid tumors.

In some embodiments, the pseudotyped VSV vectors have one or more keyattributes including: (i) the VSV is not cell-toxic; (ii) the vectorsare concentrated by ultracentrifugation without loss of infectivity; and(iii) the vectors show a tropism for tumor cells, whereas neurons andother non-tumor cells are infected inefficiently. To increase the safetyduring the use of replicable viruses in therapeutic uses, someembodiments of the present invention provide a vector system whichensures that replication, oncolysis and the production of VSV virusestakes place only in cells which are infected by at least tworeplication-deficient, mutually complementing vectors.

In some embodiments, the genetic material (e.g., the viral coat proteinor the core genetic material) for generating a pseudotyped oncolyticvirus is obtained from a DNA virus, an RNA virus, or from both virustypes. In some embodiments, a DNA virus is a single-stranded (ss) DNAvirus, a double-stranded (ds) DNA virus, or a DNA virus that containsboth ss and ds DNA regions. In some embodiments, an RNA virus is asingle-stranded (ss) RNA virus or a double-stranded (ds) RNA virus. Insome embodiments, an ssRNA virus is further classified into apositive-sense RNA virus or a negative-sense RNA virus.

In some instances, the genetic material for generating a pseudotypedoncolytic virus is obtained from a dsDNA virus of any one of thefollowing families: Myoviridae, Podoviridae, Siphoviridae,Alloherpesviridae, Herpesviridae, Malacoherpesviridae, Lipothrixviridae,Rudiviridae, Adenoviridae, Ampullaviridae, Ascoviridae, Asfaviridae,Baculoviridae, Bicaudaviridae, Clavaviridae, Corticoviridae,Fuselloviridae, Globuloviridae, Guttaviridae, Hytrosaviridae,Iridoviridae, Marseilleviridae, Mimiviridae, Nimaviridae,Pandoraviridae, Papillomaviridae, Phycodnaviridae, Plasmaviridae,Polydnaviruses, Polyomaviridae, Poxviridae, Sphaerolipoviridae, orTectiviridae.

In some cases, the genetic material for generating a pseudotypedoncolytic virus is obtained from a ssDNA virus of any one of thefollowing families: Anelloviridae, Bacillariodnaviridae, Bidnaviridae,Circoviridae, Geminiviridae, Inoviridae, Microviridae, Nanoviridae,Parvoviridae, or Spiraviridae.

In some embodiments, the genetic material for generating a pseudotypedoncolytic virus is obtained from a DNA virus that contains both ssDNAand dsDNA regions. In some cases, the DNA virus is from the grouppleolipoviruses. In some cases, the pleolipoviruses include Haloarculahispanica pleomorphic virus 1, Halogeometricum pleomorphic virus 1,Halorubrum pleomorphic virus 1, Halorubrum pleomorphic virus 2,Halorubrum pleomorphic virus 3, or Halorubrum pleomorphic virus 6.

In some cases, the genetic material for generating a pseudotypedoncolytic virus is obtained from a dsRNA virus of any one of thefollowing families: Birnaviridae, Chrysoviridae, Cystoviridae,Endornaviridae, Hypoviridae, Megavirnaviridae, Partitiviridae,Picobirnaviridae, Reoviridae, Rotavirus or Totiviridae.

In some instances, the genetic material for generating a pseudotypedoncolytic virus is obtained from a positive-sense ssRNA virus of any oneof the following families: Alphaflexiviridae, Alphatetraviridae,Alvernaviridae, Arteriviridae, Astroviridae, Barnaviridae,Betaflexiviridae, Bromoviridae, Caliciviridae, Carmotetraviridae,Closteroviridae, Coronaviridae, Dicistroviridae, Flaviviridae,Gammaflexiviridae, Iflaviridae, Leviviridae, Luteoviridae, Marnaviridae,Mesoniviridae, Narnaviridae, Nodaviridae, Permutotetraviridae,Picornaviridae, Potyviridae, Roniviridae, Secoviridae, Togaviridae,Tombusviridae, Tymoviridae, or Virgaviridae.

In some cases, the genetic material for generating a pseudotypedoncolytic virus is obtained from a negative-sense ssRNA virus of any oneof the following families: Bornaviridae, Filoviridae, Paramyxoviridae,Rhabdoviridae, Nyamiviridae, Arenaviridae, Bunyaviridae, Ophioviridae,or Orthomyxoviridae.

In some instances, the genetic material for generating a pseudotypedoncolytic virus is obtained from oncolytic DNA viruses that comprisecapsid symmetry that is isocahedral or complex. In some cases,isosahedral oncolytic DNA viruses are naked or comprise an envelope.Exemplary families of oncolytic DNA viruses include the Adenoviridae(for example, Adenovirus, having a genome size of 36-38 kb),Herpesviridae (for example, HSV1, having a genome size of 120-200 kb),and Poxviridae (for example, Vaccinia virus and myxoma virus, having agenome size of 130-280 kb).

In some cases, the genetic material for generating a pseudotypedoncolytic virus is obtained from oncolytic RNA viruses include thosehaving icosahedral or helical capsid symmetry. In some cases,icosahedral oncolytic viruses are naked without envelope and includeReoviridae (for example, Reovirus, having a genome of 22-27 kb) andPicornaviridae (for example, Poliovirus, having a genome size of 7.2-8.4kb). In other cases, helical oncolytic RNA viruses are enveloped andinclude Rhabdoviridae (for example, VSV, having genome size of 13-16 kb)and Paramyxoviridae (for example MV and NDV, having genome sizes of16-20 kb).

In some instances, the genetic material for generating a pseudotypedoncolytic virus is obtained from a virus such as Abelson leukemia virus,Abelson murine leukemia virus, Abelson's virus, Acutelaryngotracheobronchitis virus, Adelaide River virus, Adeno associatedvirus group, Adenovirus, African horse sickness virus, African swinefever virus, AIDS virus, Aleutian mink disease parvovirus,Alpharetrovirus, Alphavirus, ALV related virus, Amapari virus,Aphthovirus, Aquareovirus, Arbovirus, Arbovirus C, arbovirus group A,arbovirus group B, Arenavirus group, Argentine hemorrhagic fever virus.Argentine hemorrhagic fever virus, Arterivirus, Astrovirus, Atelineherpesvirus group, Aujezky's disease virus, Aura virus, Ausduk diseasevirus, Australian bat lyssavirus, Aviadenovirus, avian erythroblastosisvirus, avian infectious bronchitis virus, avian leukemia virus, avianleukosis virus, avian lymphomatosis virus, avian myeloblastosis virus,avian paramyxovirus, avian pneumoencephalitis virus, avianreticuloendotheliosis virus, avian sarcoma virus, avian type Cretrovirus group, Avihepadnavirus, Avipoxvirus, B virus, B19 virus,Babanki virus, baboon herpesvirus, baculovirus, Barmah Forest virus,Bebaru virus, Berrimah virus, Betaretrovirus, Birnavirus, Bittner virus,BK virus, Black Creek Canal virus, bluetongue virus, Bolivianhemorrhagic fever virus, Boma disease virus, border disease of sheepvirus, borna virus, bovine alphaherpesvirus 1, bovine alphaherpesvirus2, bovine coronavirus, bovine ephemeral fever virus, bovineimmunodeficiency virus, bovine leukemia virus, bovine leukosis virus,bovine mammillitis virus, bovine papillomavirus, bovine papularstomatitis virus, bovine parvovirus, bovine syncytial virus, bovine typeC oncovirus, bovine viral diarrhea virus, Buggy Creek virus, bulletshaped virus group, Bunyamwera virus supergroup, Bunyavirus, Burkitt'slymphoma virus, Bwamba Fever, CA virus, Calicivirus, Californiaencephalitis virus, camelpox virus, canarypox virus, canid herpesvirus,canine coronavirus, canine distemper virus, canine herpesvirus, canineminute virus, canine parvovirus, Cano Delgadito virus, caprine arthritisvirus, caprine encephalitis virus, Caprine Herpes Virus, Capripox virus,Cardiovirus, caved herpesvirus 1, Cercopithecid herpesvirus 1,cercopithecine herpesvirus 1, Cercopithecine herpesvirus 2, Chandipuravirus, Changuinola virus, channel catfish virus, Charleville virus,chickenpox virus, Chikungunya virus, chimpanzee herpesvirus, chubreovirus, chum salmon virus, Cocal virus, Coho salmon reovirus, coitalexanthema virus, Colorado tick fever virus, Coltivirus, Columbia. SKvirus, common cold virus, contagious eethyma virus, contagious pustulardermatitis virus, Coronavirus, Corriparta virus, coryza virus, cowpoxvirus, coxsackie virus, CPV (cytoplasmic polyhedrosis virus), cricketparalysis virus, Crimean-Congo hemorrhagic fever virus, croup associatedvirus, Cryptovirus, Cypovirus, Cytomegalovirus, cytomegalovirus group,cytoplasmic polyhedrosis virus, deer papillomavirus, deltaretrovirus,dengue virus, Densovirus, Dependovirus, Dhori virus, diploma virus,Drosophila C virus, duck hepatitis B virus, duck hepatitis virus 1, duckhepatitis virus 2, duovirus, Duvenhage virus, Deformed wing virus DWV,eastern equine encephalitis virus, eastern equine encephalomyelitisvirus, EB virus, Ebola virus, Ebola-like virus, echo virus, echovirus,echovirus 10, echovirus 28, echovirus 9, ectromelia virus, EEE virus,EIA virus, EIA virus, encephalitis virus, encephalomyocarditis groupvirus, encephalomyocarditis virus, Enterovirus, enzyme elevating virus,enzyme elevating virus (LDH), epidemic hemorrhagic fever virus,epizootic hemorrhagic disease virus, Epstein-Barr virus, equidalphaherpesvirus 1, equid alphaherpesvirus 4, equid herpesvirus 2,equine abortion virus, equine arteritis virus, equine encephalosisvirus, equine infectious anemia virus, equine morbillivirus, equinerhinopneumonitis virus, equine rhinovirus, Eubenangu virus, European elkpapillomavirus, European swine fever virus, Everglades virus, Eyachvirus, fetid herpesvirus 1, feline calicivirus, feline fibrosarcomavirus, feline herpesvirus, feline immunodeficiency virus, felineinfectious peritonitis virus, feline leukemia/sarcoma virus, felineleukemia virus, feline panleukopenia virus, feline parvovirus, felinesarcoma virus, feline syncytial virus, Filovirus, Flanders virus,Flavivirus, foot and mouth disease virus, Fort Morgan virus, FourCorners hantavirus, fowl adenovirus 1, fowlpox virus, Friend virus,Gammaretrovirus, GB hepatitis virus, GB virus, German measles virus,Getah virus, gibbon ape leukemia virus, glandular fever virus, goatpoxvirus, golden spinner virus, Gonometa virus, goose parvovirus,granulosis virus, Gross' virus, ground squirrel hepatitis B virus, groupA arbovirus, Guanarito virus, guinea pig cytomegalovirus, guinea pigtype C virus, Hantaan virus, Hantavirus, hard clam reovirus, harefibroma virus, HCMV (human cytomegalovirus), hemadsorption virus 2,hemagglutinating virus of Japan, hemorrhagic fever virus, hendra virus,Henipaviruses, Hepadnavirus, hepatitis A virus, hepatitis B virus group,hepatitis C virus, hepatitis D virus, hepatitis delta virus, hepatitis Evirus, hepatitis F virus, hepatitis G virus, hepatitis nonA nonB virus,hepatitis virus, hepatitis virus (nonhuman), hepatoencephalomyelitisreovirus 3, Hepatovirus, heron hepatitis B virus, herpes B virus, herpessimplex virus, herpes simplex virus 1, herpes simplex virus 2,herpesvirus, herpesvirus 7, Herpesvirus ateles, Herpesvirus hominis,Herpesvirus infection, Herpesvirus saimiri, Herpesvirus suis,Herpesvirus varicellae, Highlands J virus, Hirame rhabdovirus, hogcholera virus, human adenovirus 2, human alphaherpesvirus 1, humanalphaherpesvirus 2, human alphaherpesvirus 3, human B lymphotropicvirus, human betaherpesvirus 5, human coronavirus, human cytomegalovirusgroup, human foamy virus, human gammaherpesvirus 4, humangammaherpesvirus 6, human hepatitis A virus, human herpesvirus 1 group,human herpesvirus 2 group, human herpesvirus 3 group, human herpesvirus4 group, human herpesvirus 6, human herpesvirus 8; humanimmunodeficiency virus, human immunodeficiency virus 1, humanimmunodeficiency virus 2, human papillomavirus, human T cell leukemiavirus, human T cell leukemia virus I, human T cell leukemia virus II,human T cell leukemia virus III, human T cell lymphoma virus I, human Tcell lymphoma virus II, human T cell lymphotropic virus type 1, humancell lymphotropic virus type 2, human lymphotropic virus I, human Tlymphotropic virus II, human T lymphotropic virus III, Ichnovirus,infantile gastroenteritis virus, infectious bovine rhinotracheitisvirus, infectious haematopoietic necrosis virus, infectious pancreaticnecrosis virus; influenza virus A, influenza virus B; influenza virus C,influenza virus D, influenza virus pr8, insect iridescent virus, insectvirus, iridovirus, Japanese B virus, Japanese encephalitis virus, JCvirus, Junin virus, Kaposi's sarcoma-associated herpesvirus, Kemerovovirus, Kilham's rat virus, Klamath virus, Kolongo virus, Koreanhemorrhagic fever virus, kumba virus, Kysanur forest disease virus,Kyzylagach virus, La Crosse virus, lactic dehydrogenase elevating virus,lactic dehydrogenase virus, Lagos bat virus, Langur virus, lapineparvovirus, Lassa fever virus, Lassa virus, latent rat virus, LCM virus,Leaky virus, Lentivirus, Leporipoxvirus, leukemia virus, leukovirus,lumpy skin disease virus, lymphadenopathy, associated virus,Lymphocryptovirus, lymphocytic choriomeningitis virus,lymphoproliferative virus group, Machupo virus, mad itch virus;mammalian type B oncovirus group, mammalian type B retroviruses,mammalian type C retrovirus group, mammalian type D retroviruses,mammary tumor virus, Mapuera virus, Marburg virus, Marburg-like virus,Mason Pfizer monkey virus, Mastadenovirus, Mayaro virus, ME virus,measles virus, Menangle virus, Mengo virus, Mengovirus, Middelburgvirus, milkers nodule virus, mink enteritis virus, minute virus of mice,MLV related virus, MM virus, Mokola virus, Molluscipoxvirus, Molluscumcontagiosum virus, monkey B virus, monkeypox virus; Mononegavirales,Morbillivirus, Mount Elgon bat virus, mouse cytomegalovirus, mouseencephalomyelitis virus, mouse hepatitis virus, mouse K virus, mouseleukemia virus, mouse mammary tumor virus, mouse minute virus, mousepneumonia virus, mouse poliomyelitis virus, mouse polyomavirus, mousesarcoma virus, mousepox virus, Mozambique virus, Mucambo virus, mucosaldisease virus, mumps virus, murid betaherpesvirus 1, muridcytomegalovirus 2, murine cytomegalovirus group, murineencephalomyelitis virus, murine hepatitis virus, murine leukemia virus,murine nodule inducing virus, murine polyomavirus, murine sarcoma virus,Muromegalovirus, Murray Valley encephalitis virus, myxoma virus,Myxovirus, Myxovirus multiforme, Myxovirus parotitidis, Nairobi sheepdisease virus, Nairovirus, Nanirnavirus, Nariva virus, Ndumo virus,Neethling virus, Nelson Bay virus, neurotropic virus, New WorldArenavirus, newborn pneumonitis virus, Newcastle disease virus, Nipahvirus, noncytopathogenic virus, Norwalk virus, nuclear polyhedrosisvirus (NPV), nipple neck virus, O'nyong'nyong virus, Ockelbo virus,oncogenic virus, oncogenic viruslike particle, oncornavirus, Orbivirus,Orf virus, Oropouche virus, Orthohepadnavirus, Orthomyxovirus,Orthopoxvirus, Orthoreovirus, Orungo, ovine papillomavirus, ovinecatarrhal fever virus, owl monkey herpesvirus, Palyam virus,Papillomavirus, Papillomavirus sylvilagi, Papovavirus, parainfluenzavirus, parainfluenza virus type 1, parainfluenza virus type 2,parainfluenza virus type 3, parainfluenza virus type 4, Paramyxovirus,Parapoxvirus, paravaccinia virus, Parvovirus, Parvovirus B19, parvovirusgroup, Pestivirus, Phlebovirus, phocine distemper virus, Picodnavirus,Picornavirus, pig cytomegalovirus-pigeonpox virus, Piry virus, Pixunavirus, pneumonia virus of mice, Pneumovirus, poliomyelitis virus,poliovirus, Polydnavirus, polyhedral virus, polyoma virus, Polyomavirus,Polyomavirus bovis, Polyomavirus cercopitheci, Polyomavirus hominis 2,Polyomavirus maccacae 1, Polyomavirus muris 1, Polyomavirus muris 2,Polyomavirus papionis 1, Polyomavirus papionis 2, Polyomavirussylvilagi, Pongine herpesvirus 1, porcine epidemic diarrhea virus,porcine hemagglutinating encephalomyelitis virus, porcine parvovirus,porcine transmissible gastroenteritis virus, porcine type C virus, poxvirus, poxvirus, poxvirus variolae, Prospect Hill virus, Provirus,pseudocowpox virus, pseudorabies virus, psittacinepox virus, quailpoxvirus, rabbit fibroma virus, rabbit kidney vaculolating virus, rabbitpapillomavirus, rabies virus, raccoon parvovirus, raccoonpox virus,Ranikhet virus, rat cytomegalovirus, rat parvovirus, rat virus,Rauscher's virus, recombinant vaccinia virus, recombinant virus,reovirus, reovirus 1, reovirus 2, reovirus 3, reptilian type C virus,respiratory infection virus, respiratory syncytial virus, respiratoryvirus, reticuloendotheliosis virus, Rhabdovirus, Rhabdovirus carpia,Rhadinovirus, Rhinovirus, Rhizidiovirus, Rift Valley fever virus,Riley's virus, rinderpest virus, RNA tumor virus, Ross River virus,Rotavirus, rougeole virus, Rous sarcoma virus, rubella virus, rubeolavirus, Rubivirus, Russian autumn encephalitis virus, SA 11 simian virus,SA2 virus, Sabia virus, Sagiyama virus, Saimirine herpesvirus 1,salivary gland virus, sandfly fever virus group, Sandjimba virus, SARSvirus, SDAV (sialodacryoadenitis virus), sealpox virus, Semliki ForestVirus, Seoul virus, sheeppox virus, Shope fibroma virus, Shope papillomavirus, simian foamy virus, simian hepatitis A virus, simian humanimmunodeficiency virus, simian immunodeficiency virus, simianparainfluenza virus, simian T cell lymphotrophic virus, simian virus,simian virus 40, Simplexvirus, Sin Nombre virus, Sindbis virus, smallpoxvirus, South American hemorrhagic fever viruses, sparrowpox virus,Spumavirus, squirrel fibroma virus, squirrel monkey retrovirus, SSV 1virus group, STLV (simian T lymphotropic virus) type I, STLV (simian Ilymphotropic virus) type II, STLV (simian T lymphotropic virus) typeIII, stomatitis papulosa virus, submaxillary virus, suidalphaherpesvirus 1, suid herpesvirus 2, Suipoxvirus, swamp fever virus,swinepox virus, Swiss mouse leukemia virus, TAC virus, Tacaribe complexvirus, Tacaribe virus, Tanapox virus, Taterapox virus, Tench reovirus,Theiler's encephalomyelitis virus, Theilees virus, Thogoto virus,Thottapalayam virus, Tick borne encephalitis virus, Tioman virus,Togavirus, Torovirus, tumor virus, Tupaia virus, turkey rhinotracheitisvirus, turkeypox virus, type C retroviruses, type D oncovirus, type Dretrovirus group, ulcerative disease rhabdovirus, Una virus, Uukuniemivirus group, vaccinia virus, vacuolating virus, varicella zoster virus,Varicellovirus, Varicola virus, variola major virus, variola virus,Vasin Gishu disease virus, VEE virus, Venezuelan equine encephalitisvirus, Venezuelan equine encephalomyelitis virus, Venezuelan hemorrhagicfever virus, vesicular stomatitis virus, Vesiculovirus, Vilyuisk virus,viper retrovirus, viral haemorrhagic septicemia virus, Visna Maedivirus, Visna virus, volepox virus, VSV (vesicular stomatitis virus),Wallal virus, Warrego virus, wart virus, WEE virus, West Nile virus,western equine encephalitis virus, western equine encephalomyelitisvirus, Whataroa virus, Winter Vomiting Virus, woodchuck hepatitis Bvirus, woolly monkey sarcoma virus, wound tumor virus, WRSV virus, Yabamonkey, tumor virus, Yaba virus, Yatapoxvirus, yellow fever virus, andthe Yug Bogdanovac virus.

Methods of Producing Pseudotyped Oncolytic Viruses

In some instances, a pseudotyped oncolytic virus described herein isgenerated using methods well known in the art. In some instances, themethods involve one or more transfection steps and one or more infectionsteps. In some instances, a cell line such as a mammalian cell line, aninsect cell line, or a plant cell line is infected with a pseudotypedoncolytic virus described herein to produce one or more viruses.Exemplary mammalian cell lines include: 293A cell line, 293FT cell line,293F cells, 293 H cells, CHO DG44 cells, CHO-S cells, CHO-K1 cells,Expi293F™ cells, Flp-In™ T-REx™ 293 cell line, Flp-In™-293 cell line,Flp-In™-3T3 cell line, Flp-In™-BHK cell line, Flp-In™-CHO cell line,Flp-In™-CV-1 cell line, Flp-In™-Jurkat cell line, FreeStyle™ 293-Fcells, FreeStyle™ CHO-S cells, GripTite™ 293 MSR cell line, GS-CHO cellline, HepaRG™ cells, T-REx™ Jurkat cell line, Per.C6 cells, T-REx™-293cell line, T-REx™-CHO cell line, T-REx™-HeLa cell line, 3T6, A549, A9,AtT-20, BALB/3T3, BHK-21, BHL-100, BT, Caco-2, Chang, Clone 9, CloneM-3, COS-1, COS-3, COS-7, CRFK, CV-1, D-17, Daudi, GH1, GH3, H9, HaK,HCT-15, HEp-2, HL-60, HT-1080, HT-29, HUVEC, I-10, IM-9, JEG-2, Jensen,K-562, KB, KG-1, L2, LLC-WRC 256, McCoy, MCF7, VERO, WI-38, WISH, XC, orY-1. Exemplary insect cell lines include Drosophila S2 cells, Sf9 cells,Sf21 cells, High Five™ cells, or expresSF+® cells. Exemplary plant celllines include algae cells such as for example Phaeocystis pouchetii.

Any method known to one skilled in the art is used for large scaleproduction of recombinant oncolytic vectors and vector constructs, suchas pseudotyped oncolytic vectors. For example, master and working seedstocks can be prepared under GMP conditions in qualified primary CEFs orby other methods. In some instances, cells are plated on large surfacearea flasks, grown to near confluency, and infected at selected MOI. Theproduced virus can then be purified. In some cases, cells are harvestedand intracellular virus is released by mechanical disruption. In someembodiments, cell debris is removed by large-pore depth filtrationand/or host cell DNA is digested with an endonuclease. In some cases,virus particles are subsequently purified and concentrated bytangential-flow filtration, followed by diafiltration. The resultingconcentrated virus can formulated by dilution with a buffer containingone or more stabilizers, filled into vials, and lyophilized.Compositions and formulations can be stored for later use. In someembodiments, a lyophilized virus is reconstituted by addition of one ormore diluents.

Engager Molecules

In some embodiments, the oncolytic viral vectors provided herein arepseudotyped oncolytic viruses that are further engineered to include apolynucleotide sequence that encodes an engager molecule, e.g., anengager polypeptide. The engager molecules of the present inventioncomprise at least two domains each capable of binding to a differentcell surface molecule. In some embodiments, engager polypeptidescomprise an antigen recognition domain and an activation domain thatrecognize particular cell surface proteins (e.g., cell-surface receptorsor ligands) expressed by target and effector cells, respectively. Asused herein, an “antigen recognition domain” is a polypeptide that bindsone or more molecules present on the cell surface of a target cell(e.g., a tumor antigen), and an “activation domain” is a polypeptidethat binds to one or more molecules present on the cell surface of aneffector cell (e.g., an activation molecule). An activation domain mayalso be referred to as an “engager domain.”

In some embodiments, engager polypeptides comprise a therapeuticmolecule domain and an activation domain. A therapeutic molecule domainis a polypeptide that binds to a particular cell surface proteinexpressed on an effector cell (e.g., cell-surface receptors or ligands)and that is distinct from the cell surface protein recognized by theactivation domain. In particular embodiments, the therapeutic moleculedomain binds to a cell surface protein that is a negative regulator ofeffector cell function (e.g., an immune checkpoint molecule or otherinhibitory molecule). Exemplary cell-surface antigen for targeting by atherapeutic domain include CD47, PD1, PDL1, CTLA4, TIM2, LAG3, BTLA,KIR, TIGIT, OX40, FITR, CD27, SLAMF7, and CD200.

In some embodiments, binding of an activation domain to a moleculepresent on the surface of the effector cell results in activation of theeffector cell. In certain embodiments, binding of an activation domainto a molecule on an effector cell and binding of an antigen recognitiondomain to a molecule present on a target cell brings the effector cellin close proximity to the target cell and thereby facilitates thedestruction of the target cell by the effector cell. In certainembodiments, binding of an activation domain to an activation moleculeon an effector cell and binding of a therapeutic molecule domain to aninhibitory molecule present on an effector cell enhances the activationof the effector cell and thereby facilitates the destruction of one ormore bystander target cells by the effector cell.

In certain embodiments, the engager molecule is a protein, e.g., anengineered protein. In some embodiments, the engager molecule is abipartite polypeptide. In some embodiments, the engager molecule is atripartite or multipartite polypeptide. In such embodiments, the engagermolecule may comprise one or more activation domains and/or antigenrecognition domains, or other domains, including one or moreco-stimulatory domains, one or more dimerization or trimerizationdomains, or other domain capable of binding a molecule expressed on thecell surface. Alternatively, the one or more additional domains areoptionally present on a separate polypeptide. In some embodiments, theengager molecule comprises an antibody or antibody fragment. In someembodiments, the engager molecule is a is a trifunctional antibody, anFab₂, a bi-specific scFv such as a bi-specific T-cell engager (BiTE), abivalent minibody, a bispecific diabody, a DuoBody, or an Mab2. Incertain embodiments, the engager molecule is a bipartite T cell engager(BiTE) or a tripartite T cell engager (TiTE).

In some embodiments, the activation domain, the antigen recognitiondomain, and/or the therapeutic molecule domain of the engager moleculecomprises an antibody or an antigen-binding fragment thereof, e.g., asingle chain variable fragment (scFv), a monoclonal antibody, Fv, Fab,minibody, diabody. In some embodiments, the activation domain, theantigen recognition domain, and/or the therapeutic molecule domain ofthe engager molecule comprises a ligand, a peptide, a peptide thatrecognize and interacts with a soluble TCR, or combinations thereof. Insome embodiments, these antibody-derived fragments or derivatives may bemodified by chemical, biochemical, or molecular biological methods.Corresponding methods are known in the art and described, inter alia, inlaboratory manuals (see Sambrook et al.; Molecular Cloning: A LaboratoryManual; Cold Spring Harbor Laboratory Press, 2nd edition 1989 and 3rdedition 2001; Gerhardt et al.; Methods for General and MolecularBacteriology; ASM Press, 1994; Lefkovits; Immunology Methods Manual: TheComprehensive Sourcebook of Techniques; Academic Press, 1997; Golemis;Protein-Protein Interactions: A Molecular Cloning Manual; Cold SpringHarbor Laboratory Press, 2002). In some instances, the polypeptides,antibodies, or antigen-binding fragments thereof used in theconstruction of the engager molecules described herein are humanized ordeimmunized constructs. Methods for the humanization and/ordeimmunization of polypeptides and, in particular, antibody constructsare known to the person skilled in the art.

In some embodiments, for any of the engagers described herein, therespective domains are in any order from N-terminus to C-terminus. Forexample, in some embodiments, the engager molecule may comprise anN-terminal activation domain and a C-terminal antigen recognitiondomain. In some embodiments, the engager molecule may comprise anN-terminal antigen recognition domain and a C-terminal activationdomain. In some embodiments, the engager molecule may comprise anN-terminal activation domain and a C-terminal therapeutic moleculedomain. In some embodiments, the engager molecule may comprise anN-terminal therapeutic molecule domain and a C-terminal activationdomain. In certain embodiments, T-cells are modified to secrete engagermolecules that have an antigen recognition domain or therapeuticmolecule domain N-terminal to an activation domain.

In particular embodiments, two or more of the domains of an engagermolecule are linked by a linker. In some instances, the linker is of anysuitable length, and such a parameter is routinely optimized in the art.For example, linkers are of a length and sequence sufficient to ensurethat each of the first and second domains can, independently from oneanother, retain their differential binding specificities. The term“peptide linker” refers to an amino acid sequence by which the aminoacid sequences of a first domain (e.g., an activation domain) and asecond domain (e.g., an antigen recognition domain or therapeuticmolecule domain) of a defined construct are linked together. In someinstance, one technical feature of such peptide linker is that saidpeptide linker does not comprise any polymerization activity and/or doesnot promote formation of secondary structures. Such peptide linkers areknown in the art and described, for example, in Dall'Acqua et al.(Biochem. (1998) 37, 9266-9273); Cheadle et al. (Mol Immunol (1992) 29,21-30); and Raag and Whitlow (FASEB (1995) 9(1), 73-80). In someembodiments, the peptide linkers of the present invention comprise lessthan 5 amino acids, less than 4 amino acids, less than 3 amino acids,less than 2 amino acids, or 1 amino acid. In some embodiments, thepeptide linker is a single amino acid linker. In such embodiments, thesingle amino acid is typically a glycine (Gly). In some embodiments,peptide linkers that also do not promote any secondary structures arepreferred. Methods for preparing fused, operatively-linked constructsand their expression in mammalian or bacterial cells are well-known inthe art (See e.g., International PCT Publication No. WO 99/54440;Ausubel, Current Protocols in Molecular Biology, Green PublishingAssociates and Wiley Interscience, N.Y. 1989 and 1994; and Sambrook etal., Molecular Cloning: A Laboratory Manual, Cold Spring HarborLaboratory Press, Cold Spring Harbor, N.Y., 2001).

In some embodiments, the engager molecule is a single chain bi-specificantibody construct. The term “single chain bispecific antibodyconstruct” refers to a construct comprising two antibody-derived bindingdomains. One of the binding domains comprises variable regions (or partsthereof) of both heavy chain (VH) and light chain (VL) of an antibody orantigen binding fragments or derivatives thereof, capable ofspecifically binding to/interacting with an activation moleculeexpressed on an effector cell (e.g., CD3). The second binding domaincomprises variable regions (or parts thereof) of both heavy chain (VH)and light chain (VL) of an antibody or antigen binding fragments orderivatives thereof, capable of specifically binding to/interacting witha target antigen expressed on a target cell (e.g., CD19) or an antigenexpressed by and effector cell (e.g., an inhibitor molecule). Inparticular embodiments, each of the two antibody or antigen bindingfragments or derivatives comprise at least one complementary determiningregion (CDR), particularly a CDR3. In some embodiments, the single chainbi-specific antibody construct is a bispecific scFv or diabody.

In specific embodiments, the single chain bispecific antibody constructis a single chain bispecific scFv. An scFv in general contains a VH andVL domain connected by a linker peptide. In some embodiments, a singlechain bispecific scFv is comprised of a signal peptide to allow forsecretion from cells, followed by two scFvs connected by one or morelinker peptides (Lx, Ly, Lz). Bispecific single chain molecules areknown in the art and are described in International PCT Publication No.WO 99/54440; Mack, J. Immunol. (1997), 158, 3965-3970; Mack, PNAS,(1995), 92, 7021-7025; Kufer, Cancer Immunol. Immunother., (1997), 45,193-197; Loftier, Blood, (2000), 95, 6, 2098-2103; and Bruhl, J.Immunol., (2001), 166, 2420-2426.

In some embodiments, the molecular format of the polynucleotide encodinga single chain bi-specific scFv polypeptide comprises nucleic acidsequence encoding a signal peptide (such as the signal sequences of SEQID NO: 2 and 4) followed by two or more antibody-derived regions (e.g.,a first scFv and a second scFv). Each antibody-derived region (e.g.,scFv) comprises one VH and one VL chain. In specific embodiments, thetwo or more antibody-derived regions are scFvs and are linked by apeptide linker to form a single chain bi-specific scFv construct. Insome embodiments, the bi-specific scFv is a tandem bi-scFv or a diabody.Bispecific scFvs can be arranged in different formats including thefollowing: VHO—Lx-V_(L)a-Ly-V_(H)-Lz-ViJ3,V_(L)a-Lx-V_(H)a-Ly-VH-Lz-ViJ3, V_(L)a-Lx-V_(H)-Ly-VL-Lz-VH,V_(H)-Lx-V_(L)a-Ly-VL-Lz-VH, V_(H)-Lx-VL-Ly-VH-Lz-V_(L)a,V_(L)a-Lx-VL-Ly-VH-Lz-V_(H), VH-Lx-VH-Ly-VL-Lz-VLa,VLa-Lx-VH-Ly-VL-Lz-V_(H), VH-Lx-V_(L)a-Ly-V_(H)-Lz-VL,VL-Lx-V_(L)a-Ly-V_(H)-Lz-VH, V_(H)-Lx-VH-Ly-VLa-Lz-VL,VL-Lx-VH-Ly-VLa-Lz-V_(H).

In some embodiments, the engager molecule comprises multiple (e.g., 2,3, 4, 5 or more) antigen binding domains to allow targeting of multipleantigens. In some embodiments, the engager molecule comprises multiple(e.g., 2, 3, 4, 5 or more) activation domains to activate effectorcells. In some embodiments, the engager molecule comprises multiple(e.g., 2, 3, 4, 5 or more) therapeutic molecule domains to activateeffector cells.

In specific embodiments of the disclosure, the engager moleculecomprises additional domains for the isolation and/or preparation ofrecombinantly produced constructs, such as a tag or a label. The tag orlabel may be a short peptide sequence, such as a histidine tag (SEQ IDNO: 12), or may be a tag or label that is capable of being imaged, suchas fluorescent or radioactive label.

In particular embodiments, the engager molecules of the presentinvention specifically bind to/interact with a particularconformational/structural epitope(s) of a target antigen expressed on atarget cell and an activation molecule expressed on an effector cell(e.g., an activation domain that specifically binds to one of the tworegions of the human CD3 complex, or parts thereof). In particularembodiments, the engager molecules of the present invention specificallybind to/interact with a particular conformational/structural epitope(s)of an activation molecule expressed on an effector cell and a differentcell-surface protein expressed on an effector cell. Accordingly,specificity in some instances is determined experimentally by methodsknown in the art and methods as disclosed and described herein. Suchmethods comprise, but are not limited to Western blots, enzyme-linkedimmunosorbent assay (ELISA), radioimmunoassay (RIA),radioimmunoprecipitation (RIP), electrochemiluminescence (ECL),immunoradiometric assay (IRMA), enzyme immunoassay (EIA), and peptidescans.

Activation Molecules and Target Cell Antigens

In some embodiments, binding of the activation domain of an engagermolecule to an activation molecule on the cell surface of an effectorcell results in activation of the effector cell. As used herein, theterm “effector cell” refers to any mammalian cell type that is capableof facilitating the death of a target cell. In particular embodiments,the effector cells of the present invention are immune cells, such as aT cell, a B cell, an innate lymphocyte, a natural killer (NK) cell, anatural killer T cell (NKT), a granulocyte (e.g., a neutrophil,basophil, mast cell, or eosinophil), a macrophage, a monocyte, or adendritic cell. Exemplary effector cell types include T cells, NK cells,NKT cells, and macrophages.

In some embodiments, activation of an effector cell may result in one ormore of the following: (i) increased proliferation of the effector cell;(ii) changes in the expression or activity of one or more cell surfaceproteins of the effector cell; (iii) change in expression or activity ofone or more intracellular proteins expressed by the effector cell; (iv)changes in the amount or nature of factors produced and/or secreted bythe effector cell, such as cytokines, chemokines or reactive oxygenspecies; (v) changes in the morphology of the effector cell; (vi)changes in the chemotactic potential of the effector cell, such asthrough increased or decreased expression of one or more chemokinereceptors; (vii) changes in the functional activity of the effectorcell, such as increased cytolytic activity and/or increased phagocyticactivity. Activation of an effector cell, or population of effectorcells, can be determined by any means known in the art. For example,changes in proliferation, protein expression, production, or secretioncan be determined by flow cytometry, Western blot, ELISA,immunohistochemistry, immunoprecipitation, or immunofluorescence andchanges in cell morphology can be determined by numerous types ofmicroscopy known in the art.

The skilled artisan will recognize that the nature of the activatingmolecule may vary according to the nature of the effector cell, althoughdifferent groups of effector cells may share expression of certain typesof activation molecules. For example, T cells express different surfacereceptors, i.e. different activating receptors, than NK cells ormacrophages. As an illustrative example, CD3 is an activating receptorexpressed by T-cells that is not expressed by NK cells or macrophages,whereas CD1, CD16, NKG2D, and/or NKp30 are activating receptorsexpressed by NK cells that are not expressed by T cells. Therefore, insome instances, engager molecules that activate T-cells have a differentactivation domain than engager molecules that activate NK cells,macrophages, NKT cells, or other types of effector cells. Exemplaryactivation molecules are described below and shown in Table 1.

In some embodiments, the effector cell is a T cell and the activationdomain of the engager molecule binds to an activation molecule expressedby the T cell. The T-cell repertoire is comprised of numerous sub-typesof T cell, including NKT cells, cytotoxic T cells (Tc or CTL), memory Tcells, helper T cells (e.g., Th1, Th2, Th17, Th9, and/or Th22 cells),suppressor T cells (e.g., regulator T cells (Tregs)), mucosal-associatedinvariant T cells, and γδ T cells. In some instances, one or moresurface receptors expressed by one T cell subtype are not expressed byanother T cell subtype. In some instances, one or more surface receptorsexpressed by one T cell subtype are expressed by at least one other Tcell subtype. In some instances, one or more surface receptors expressedby one T cell subtype are generally expressed by all, or most, T cellsubtypes. For example, CD3 is a signaling component of the T cellreceptor (TCR) complex and is expressed in multiple T cell subtypes.Exemplary activation molecules expressed by T cells (e.g., NKT, Tc,memory T cells, or helper T cell), include, but are not limited to oneor more components of CD3, (e.g., CD3γ, CD3δ, CD3ε or CD3ξ), CD2, CD4,CD5, CD6, CD7, CD8, CD25, CD27, CD28, CD30, CD38, CD40, CD57, CD69,CD70, CD73, CD81, CD82, CD134, CD137, CD152, or CD278. In someembodiments, the effector cell is an NKT-cell. In such embodiments, theactivation molecule includes, but is not limited to, CD3 or an invariantTCR.

In some embodiments, the effector cell is an NK cell and the activationdomain of the engager molecule binds to an activation molecule expressedby the NK cell. Exemplary activation molecules expressed by NK cellsinclude, but are not limited to, CD16, CD94/NKG2 (e.g., NKG2D), NKp30,NKp44, NKp46, or killer activation receptors (KARs).

TABLE 1 Exemplary Activation Molecules T cell Activation NKT cellActivation Molecules Molecules CD3 or components CD3 thereof (e.g.,CD3γ, CD3δ, CD3ε or CD3ξ) CD2 invariant TCR CD4 NK Cell ActivationMolecules CD5 CD16 CD6 CD94/NKG2 (e.g., NKG2D) CD7 NKp30 CD8 NKp44 CD16NKp46 CD25 KARs CD27 CD28 CD30 CD38 CD40 CD57 CD69 CD70 CD73 CD81 CD82CD134 CD137 CD152 CD278

In some embodiments, binding of an engager molecule to a target cell andan effector cell (e.g., binding of an activation domain to a molecule onan effector cell and binding of an antigen recognition domain to amolecule present on a target cell) brings the effector cell in closeproximity to the target cell and thereby facilitates the destruction ofthe target cell by the effector cell. As used herein, the term “targetcell” refers to a mammalian cell that should be killed, attacked,destroyed, and/or controlled. In particular, target cells are cells thatare in some way altered compared to a normal cell of the same cell type,such as a cancerous cell, a bacterially-infected cell, avirally-infected cell, a fungally-infected cell, and/or an autoimmunecell. In particular embodiments, the target cells of the presentinvention are cancerous cells (e.g., tumor cells). Destruction (i.e.,death) of a target cell can be determined by any means known in the art,such as flow cytometry (e.g., by AnnexinV, propidium iodide, or othermeans), cell counts, and/or microscopy to determine the cellularmorphology of the target cells.

In some embodiments, the antigen recognition domain of an engagermolecule brings a target cell (e.g., tumor cell) into the vicinity of aneffector cell via interaction between the antigen recognition domain andsurface antigens expressed by the target cell (e.g., target cellantigens). In some embodiments, the target-cell antigen is a tumorantigen. In some embodiments, a tumor antigen is a tumor-specificantigen (TSA), and is expressed only by tumor cells. In someembodiments, the target cell angien is a tumor-associated antigen (TAA),and is expressed by tumor cells and one or more types of normal cells ornon-tumor cells. In some cases, TSA is also present in one or more typesof normal cells or non-tumor cells, but is predominantly expressed bytumor cells. In some instances, a tumor antigen (e.g., TSA or TAA) ispresent in one cancer type. In some instances, a tumor antigen ispresent in multiple cancer types. In one embodiment, a tumor antigen isexpressed on a blood cancer cell. In another embodiment, a tumor antigenis expressed on a cell of a solid tumor. In some embodiments, the solidtumor is a glioblastoma, a non-small cell lung cancer, a lung cancerother than a non-small cell lung cancer, breast cancer, prostate cancer,pancreatic cancer, liver cancer, colon cancer, stomach cancer, a cancerof the spleen, skin cancer, a brain cancer other than a glioblastoma, akidney cancer, a thyroid cancer, or the like. In more specificembodiments, a tumor antigen is expressed by a tumor cell in anindividual.

Exemplary tumor antigens (e.g., TSAs or TAAs) include, but are notlimited to, alphafetoprotein (AFP), carcinoembryonic antigen (CEA),CA-125, epithelial tumor antigen (ETA), tyrosinase, CD10 (also known asneprilysin, membrane metallo-endopeptidase (MME), neutral endopeptidase(NEP), or common acute lymphoblastic leukemia antigen (CALLA)), CD15,CD19, CD20, CD21, CD22, CD30, CD33, CD38, CD44, CD44v6, CD44v7/8, CD70,CD123, CD138, CD171, ras, p53, v-raf murine sarcoma viral oncogenehomolog B1 (BRAF), calcium binding tyrosine-(Y)-phosphorylationregulated (CABYR), cysteine-rich secretory protein 3 (CRISP3), CSAGfamily, member 2 (CSAG2), cancer/testis antigen 2 (CTAG2), dihydrofolatereductase (DHFR), ferritin, heavy polypeptide 1; testis-specificexpression (FTHL17), G antigen 1 (GAGE1), lactate dehydrogenase C(LDHC), melanoma antigen family A (MAGEA) 1, MAGEA3, MAGEA4, (melanomaantigen family B, 6) MAGEB6, mitogen-activated protein kinase 1 (MAPK1),MHC Class I polypeptide-related sequence A (MICA), mucin (MUC) 1, cellsurface associated (MUC1), MUC16, NLR family, pyrin domain containing 4(NLRP4), New York esophageal squamous cell carcinoma 1 (NY-ESO-1), PDZbinding kinase (PB), preferentially expressed antigen in melanoma(PRAME), sex determining region Y-box (SOX)-2, SOX10, SOX11, spermprotein associated with the nucleus, X-linked, family member A1(SPANXA1), synovial sarcoma, X (SSX) breakpoint 2 (SSX2), SSX4, SSX5,testis specific, 10 (TSGA10), testis-specific serine kinase 6 (TSSK6),tubby like protein (TULP2), X antigen family, member 2 (XAGE2), zincfinger protein 165 (ZNF165), absent in melanoma 2 (AIM2), BMI1 polycombring finger oncogene (BMI1), cyclooxygenase-(COX-2), tyrosine relatedprotein (TRP)-1 TRP-2, glycoprotein 100 (GP100), epidermal growth factorreceptor variant III (EGFRvIII), enhancer of zeste homolog (EZH2), humanLI cell adhesion molecule (LICAM), Livin, multidrug resistance protein 3(MRP-3), Nestin, oligodendrocyte transcription factor (OLIG2), antigenrecognized by T cells (ART)-1, ART4, squamous cell carcinoma antigenrecognized by T cells (SART)-1, SART2, SART 3, B-cyclin, β-catenin,glioma-associated oncogene homlog 1 (GM), caveolin-1 (Cav-1), cathepsinB, cluster of differentiation (CD)-74, epithelial calcium-dependentadhesion (E-cadherin), EPH receptor A2 (EphA2), EphA2/epithelial kinase(EphA2/Eck), fos-related antigen 1 (Fra-1/Fosl 1), Ganglioside/GD2, GD3,acetylglucosaminyltransferase-V (GnT-V, β1,6-N), human epidermal growthfactor receptor 2 (Her2/Neu), nuclear proliferation-associated antigenof antibody Ki67 (Ki67), human Ku heterodimer proteins subunits(u70/80), interleukin-13 receptor subunit alpha-2 (IL-13Rα2), melanomaantigen recognized by T cells (MART-1), prospero homeobox protein 1(PROM), prostate stem cell antigen (PSCA), Survivin, urokinase-typeplasminogen activator receptor (UPAR), Wilms' tumor protein 1 (WT-1),Folate receptor a, Glypican-3, 5T4, 8H9, α_(v)β₆ integrin, B7-H3, B7-H6,CAIX, CA9, CSPG4, EGP2, EGP40, EpCAM, ERBB3, ERBB4, ErbB3/4, FAP, FAR,FBP, fetal AchR, HLA-AI, HLA-A2, IL-1Rα, KDR, Lambda, Lewis-Y, MCSP,Mesothelin, NCAM, NKG2D ligands, PSC1, PSMA, ROR1, TAG72, TEM1, TEM8,VEGRR2, HMW-MAA, VEGF, VEGF receptors, P-glycoprotein, erythropoietin(EPO), cadherin, CD4, CD8, CD45, CD117 (c-kit), CD133, HLA-A. HLA-B,HLA-C, chemokine receptor 5 (CCR5), stem cell marker ABCG2 transporter,immunoglobulins, integrins, prostate specific antigen (PSA), prostatestem cell antigen (PSCA), dendritic cell-specific intercellular adhesionmolecule 3-grabbing nonintegrin (DC-SIGN), thyroglobulin,granulocyte-macrophage colony stimulating factor (GM-CSF), myogenicdifferentiation promoting factor-1 (MyoD-1), Leu-7 (CD57), LeuM-1, cellproliferation-associated human nuclear antigen defined by the monoclonalantibody Ki-67 (Ki-67), viral envelope proteins, HIV gp120, andtransferrin receptor. Other exemplary tumor antigens are antigens thatare present in the extracelluar matrix of tumors, such as oncofetalvariants of fibronectin, tenascin, or necrotic regions of tumors.

TABLE 2 Exemplary Target Cell Antigens Antigen 5T4 8H9 ABCG2 transporterAFP AIM2 ART1 ART4 B7-H3 B7-H6 B-cyclin BMI1 BRAF CA9 CABYR CAIXcathepsin B Cav-1 CCR5 CD10 CD117 CD123 CD133 CD138 CD15 CD171 CD19 CD20CD21 CD22 CD30 CD33 CD38 CD4 CD44 CD44v6 CD44v7/8 CD45 CD70 CD74 CD8 CEACOX-2 CRISP3 CSAG2 CSPG4 CTAG2 DC-SIGN DHFR E-cadherin EGFR FGFRvIIIEGP2 EGP40 EPCAM EphA2 EphA2/Eck ERBB3 ErbB3/4 ERBB4 erythropoietin(EPO) ETA EZH2 FAP FAR FBP fetal AchR Folate Receptor a Fra-1/Fosl 1FTHL17 GAGE1 GD2 GD3 Glil Glypican-3 GnT-V, β1, 6-N GP100 Her2/Neu HIVsp120 HLA A HLA B HLA C HLA-A2 HLA-AI HMW-MAA IL-13Rα2 IL-1Rα kappalight chain KDR Ki67 Lambda LDHC Leu-7 (CD57) LeuM-1 Lewis-Y LICAM LivinMAGEA1 MAGEA3 MAGEA4 MAGEB6 MAPK1 MART-1 MCSP Mesothelin MICA MRP-3 MUC1MUC16 or CA125 MyoD1 NCAM necrotic regions of tumors Nestin NKG2Dligands NLRP4 NY-ESO-1 OLIG2 oncofetal variants of fibronectin p53 PBP-glycoprotein PRAME PROXl PSA PSC1 PSCA PSCA PSMA Ras ROR1 SART1 SART2SART3 SOX10 SOX11 SOX2 SPANXA1 SSX2 SSX4 SSX5 Survivin TAG72 TEM1 TEM8tenascin thyroglobulin transferrin receptor TRP-1 TRP-2 TSGA10 TSSK6TULP2 tyrosinase u70/80 UPAR VEGF VEGF Receptors VEGRR2 WT-1 XAGE2ZNF165 α_(v)β₆ integrin β-catenin

In certain embodiments, the antigen recognition domain of an engagermolecule specifically binds a tumor-associated antigen (TAA) or atumor-specific antigen (TSA). In certain embodiments, the antigenrecognition domain comprises an antibody or an antibody fragment or anantigen-binding fragment or portion thereof, such as for example, amonoclonal antibody, Fv, a scFv, Fab, minibody, or diabody that isspecific for a TAA or TSA. In certain embodiments, the antigenrecognition domain of the engager is an scFv that is specific for a TAAor TSA. In a specific embodiment, the TAA or TSA is expressed on acancer cell. In one embodiment, the TAA or TSA is expressed on a bloodcancer cell. In another embodiment, the TAA or TSA is expressed on acell of a solid tumor. In more specific embodiments, the solid tumor isa glioblastoma, a non-small cell lung cancer, a lung cancer other than anon-small cell lung cancer, breast cancer, prostate cancer, pancreaticcancer, liver cancer, colon cancer, stomach cancer, a cancer of thespleen, skin cancer, a brain cancer other than a glioblastoma, a kidneycancer, a thyroid cancer, or the like. In more specific embodiments, theTAA or TSA is expressed by a tumor cell in an individual. In someembodiments, the antigen-recognition domain of the engager molecule isspecific for one or more target cell antigens shown in Table 2.

EphA2

In some embodiments, EphA2 is referred to as EPH receptor A2 (ephrintype-A receptor 2; EPHA2; ARCC2; CTPA; CTPP1; or ECK), which is aprotein that in humans is encoded by the EPHA2 gene in the ephrinreceptor subfamily of the protein-tyrosine kinase family. Receptors inthis subfamily generally comprise a single kinase domain and anextracellular region comprising a Cys-rich domain and 2 fibronectin typeIII repeats; embodiments of the antibodies of the disclosure target anyof these domains. An exemplary human EphA2 nucleic sequence is inGenBank® Accession No. NM_004431, and an exemplary human EphA2polypeptide sequence is in GenBank® Accession No. NP_004422, both ofwhich sequences are incorporated herein in their entirety. An exemplaryhuman EphA2 nucleic sequence is in GenBank® Accession No. NM_004448.2,and an exemplary human EphA2 polypeptide sequence is in GenBank®Accession No. NP_004439, both of which sequences are incorporated hereinin their entirety.

The Eph family, the largest group among tyrosine kinase receptorfamilies, is comprised of the EphA (EphA1-10) or EphB (EphB1-6)subclasses of receptors classified as per their sequence homologies andtheir binding affinity for their ligands, Ephrins (Eph receptorinteracting protein). The human EphA2 gene is located on chromosome 1,encodes a receptor tyrosine kinase of 976 amino acids with an apparentmolecular weight of 130 kDa and has a 90% amino acid sequence homologyto the mouse EphA2. The Eph family contains an extracellular conservedN-terminal ligand-binding domain followed by a cysteine-rich domain withan epidermal growth factor-like motif and two fibronectin type-IIIrepeats. The extracellular motif is followed by a membrane spanningregion and a cytoplasmic region that encompasses a juxtamembrane region,a tyrosine kinase domain, a sterile alpha motif (SAM), and a postsynaptic domain (disc large and zona occludens protein (PDZ)domain-binding motif). EphA2 shows 25-35% sequence homologies with otherEph receptors, and the tyrosine residues are conserved within thejuxtamembrane and kinase domain.

EphA2 mRNA expression is observed in the skin, bone marrow, thymus,uterus, testis, prostate, urinary bladder, kidney, small intestine,colon, spleen, liver, lung and brain. EphA2 expression in the colon,skin, kidney and lung was over ten-fold relative to the bone marrow.EphA2 is also expressed during gastrulation in the ectodermal cells andearly embryogenesis in the developing hind brain. In the skin, EphA2 ispresent in keratinocytes of epidermis and hair follicles but not indermal cells (fibroblasts, vascular cells and inflammatory cells). EphA2is also expressed in proliferating mammary glands in female mice atpuberty and differentially expressed during the estrous cycle. Besidesits expression in embryo and in normal adult tissues, EphA2 isoverexpressed in several cancers, such as breast cancer, gastric cancer,melanoma, ovarian cancer, lunch cancer, gliomas, urinary bladder cancer,prostate cancer, esophageal, renal, colon and vulvar cancers. Inparticular, a high level of EphA2 is detected in malignantcancer-derived cell lines and advanced forms of cancer. In light of theEphA2 overexpression in pre-clinical models and clinical specimens ofmany different types of cancer, the increased level of EphA2 expressionis informative in both the prediction of cancer outcomes and in theclinical management of cancer. The differential expression of EphA2 innormal cells compared to cancer cells also signifies its importance as atherapeutic target.

HER2

In some embodiments, HER2 is referred to as human Epidermal GrowthFactor Receptor 2 (Neu, ErbB-2, CD340, or pi 85), which is a proteinthat in humans is encoded by the ERBB2 gene in the epidermal growthfactor receptor (EFR/ErbB) family. HER2 contains an extracellular ligandbinding domain, a transmembrane domain, and an intracellular domain thatinteracts with a multitude of signaling molecules. HER2 is a member ofthe epidermal growth factor receptor family having tyrosine kinaseactivity. Dimerization of the receptor results in theautophosphorylation of tyrosine residues within the cytoplasmic domainof the receptors and initiates a variety of signaling pathways leadingto cell proliferation and tumorigenesis. Amplification or overexpressionof HER2 occurs in approximately 15-30% of breast cancers and 10-30% ofgastric/gastroesophageal cancers and serves as a prognostic andpredictive biomarker. HER2 overexpression has also been seen in othercancers like ovary, endometrium, bladder, lung, colon, and head andneck. HER2 is overexpressed in 15-30% of invasive breast cancers, whichhas both prognostic and predictive implications. Overexpression of HER2protein, determined using IHC was found in 23% and gene amplificationdetermined using FISH in 27% of 200 resected tumors in a gastric cancerstudy. HER2 overexpression is directly correlated with poorer outcome ingastric cancer. In a study of 260 gastric cancers, HER2 overexpressionwas an independent negative prognostic factor and HER2 stainingintensity was correlated with tumor size, serosal invasion, and lymphnode metastases. Other studies also confirmed the negative impact ofHER2 overexpression in gastric cancer. HER2 overexpression is reportedin 0-83% of esophageal cancers, with a tendency towards higher rates ofpositivity in adenocarcinoma (10-83%) compared to squamous cellcarcinomas (0-56%). Overexpression of HER2 is seen in 20-30% patientswith ovarian cancer. In endometrial serous carcinoma, the reported ratesof HER2 overexpression range between 14% and 80% with HER2 amplification(by fluorescence in situ hybridization [FISH]) ranging from 21% to 47%.Embodiments of the antibodies of the disclosure target the extracellularligand binding domain.

Disialoganglioside GD2

Disialoganglioside GD2 is a sialic acid-containing glycosphingolipidexpressed primarily on the cell surface. The function of thiscarbohydrate antigen is not completely understood; however, it isthought to play an important role in the attachment of tumor cells toextracellular matrix proteins. GD2 expression in normal fetal and adulttissues is primarily restricted to the central nervous system,peripheral nerves, and skin melanocytes, although GD2 expression hasbeen described in the stromal component of some normal tissues and whitepulp of the spleen. In malignant cells, GD2 is uniformly expressed inneuroblastomas and most melanomas and to a variable degree in a varietyof other tumors, including bone and soft-tissue sarcomas, small celllung cancer, and brain tumors. GD2 is present and concentrated on cellsurfaces, with the two hydrocarbon chains of the ceramide moietyembedded in the plasma membrane and the oligosaccharides located on theextracellular surface, where they present points of recognition forextracellular molecules or surfaces of neighboring cells. Because of therelatively tumor-selective expression combined with its presence on thecell surface, GD2 is an attractive target for tumor-specific antibodytherapy. Embodiments of the antibodies of the disclosure target theextracellular domain.

Therapeutic Molecules

In some embodiments, the pseudotyped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule and one or moreadditional nucleic acid sequences that encode one or more therapeuticmolecules. As used herein, a “therapeutic molecule” refers to a moleculethat enhances the therapeutic efficacy of an oncolytic virus describedherein. In general, the therapeutic molecules described herein areproteins, nucleic acids, or a combination thereof. Exemplary therapeuticmolecules include cytokines, chemokines, antibodies or antigen bindingfragments thereof, proteases, RNA polynucleotides, and DNApolynucleotides.

In some embodiments, the therapeutic molecule is capable of increasingor enhancing the therapeutic efficacy of an oncolytic virus describedherein by stimulating, or activating, a cellular immune response. Insome embodiments, the therapeutic molecule is capable of increasing orenhancing the therapeutic efficacy of an oncolytic virus describedherein by antagonizing a suppressive or regulatory immune response. Insome embodiments, reduction of a suppressive immune response occurs in atumor microenvironment. In some instances, reduction of a suppressiveimmune response by the therapeutic molecule enhances the oncolyticeffects of a pseudotyped oncolytic virus described herein. In someembodiments, the therapeutic molecule further reduces immunoregulatory Tcell activity in a subject treated with a pseudotyped oncolytic virusdescribed herein. In some embodiments, the therapeutic moleculemodulates or impairs the production level of a protein at a nucleic acidlevel or at a protein level, or disrupts a protein function.

In some embodiments, a nucleic acid sequence encoding an engagermolecule and a nucleic acid sequence encoding one or more therapeuticmolecules are comprised within the same vector. In some embodiments, anucleic acid sequence encoding an engager molecule and a nucleic acidsequence encoding one or more therapeutic molecules are comprised indifferent vectors. In some embodiments, the vector is a viral vector. Insome instances, a therapeutic molecule comprises a polypeptide or anucleic acid polymer. In some embodiments, the additional nucleic acidsequence is inserted into a viral vector which allows higher expressionlevels and production of the therapeutic molecule.

In some embodiments, the therapeutic molecule is a polypeptide. In someinstances, the polypeptide is an immune modulator polypeptide. In somecases, the immune modulator polypeptide is a cytokine, a co-stimulatorydomain, a domain that inhibits negative regulatory molecules of T-cellactivation (e.g., an immune checkpoint inhibitor), or a combinationthereof.

In some embodiments, the immune modulator polypeptide modulates theactivity of one or more cell types, such as regulatory T cells (Tregs),myeloid-derived suppressor cells (MDSCs), dendritic cells, and/or Tcells. Exemplary Treg modulatory polypeptides include CCR4, Helios,TIGIT, GITR, neuropilin, neuritin, CD103, CTLA-4, ICOS, and Swap70.Exemplary MDSC modulatory polypeptides include TGF-βR1, GM-CSF, INFγ,interleukins such as IL-β, IL-1F2, IL-6, IL-10, IL-12, IL-13, IL-6,IL-6Rα, IL-6/IL-6R complex, TGF-β1, M-CSF, Prostaglandin E2/PGE2,Prostaglandin E Synthase 2, S100A8, and VEGF. Exemplary dendritic-celldirected modulatory polypeptides include GM-CSF and/or IL-13. ExemplaryT cell-directed modulatory polypeptides include IL-12, OX-40, GITR,CD28, or IL-28, or an antibody that agonizes a pathway comprising IL-12,OX-40, GITR, CD28, or IL-28.

In other embodiments, the therapeutic polypeptides modulate the fibroticstroma. Exemplary fibrotic stromal polypeptides include fibroblastactivation protein-alpha (FAP). In some embodiments, the therapeuticpolypeptide is a protease. In particular embodiments, the protease iscapable of altering the extracellular matrix, particularly theextracellular matrix within a tumor microenvironment. Exemplaryproteases include matrixmetalloproteases (MMP), such as MMP9,collagenases, and elastases.

Cytokines as Therapeutic Molecules

In some cases, the immune modulator polypeptide is a cytokine. Cytokinesare a category of small proteins between about 5-20 kDa that areinvolved in cell signaling and include chemokines, interferons (INF),interleukins (IL), and tumor necrosis factors (TNF), among others.Chemokines play a role as a chemoattractant to guide the migration ofcells and are classified into four subfamilies: CXC, CC, CX3C, and XC.Exemplary chemokines include chemokines from the CC subfamily, such asCCL1, CCL2 (MCP-1), CCL3, CCL4, CCL5 (RANTES), CCL6, CCL7, CCL8, CCL9(or CCL10), CCL11, CCL12, CCL13, CCL14, CCL15, CCL16, CCL17, CCL18,CCL19, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, CCL27, andCCL28; the CXC subfamily, such as CXCL1, CXCL2, CXCL3, CXCL4, CXCL5,CXCL6, CXCL7, CXCL8, CXCL9, CXCL10, CXCL11, CXCL12, CXCL13, CXCL14,CXCL15, CXCL16, and CXCL17; the XC subfamily, such as XCL1 and XCL2; andthe CX3C subfamily, such as CX3CL1.

Interferons (IFNs) comprise Type I IFNs e.g. IFN-α, IFN-β, IFN-ε, IFN-κ,and IFN-ω), Type II IFNs (e.g. IFN-γ), and Type III IFNs. In someembodiments, IFN-α is further classified into about 13 subtypesincluding IFNA1, IFNA2, IFNA4, IFNA5, IFNA8, IFNA10, IFNA13, IFNA14,IFNA16, IFNA17, and IFNA21.

Interleukins are a broad class of cytokine that promote the developmentand differentiation of immune cells, including T and B cells, and otherhematopoietic cells. Exemplary interleukins include IL-1, IL-3, IL-5,IL-6, IL-7, IL-8 (CXCL8), IL-9, IL-10, IL-11, IL-12, IL-13, IL-14,IL-15, IL-16, IL-17, IL-18, IL-19, IL-20, IL-21, IL-22, IL-23, IL-24,IL-25, IL-26, IL-27, IL-28, IL-29, IL-30, IL-32, IL-33, IL-35, andIL-36.

Tumor necrosis factors (TNFs) are a group of cytokines that modulateapoptosis. In some instances, there are about 19 members within the TNFfamily, including, not limited to, TNFα, lymphotoxin-alpha (LT-α),lymphotoxin-beta (LT-β), T cell antigen gp39 (CD40L), CD27L, CD30L,FASL, 4-1BBL, OX40L, and TNF-related apoptosis inducing ligand (TRAIL).

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager and an additional nucleic acidsequence that encodes a cytokine selected from chemokine, interferon,interleukin, or tumor necrosis factor. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager molecule and an additional nucleic acid sequence thatencodesa chemokine, an interferon, an interleukin, and/or a tumornecrosis factor.

Co-Stimulatory Domains as Therapeutic Molecules

In some embodiments, the immune modulator polypeptide is aco-stimulatory domain. In some cases, the co-stimulatory domain enhancesantigen-specific cytotoxicity. In some cases, the co-stimulatory domainfurther enhances cytokine production. In some embodiments, theco-stimulatory domain comprises CD27, CD28, CD70, CD80, CD83, CD86,CD134 (OX-40), CD134L (OK-40L), CD137 (41BB), CD137L (41BBL), or CD224.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager and an additional nucleic acidsequence that encodes a co-stimulatory domain. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager and an additional nucleic acid sequence that encodesa co-stimulatory domain selected from CD27, CD28, CD80, CD83, CD86,CD134, CD134L, CD137, CD137L, or CD224.

Immune Checkpoint Inhibitors as Therapeutic Molecules

In some embodiments, the immune modulator polypeptide is an immunecheckpoint inhibitor polypeptide that inhibits a negative regulatorymolecule of T-cell activation. Immune checkpoint inhibitor bind toimmune checkpoint molecules, which are a group of molecules on the cellsurface of CD4 and CD8 T cells. In some instances, these moleculeseffectively serve as “brakes” to down-modulate or inhibit an anti-tumorimmune response. An immune checkpoint inhibitor refers to any moleculethat modulates or inhibits the activity of an immune checkpointmolecule. In some instances, immune checkpoint inhibitors includeantibodies, antibody-derivatives (e.g., Fab fragments, scFvs,minobodies, diabodies), antisense oligonucleotides, siRNA, aptamers, orpeptides.

Exemplary immune checkpoint molecules include, but are not limited to,programmed death-ligand 1 (PDL1, also known as B7-H1, CD274), programmeddeath 1 (PD-1), PD-L2 (B7-DC, CD273), LAG3, TIM3, 2B4, A2aR, B7H1, B7H3,B7H4, BTLA, CD2, CD16, CD27, CD28, CD30, CD40, CD70, CD80, CD86, CD137,CD160, CD226, CD276, DR3, GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2,inducible T cell costimulatory (ICOS), KIR, LAIR1, LIGHT, macrophagereceptor with collageneous structure (MARCO), OX-40, phosphatidylserine(PS), SLAM, TIGHT, VISTA, and VTCN1. In some embodiments, an immunecheckpoint inhibitor inhibits on or more of PDL1, PD-1, CTLA-4, PD-L2,LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28, CD30,CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9, GITR,HAVCR2, HVEM, IDO1, IDO2, ICOS, KIR, LAIR1, LIGHT, MARCO, OX-40, PS,SLAM, TIGHT, VISTA, and VTCN1.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule and an additional nucleicacid sequence that encodes an immune checkpoint inhibitor. In someembodiments, the immune checkpoint inhibitor reduces the expression oractivity of one or more immune checkpoint molecules. In someembodiments, the immune checkpoint inhibitor reduces the interactionbetween an immune checkpoint molecule and its ligand (e.g., reduced theinteraction between PD-1 and PDL1). In some embodiments, a pseudytopedoncolytic virus comprises a nucleic acid sequence that encodes anengager and an additional nucleic acid sequence that encodes an immunecheckpoint inhibitor that inhibits one or more of PDL1, PD-1, CTLA-4,PD-L2, LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27, CD28,CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3, GAL9,GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS, KIR, LAIR1, LIGHT, MARCO, OX-40,PS, SLAM, TIGHT, VISTA, and VTCN1.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain, wherein the therapeuticmolecule domain is an immune checkpoint inhibitor. In some embodiments,a pseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager molecule comprising an activation domain and atherapeutic molecule domain, wherein the therapeutic molecule domain isan immune checkpoint inhibitor that inhibits one or more of PDL1, PD-1,CTLA-4, PD-L2, LAG3, TIM3, 2B4, A2aR, B7H1, B7H3, B7H4, BTLA, CD2, CD27,CD28, CD30, CD40, CD70, CD80, CD86, CD137, CD160, CD226, CD276, DR3,GAL9, GITR, HAVCR2, HVEM, IDO1, IDO2, ICOS, KIR, LAIR1, LIGHT, MARCO,OX-40, PS, SLAM, TIGHT, VISTA, and VTCN1.

a) PDL1 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofPDL1. In some embodiments, the immune checkpoint inhibitor is anantibody (e.g., a monoclonal antibody or antigen-binding fragmentsthereof, or a humanized or chimeric antibody or antigen-bindingfragments thereof) against PDL1. In some embodiments, the inhibitor ofPDL1 reduces the expression or activity of PDL1. In some embodiments,the inhibitor of PDL1 reduces the interaction between PD-1 and PDL1.Exemplary inhibitors of PDL1 include anti-PDL1 antibodies, RNAimolecules (e.g., anti-PDL1 RNAi), antisense molecules (e.g., ananti-PDL1 antisense RNA), or dominant negative proteins (e.g., adominant negative PDL1 protein). Exemplary anti-PDL1 antibodies includesclone EH12; MPDL3280A (Genentech, RG7446); anti-mouse PDL1 antibodyClone 10F.9G2 (BioXcell, Cat # BE0101); anti-PDL1 monoclonal antibodyMDX-1105 (BMS-936559 and BMS-935559 from Bristol-Meyers Squibb;MSB0010718C; mouse anti-PDL1 Clone 29E.2A3; and AstraZeneca's MEDI4736.

In some embodiments, the anti-PDL1 antibody is an anti-PDL1 antibodydisclosed in International PCT Publication Nos. WO 2013/079174; WO2010/036959; WO 2013/056716; WO 2007/005874; WO 2010/089411; WO2010/077634; WO 2004/004771; WO 2006/133396; WO 2013/09906; WO2012/145493; WO 2013/181634; U.S. Patent Application Publication No.20140294898; or Chinese Patent Application Publication No. CN 101104640.

In some embodiments, the PDL1 inhibitor is a nucleic acid inhibitor ofPDL1 expression. In some embodiments, the PDL1 inhibitor is onedisclosed in International PCT Publication Nos. WO 2011/127180 or WO2011/000841. In some embodiments, the PDL1 inhibitor is rapamycin.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to PDL1 (e.g., an anti-PDL1 scFv). In suchembodiments, the pseudytoped oncolytic virus may further comprise anadditional nucleic acid sequence that encodes an additional therapeuticmolecule.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to PDL1. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes a PDL1 inhibitor. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager and an additional nucleic acid sequence that encodesPDL1 inhibitor selected from EH12, Genentech's MPDL3280A (RG7446);Anti-mouse PDL1 antibody Clone 10F.9G2 (Cat # BE0101) from BioXcell;anti-PDL1 monoclonal antibody MDX-1105 (BMS-936559) and BMS-935559 fromBristol-Meyer's Squibb; MSB0010718C; mouse anti-PDL1 Clone 29E.2A3; andAstraZeneca's MEDI4736.

b) PD-L2 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofPD-L2. In some embodiments, the inhibitor of PD-L2 is an antibody (e.g.,a monoclonal antibody or fragments, or a humanized or chimeric antibodyor fragments thereof) against PD-L2. In some embodiments, the inhibitorof PD-L2 reduces the expression or activity of PD-L2. In otherembodiments, the inhibitor of PD-L2 reduces the interaction between PD-1and PD-L2. Exemplary inhibitors of PD-L2 include antibodies (e.g., ananti-PD-L2 antibody), RNAi molecules (e.g., an anti-PD-L2 RNAi),antisense molecules (e.g., an anti-PD-L2 antisense RNA), or dominantnegative proteins (e.g., a dominant negative PD-L2 protein).

In some embodiments, the PD-L2 inhibitor is GlaxoSmithKline's AMP-224(Amplimmune). In some embodiments, the PD-L2 inhibitor is rHIgM12B7.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes a PD-L2 inhibitor. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager and an additional nucleic acid sequence that encodesPD-L2 inhibitor selected from AMP-224 (Amplimmune) or rHIgM12B7.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to PDL2. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to PD-L2 (e.g., an anti-PDL2 scFv). In suchembodiments, the pseudytoped oncolytic virus may further comprise anadditional nucleic acid sequence that encodes an additional therapeuticmolecule.

c) PD-1 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofPD1. In some embodiments, the inhibitor of PDL1 is an antibody (e.g., amonoclonal antibody or fragments, or a humanized or chimeric antibody orfragments thereof) against PD-1. Exemplary antibodies against PD-1include: anti-mouse PD-1 antibody Clone J43 (Cat # BE0033-2) fromBioXcell; anti-mouse PD-1 antibody Clone RMP1-14 (Cat # BE0146) fromBioXcell; mouse anti-PD-1 antibody Clone EH12; Merck's MK-3475anti-mouse PD-1 antibody (Keytruda, pembrolizumab, lambrolizumab); andAnaptysBio's anti-PD-1 antibody, known as ANB011; antibody MDX-1 106(ONO-4538); Bristol-Myers Squibb's human IgG4 monoclonal antibodynivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514, andAMP-224; and Pidilizumab (CT-011), CureTech Ltd.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes a PD1 inhibitor selected from ANB011; antibodyMDX-1 106 (ONO-4538); Bristol-Myers Squibb's human IgG4 monoclonalantibody nivolumab (Opdivo®, BMS-936558, MDX1106); AstraZeneca'sAMP-514, and AMP-224; and Pidilizumab (CT-011). In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager and an additional nucleic acid sequence that encodesPD-1 inhibitor selected from ANB011; antibody MDX-1 106 (ONO-4538);Bristol-Myers Squibb's human IgG4 monoclonal antibody nivolumab(Opdivo®, BMS-936558, MDX1106); AstraZeneca's AMP-514, and AMP-224; andPidilizumab (CT-011).

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes a PD-L2 inhibitor. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager molecule and an additional nucleic acid sequence thatencodes PD-L2 inhibitor selected from AMP-224 (Amplimmune) or rHIgM12B7.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to PD1. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to PD1 (e.g., an anti-PD1 scFv). In suchembodiments, the pseudytoped oncolytic virus may further comprise anadditional nucleic acid sequence that encodes an additional therapeuticmolecule.

d) CTLA-4 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofCTLA-4. In some embodiments, the an inhibitor of CTLA-4 is an antibody(e.g., a monoclonal antibody or fragments, or a humanized or chimericantibody or fragments thereof) against CTLA-4. In one embodiment, theanti-CTLA-4 antibody blocks the binding of CTLA-4 to CD80 (B7-1) and/orCD86 (B7-2) expressed on antigen presenting cells. Exemplary antibodiesagainst CTLA-4 include ipilimumab (also known as Yervoy®, MDX-010,BMS-734016 and MDX-101, Bristol Meyers Squibb); anti-CTLA4 antibodyclone 9H10 from Millipore; tremelimumab (CP-675,206, ticilimumab,Pfizer); and anti-CTLA4 antibody clone BNI3 from Abcam.

In some embodiments, the anti-CTLA-4 antibody is one disclosed in any ofInternational PCT Publication Nos. WO 2001/014424; WO 2004/035607; WO2003/086459; WO 2012/120125; WO 2000/037504; WO 2009/100140; WO2006/09649; WO 2005/092380; WO 2007/123737; WO 2006/029219; WO2010/0979597; WO 2006/12168; WO 1997/020574 U.S. Patent ApplicationPublication No. 2005/0201994; or European Patent Application PublicationNo. EP 1212422. Additional CTLA-4 antibodies are described in U.S. Pat.Nos. 5,811,097; 5,855,887; 5,977,318; 6,051,227; 6,682,736; 6,984,720;7,109,003; 7,132,281; International PCT Publication Nos. WO 01/14424 andWO 00/37504; and in U.S. Patent Application Publication Nos.2002/0039581 and 2002/086014. In some embodiments, the anti-CTLA-4antibody is one disclosed in any of International PCT Publication Nos.WO 1998/42752; U.S. Pat. Nos. 6,682,736 and 6,207,156; Hurwitz et al,Proc. Natl. Acad. Sci. USA, 95(17): 10067-10071 (1998); Camacho et al,J. Clin. Oncol., 22(145): Abstract No. 2505 (2004) (antibody CP-675206);Mokyr et al, Cancer Res., 58:5301-5304 (1998).

In some embodiments, the CTLA-4 inhibitor is a CTLA-4 ligand asdisclosed in International PCT Publication No. WO 1996/040915.

In some embodiments, the CTLA-4 inhibitor is a nucleic acid inhibitor ofCTLA-4 expression, such as an RNAi molecule. In some embodiments,anti-CTLA4 RNAi molecules take the form of those described in any ofInternational PCT Publication Nos. WO 1999/032619 and WO 2001/029058;U.S. Patent Application Publication Nos. 2003/0051263, 2003/0055020,2003/0056235, 2004/265839, 2005/0100913, 2006/0024798, 2008/0050342,2008/0081373, 2008/0248576, and 2008/055443; and/or U.S. Pat. Nos.6,506,559; 7,282,564; 7,538,095; and 7,560,438. In some instances, theanti-CTLA4 RNAi molecules are double stranded RNAi molecules, such asthose disclosed in European Patent No. EP 1309726. In some instances,the anti-CTLA4 RNAi molecules are double stranded RNAi molecules, suchas those described in U.S. Pat. Nos. 7,056,704 and 7,078,196. In someembodiments, the CTLA4 inhibitor is an aptamer, such as those describedin International PCT Publication No. WO 2004/081021, such as Del 60 orM9-14 del 55. Additionally, in some embodiments, the anti-CTLA4 RNAimolecules of the present invention are RNA molecules, such as thosedescribed in U.S. Pat. Nos. 5,898,031, 6,107,094, 7,432,249, and7,432,250, and European Application No. EP 0928290.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes a CTLA-4 inhibitor. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager molecule and an additional nucleic acid sequence thatencodes a CTLA-4 inhibitor selected from ipilimumab (also known asYervoy®, MDX-010, BMS-734016 and MDX-101); anti-CTLA4 Antibody, clone9H10 from Millipore; Pfizer's tremelimumab (CP-675,206, ticilimumab);and anti-CTLA4 antibody clone BNI3 from Abcam.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to CTLA-4. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to CTLA-4 (e.g., an anti-CTLA-4 scFv). Insuch embodiments, the pseudytoped oncolytic virus may further comprisean additional nucleic acid sequence that encodes an additionaltherapeutic molecule.

e) LAG3 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofLAG3 (CD223). In some embodiments, the inhibitor of LAG3 is an antibody(e.g., a monoclonal antibody or fragments, or a humanized or chimericantibody or fragments thereof) against LAG3. In additional embodiments,an antibody against LAG3 blocks the interaction of LAG3 with majorhistocompatibility complex (MHC) class II molecules. Exemplaryantibodies against LAG3 include: anti-Lag-3 antibody clone eBioC9B7W(C9B7W) from eBioscience; anti-Lag3 antibody LS-B2237 from LifeSpanBiosciences; IMP321 (ImmuFact) from Immutep; anti-Lag3 antibodyBMS-986016; and the LAG-3 chimeric antibody A9H12. In some embodiments,the anti-LAG3 antibody is an anti-LAG3 antibody disclosed inInternational PCT Publication Nos. WO 2010/019570; WO 2008/132601; or WO2004/078928.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes LAG3 inhibitor. In some embodiments, a pseudytopedoncolytic virus comprises a nucleic acid sequence that encodes anengager molecule and an additional nucleic acid sequence that encodesLAG3 inhibitor selected from anti-Lag-3 antibody clone eBioC9B7W (C9B7W)from eBioscience; anti-Lag3 antibody LS-B2237 from LifeSpan Biosciences;IMP321 (ImmuFact) from Immutep; anti-Lag3 antibody BMS-986016; and theLAG-3 chimeric antibody A9H12.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to LAG3. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to LAG3 (e.g., an anti-LAG3 scFv). In suchembodiments, the pseudytoped oncolytic virus may further comprise anadditional nucleic acid sequence that encodes an additional therapeuticmolecule.

f) TIM3 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofTIM3. In some embodiments, the inhibitor of TIM3 is an antibody (e.g., amonoclonal antibody or fragments, or a humanized or chimeric antibody orfragments thereof) against TIM3 (also known as HAVCR2). In additionalembodiments, an antibody against TIM3 blocks the interaction of TIM3with galectin-9 (Gal9). In some embodiments, the anti-TIM3 antibody isan anti-TIM3 antibody disclosed in International PCT Publication Nos. WO2013/006490; WO 2011/55607; WO 2011/159877; or WO 2001/17057. In anotherembodiment, a TIM3 inhibitor is a TIM3 inhibitor disclosed inInternational PCT Publication No. WO 2009/052623.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes TIM3 inhibitor. In some embodiments, a pseudytopedoncolytic virus comprises a nucleic acid sequence that encodes anengager molecule and an additional nucleic acid sequence that encodesTIM3 inhibitor such as an antibody against TIM3 blocks the interactionof TIM3 with galectin-9 (Gal9).

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to TIM3. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to LAG3 (e.g., an anti-TIM3 scFv). In suchembodiments, the pseudytoped oncolytic virus may further comprise anadditional nucleic acid sequence that encodes an additional therapeuticmolecule.

g) B7 H3 Inhibitors

In some embodiments, the immune checkpoint inhibitor is an inhibitor ofB7-H3. In some embodiments, the inhibitor of B7-H3 is an antibody (e.g.,a monoclonal antibody or fragments, or a humanized or chimeric antibodyor fragments thereof) against B7-H3. In some embodiments, the inhibitorof B7-H3 is MGA271 (MacroGenics).

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and an antigen recognition domain, and an additional nucleic acidsequence that encodes a B7-H3 inhibitor. In some embodiments, apseudytoped oncolytic virus comprises a nucleic acid sequence thatencodes an engager and an additional nucleic acid sequence that encodesa B7-H3 inhibitor such as MGA271.

In some embodiments, a pseudytoped oncolytic virus comprises a nucleicacid sequence that encodes an engager molecule comprising an activationdomain and a therapeutic molecule domain that binds to B7-H3. In someembodiments, a pseudytoped oncolytic virus comprises a nucleic acidsequence that encodes an engager molecule comprising an activationdomain that binds to CD3 (e.g., an anti-CD3 scFv) and a therapeuticmolecule domain that binds to B7-H3 (e.g., an anti-B7-H3 scFv). In suchembodiments, the pseudytoped oncolytic virus may further comprise anadditional nucleic acid sequence that encodes an additional therapeuticmolecule.

In certain other embodiments, the engager molecule additionallycomprises one or more other domains, e.g., one or more of a cytokine, aco-stimulatory domain, a domain that inhibits negative regulatorymolecules of T-cell activation, or a combination thereof. In alternativeembodiments, the engager is a first polypeptide provided within thepseudotyped oncolytic virus with a second polypeptide having one or moreother domains, e.g., one or more of a cytokine, a co-stimulatory domain,a domain that inhibits negative regulatory molecules of T-cellactivation, or a combination thereof. In some embodiments, the firstpolypeptide and the second polypeptide are encoded in the same vector(e.g., viral vector). In some embodiments, the first polypeptide and thesecond polypeptide are encoded in different vectors (e.g., viralvectors). In specific embodiments, the cytokine is IL-15, IL-2, and/orIL-7. In other specific embodiments, the co-stimulatory domain is CD27,CD80, CD83, CD86, CD134, or CD137. In other specific embodiments, thedomain that inhibits negative regulatory molecules of T-cell activationis PD-1, PDL1, CTLA4, or B7-H4.

Anti-Angiogenic Factors as Therapeutic Molecules

In some embodiments, the therapeutic molecule is a polypeptide such asan anti-angiogenic factor. Angiogenesis or neovascularization is theformation of new microvessels from an established vascular network. Insome instances, the angiogenic process involves communications frommultiple cell types such as endothelial cells (EC) and circulatingendothelial progenitor cells, pericytes, vascular smooth muscle cells,stromal cells, including stem cells, and parenchymal cells. Thesecommunications or interactions occur through secreted factors such asVEGF, fibroblast growth factor (FGF), platelet-derived growth factor(PDGF), or angiopoietins. In some instances, an anti-angiogenic factoris a polypeptide that disrupts one or more of the interactions of thecell types: endothelial cells (EC) and circulating endothelialprogenitor cells, pericytes, vascular smooth muscle cells, stromalcells, including stem cells, and parenchymal cells. In some instances,an anti-angiogenic factor is a polypeptide that disrupts one or more ofthe interactions of secreted factors such as VEGF, fibroblast growthfactor (FGF), platelet-derived growth factor (PDGF) or angiopoietins.

In other embodiments, provided are pseudotyped oncolytic virusescomprising nucleic acids that encode therapeutic polypeptides thatmodulate regulatory T cells. In some instances, regulatory T cellsmaintain the tolerance to self-antigens and in some instances abrogateautoimmune. In some cases, Treg supresses or downregulates induction andproliferation of effector T cells. Exemplary Treg modulatorypolypeptides include CCR4, Helios, TIGIT, GITR, neuropilin, neuritin,CD103, CTLA-4, ICOS, and Swap70.

In other embodiments, provided are pseudotyped oncolytic virusescomprising nucleic acids that encode therapeutic polypeptides thatmodulate myeloid-derived suppressor cells (MDSCs). MDSCs are aheterogenous population of immune cells from the myeloid lineage (acluster of different cell types that originate from bone marrow stemcells), to which also includes dendritic cells, macrophages andneutrophils. In some instances, myeloid cells interact with T cells toregulate the T cell's function. Exemplary MDSC modulatory polypeptidesinclude TGF-βR1, GM-CSF, IFN-γ, Interleukins (e.g., IL-β, IL-1F2, IL-6,IL-10, IL-12, IL-13, IL-6, IL-6Rα, IL-6/IL-6R complex, TGF-01, M-CSF,Prostaglandin E2/PGE2, Prostaglandin E Synthase 2, S100A8, and VEGF.

In other embodiments, provided are pseudotyped oncolytic virusescomprising nucleic acids that encode therapeutic polypeptides thatmodulate the fibrotic stroma. In some embodiments, fibrosis occurs inresponse to inflammation, either chronic or recurrent. Over time, therepeated bouts of inflammation irritate and scar the tissue, causingbuildups of fibrous tissue. In some instances, if enough fibrousmaterial develops, it turns into stromal fibrosis. Exemplary fibroticstromal polypeptides include fibroblast activation protein-alpha (FAP).

Nucleic Acid Polymers as Therapeutic Molecules

In some embodiments, the therapeutic molecule is a nucleic acid polymer.In some instances, the nucleic acid polymer is a RNA polymer. In someinstances, the RNA polymer is an antisense polymer those sequence iscomplementary to a microRNA (miRNA or miR) target sequence. In someinstances, the RNA polymer is a microRNA polymer. In some embodiments,the RNA polymer comprises a DNA-directed RNAi (ddRNAi) sequence, whichenables in vivo production of short hairpin RNAs (shRNAs).

In some embodiments, a microRNA polymer is a short non-coding RNA thatis expressed in different tissue and cell types which suppresses theexpression of a target gene. For example, miRNAs are transcribed by RNApolymerase II as part of the capped and polyadenylated primarytranscripts (pri-miRNAs). In some instances, the primary transcript iscleaved by the Drosha ribonuclease III enzyme to produce anapproximately 70-nt stem-loop precursor miRNA (pre-miRNA), which isfurther cleaved by the cytoplasmic Dicer ribonuclease to generate themature miRNA and antisense miRNA star (miRNA*) products. In someinstances, the mature miRNA is incorporated into a RNA-induced silencingcomplex (RISC), which recognizes target mRNAs through imperfect basepairing with the miRNA and in some instances results in translationalinhibition or destabilization of the target mRNA.

In some instances, dysregulated microRNA expression is correlated withone or more types of cancer. In some embodiments, the microRNA isreferred to as an oncomiR. In some instances, the dysregulated microRNAexpression is an elevated expression. In some instances, the elevatedexpression level of microRNA correlates to one or more types of cancer.For example, overexpression of microRNA-155 (miR-155) has been observedin cancers such as Burkitt lymphoma, or laryngeal squamous cellcarcinoma (LSCC) and overexpression of microRNA-21 (miR-21) has beenobserved in breast cancer.

In some embodiments, exemplary microRNAs with an elevated expressionlevel include, but are not limited to, miR-10 family (e.g., miR-10b),miR-17, miR-21, miR-106 family (e.g., miR-106a), miR-125 family (e.g.,miR-125b), miR-145, miR-146 family (e.g., miR-146a, miR-146b), miR-155,miR-96, miR-182, miR-183, miR-221, miR-222, and miR-1247-5p.

In some instances, the nucleic acid polymer is an antisense polymerthose sequence complements an oncomiR. In some instances, the nucleicacid polymer is an antisense polymer those sequence complements anoncomiR that is characterized with an overexpression. In some instances,the nucleic acid polymer is an antisense polymer those sequencecomplements a microRNA target sequence. In some instances, the nucleicacid polymer is an antisense polymer those sequence complements amicroRNA target sequence that is characterized with an overexpression.In some instances, the therapeutic molecule is an antisense polymerthose sequence complements a microRNA target sequence. In someinstances, the therapeutic molecule is an antisense polymer thosesequence complements a microRNA target sequence that is characterizedwith an overexpression. In some instances, the overexpression level isrelative to the endogenous expression level of the microRNA.

In some instances, the dysregulated microRNA expression is a reducedexpression. In some instances, the reduced expression level of microRNAcorrelates to one or more types of cancer. For example, a depleted levelof miR-31 has been observed in both human and mouse metastatic breastcancer cell lines.

In some embodiments, exemplary microRNAs with reduced expression levelsinclude, but are not limited to, miR-31, miR-34 family (e.g., miR34a,miR-34b, and miR-34c), miR-101, miR-126, miR-145, miR-196a, and themiR-200 family.

In some instances, the nucleic acid polymer is an oncomiR. In someinstances, the oncomiR is equivalent to an endogeous oncomiR wherein theendogeous oncomiR is characterized with a reduced expression level. Insome instances, the nucleic acid polymer is a microRNA polymer. In someinstances, the therapeutic molecule is a microRNA polymer. In someinstances, the microRNA is equivalent to an endogeous microRNA polymerwherein the endogenous microRNA is characterized with a reducedexpression level.

As described above, in some instances the RNA polymer comprises aDNA-directed RNAi (ddRNAi) sequence. In some instances, a ddRNAiconstruct encoding a shRNA is packaged into a viral vector such as aviral vector of a pseudotyped oncolytic virus described herein. In someinstances upon entry into the target cell (e.g., a tumor cell), theviral genome is processed to produce the encoded shRNAs. The shRNAs arethen processed by endogenous host systems and enter the RNAi pathway tomodulate or silence the desired gene target. In some instances, the genetarget is a gene that is overexpressed in a cancer type. In someinstances, the gene target is a gene that is overexpressed in a solidtumor. In some instances, the gene target is a gene that isoverexpressed in a hematologic cancer. Exemplary genes that areoverexpressed in cancer include, but are not limited to, TP53, humanepidermal growth factor receptor 2 (HER2), mucin 1-cell surfaceassociated (MUC1), human pituitary tumour-transforming gene 1 (hPPTG1),prostate and breast cancer overexpressed gene 1 protein (PBOV1), and thelike.

In some instances, the nucleic acid polymer comprises a ddRNAi sequence.In some instances, the nucleic acid polymer is comprises a ddRNAisequence which targets a gene that is overexpressed in a cancer. In someinstances, the therapeutic molecule comprises a ddRNAi sequence. In someinstances, the therapeutic molecule comprises a ddRNAi sequence whichtargets a gene that is overexpressed in a cancer.

Exemplary Engager Molecules

In some embodiments, the engager molecules described herein comprise abi-specific antibody construct comprising an activation domain and anantigen recognition domain, in which the activation domain interacts orbinds to an effector cell surface receptor shown in Table 1; and theantigen recognition domain interacts or binds to a target-cell antigenshown in Table 2 In some embodiments, the engager molecules describedherein comprise a bi-specific antibody construct comprising anactivation domain and a therapeutic molecule domain, in which theactivation domain interacts or binds to an effector cell surfacereceptor shown in Table 1; and the therapeutic molecule domain interactsor binds to a cell surface antigen shown in Table 2.

In some embodiments, the engager molecules provided herein comprise anactivation domain, wherein the activation domain comprises an anti-CD3scFv. In some embodiments, the anti-CD3 scFv comprises a light chainvariable fragment comprising an amino acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the amino acid sequenceof SEQ ID NO: 20 and a heavy chain variable fragment comprising an aminoacid sequence that is at least 80%, at least, 85%, at least 90%, atleast 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the amino acid sequence of SEQ ID NO: 22. In someembodiments, the anti-CD3 scFv comprises a light chain variable fragmentcomprising an amino acid sequence that is 100% identical to the aminoacid sequence of SEQ ID NO: 20 and a heavy chain variable fragment thatis 100% identical to the amino acid sequence of SEQ ID NO: 22. In someembodiments, the anti-CD3 scFv comprises a light chain variable fragmentcomprising the amino acid sequence of SEQ ID NO: 20 and a heavy chainvariable fragment comprising the amino acid sequence of of SEQ ID NO:22. In some embodiments, the anti-CD3 scFv comprises a light chainvariable fragment consisting of the amino acid sequence of SEQ ID NO: 20and a heavy chain variable fragment consisting of the amino acidsequence of of SEQ ID NO: 22.

In some embodiments, the engager molecules provided herein comprise anactivation domain, wherein the activation domain comprises an anti-CD3scFv, wherein the anti-CD3 scFv comprises a light chain variablefragment nucleic acid sequence that is at least 80%, at least, 85%, atleast 90%, at least 95%, at least 96%, at least 97%, at least 98%, or atleast 99% identical to the nucleic acid sequence of SEQ ID NO: 19 and aheavy chain variable fragment nucleic acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the nucleic acidsequence of SEQ ID NO: 21. In some embodiments, the anti-CD3 scFvcomprises a light chain variable fragment nucleic acid sequence that is100% identical to the nucleic acid sequence of SEQ ID NO: 19 and a heavychain variable fragment nucleic acid sequence that is 100% identical tothe amino acid sequence of SEQ ID NO: 21. In some embodiments, theanti-CD3 scFv comprises a light chain variable fragment nucleic acidsequence comprising SEQ ID NO: 19 and a heavy chain variable fragmentnucleic acid sequence comprising SEQ ID NO: 21. In some embodiments, theanti-CD3 scFv comprises a light chain variable fragment nucleic acidsequence consisting of SEQ ID NO: 19 and a heavy chain variable fragmentnucleic acid sequence consisting of SEQ ID NO: 21.

In some embodiments, the engager molecules provided herein comprise anantigen recognition domain, wherein the antigen recognition domaincomprises an anti-CD19 scFv. In some embodiments, the anti-CD19 scFvcomprises a light chain variable fragment comprising an amino acidsequence that is at least 80%, at least, 85%, at least 90%, at least95%, at least 96%, at least 97%, at least 98%, or at least 99% identicalto the amino acid sequence of SEQ ID NO: 16 and a heavy chain variablefragment comprising an amino acid sequence that is at least 80%, atleast, 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identical to the amino acid sequence of SEQID NO: 18. In some embodiments, the anti-CD19 scFv comprises a lightchain variable fragment comprising an amino acid sequence that is 100%identical to the amino acid sequence of SEQ ID NO: 16 and a heavy chainvariable fragment that is 100% identical to the amino acid sequence ofSEQ ID NO: 18. In some embodiments, the anti-CD19 scFv comprises a lightchain variable fragment comprising the amino acid sequence of SEQ ID NO:16 and a heavy chain variable fragment comprising the amino acidsequence of of SEQ ID NO: 18. In some embodiments, the anti-CD19 scFvcomprises a light chain variable fragment consisting of the amino acidsequence of SEQ ID NO: 16 and a heavy chain variable fragment consistingof the amino acid sequence of of SEQ ID NO: 18.

In some embodiments, the engager molecules provided herein comprise anantigen recognition domain, wherein the antigen recognition domaincomprises an anti-CD19 scFv, wherein the anti-CD19 scFv comprises alight chain variable fragment nucleic acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the nucleic acidsequence of SEQ ID NO: 15 and a heavy chain variable fragment nucleicacid sequence that is at least 80%, at least, 85%, at least 90%, atleast 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the nucleic acid sequence of SEQ ID NO: 17. In someembodiments, the anti-CD19 scFv comprises a light chain variablefragment nucleic acid sequence that is 100% identical to the nucleicacid sequence of SEQ ID NO: 15 and a heavy chain variable fragmentnucleic acid sequence that is 100% identical to the amino acid sequenceof SEQ ID NO: 17. In some embodiments, the anti-CD19 scFv comprises alight chain variable fragment nucleic acid sequence comprising SEQ IDNO: 15 and a heavy chain variable fragment nucleic acid sequencecomprising SEQ ID NO: 17. In some embodiments, the anti-CD19 scFvcomprises a light chain variable fragment nucleic acid sequenceconsisting of SEQ ID NO: 15 and a heavy chain variable fragment nucleicacid sequence consisting of SEQ ID NO: 17.

In some embodiments, the engager molecules provided herein comprise atherapeutic molecule domain, wherein the therapeutic molecule domaincomprises an anti-PDL1 scFv. In some embodiments, the anti-PDL1 scFvcomprises a light chain variable fragment comprising an amino acidsequence that is at least 80%, at least, 85%, at least 90%, at least95%, at least 96%, at least 97%, at least 98%, or at least 99% identicalto the amino acid sequence of SEQ ID NO: 36 and a heavy chain variablefragment comprising an amino acid sequence that is at least 80%, atleast, 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identical to the amino acid sequence of SEQID NO: 38. In some embodiments, the anti-PDL1 scFv comprises a lightchain variable fragment comprising an amino acid sequence that is 100%identical to the amino acid sequence of SEQ ID NO: 36 and a heavy chainvariable fragment that is 100% identical to the amino acid sequence ofSEQ ID NO: 38. In some embodiments, the anti-PDL1 scFv comprises a lightchain variable fragment comprising the amino acid sequence of SEQ ID NO:36 and a heavy chain variable fragment comprising the amino acidsequence of of SEQ ID NO: 38. In some embodiments, the anti-PDL1 scFvcomprises a light chain variable fragment consisting of the amino acidsequence of SEQ ID NO: 36 and a heavy chain variable fragment consistingof the amino acid sequence of of SEQ ID NO: 38.

In some embodiments, the engager molecules provided herein comprise atherapeutic molecule domain, wherein the therapeutic molecule domaincomprises an anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises alight chain variable fragment nucleic acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the nucleic acidsequence of SEQ ID NO: 35 and a heavy chain variable fragment nucleicacid sequence that is at least 80%, at least, 85%, at least 90%, atleast 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the nucleic acid sequence of SEQ ID NO: 37. In someembodiments, the anti-PDL1 scFv comprises a light chain variablefragment nucleic acid sequence that is 100% identical to the nucleicacid sequence of SEQ ID NO: 35 and a heavy chain variable fragmentnucleic acid sequence that is 100% identical to the amino acid sequenceof SEQ ID NO: 37. In some embodiments, the anti-PDL1 scFv comprises alight chain variable fragment nucleic acid sequence comprising SEQ IDNO: 35 and a heavy chain variable fragment nucleic acid sequencecomprising SEQ ID NO: 37. In some embodiments, the anti-PDL1 scFvcomprises a light chain variable fragment nucleic acid sequenceconsisting of SEQ ID NO: 35 and a heavy chain variable fragment nucleicacid sequence consisting of SEQ ID NO: 37.

In some embodiments, the engager molecules provided herein comprise atherapeutic molecule domain, wherein the therapeutic molecule domaincomprises a SIRP1α polypeptide fragment. In some embodiments, the SIRP1αpolypeptide fragment comprises an amino acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the amino acid sequenceof SEQ ID NO: 32. In some embodiments, the SIRP1α polypeptide fragmentcomprises an amino acid sequence that is 100% identical to the aminoacid sequence of SEQ ID NO: 32. In some embodiments, the SIRP1αpolypeptide fragment comprises the amino acid sequence of SEQ ID NO: 32.In some embodiments, the SIRP1α polypeptide fragment consists of theamino acid sequence of SEQ ID NO: 32.

In some embodiments, the engager molecules provided herein comprise atherapeutic molecule domain, wherein the therapeutic molecule domaincomprises a SIRP1α polypeptide fragment, wherein the SIRP1α polypeptidefragment comprises a nucleic acid sequence that is at least 80%, atleast, 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identical to the nucleic acid sequence of SEQID NO: 31. In some embodiments, the SIRP1α polypeptide fragmentcomprises a nucleic acid sequence that is 100% identical to the nucleicacid sequence of SEQ ID NO: 31. In some embodiments, the SIRP1αpolypeptide fragment comprises the nucleic acid sequence of SEQ ID NO:31. In some embodiments, the SIRP1α polypeptide fragment consists of thenucleic acid sequence of SEQ ID NO: 31.

In some embodiments, the engager molecules comprise an activation domaincomprising an scFv that binds to CD3 and an antigen recognition domaincomprising an scFv that binds to CD19, referred to herein as a CD19-CD3BiTE, or a CD19 BiTE. A schematic of an exemplary CD19-CD3 BiTE is shownin FIG. 1 (SEQ ID NO: 44). In such embodiments, the anti-CD3 scFv andthe anti-CD19 scFv are linked together by a G45 linker (SEQ ID NO: 6).In some embodiments, the oncolytic viruses described herein comprise abicistronic or multicistronic nucleic acid sequence, wherein a firstnucleic acid sequence encodes a CD19-CD3 BiTE and a second nucleic acidsequence encodes a therapeutic molecule such as IL-15 (FIG. 2, SEQ IDNO: 53), IL-12 (FIG. 3, SEQ ID NO: 54), or CXCL10 (FIG. 4, SEQ ID NO:55). In such embodiments, the CD19-CD3 BiTE (e.g., SEQ ID NO: 44) islinked to the therapeutic molecule, e.g., IL-15 (SEQ ID NO: 24), IL-12p35 (SEQ ID NO: 28), IL-12 p40 (SEQ ID NO: 26), and/or CXCL10 (SEQ IDNO: 30), by a T2A self-cleaving peptide linker (SEQ ID NO: 14).

In some embodiments, the engager molecules comprise an activation domaincomprising an scFv that binds to CD3 and a therapeutic molecule domaincomprising a SIRP1α polypeptide fragment that binds to CD47 (SEQ ID NO:32), referred to herein as an SIRP1α-CD3 BiTE or a SIRP1α BiTE. Aschematic of an exemplary SIRP1α-CD3 BiTE is shown in FIG. 5 (SIRP1α-CD3(SL), SEQ ID NO: 46) and FIG. 6 (SIRP1α-CD3 (LL), SEQ ID NO: 48). Insome embodiments, the anti-CD3 scFv and the SIRP1α peptide fragment arelinked together by a single amino acid linker, or a “short linker” (SL)(e.g., SIRP1α-CD3 (SL) as shown in FIG. 5). In some embodiments, theanti-CD3 scFv and the SIRP1α peptide fragment are linked together by G45linker, or a “long linker” (LL) (e.g., SIRP1α-CD3 (LL) as shown in FIG.6). In some embodiments, the oncolytic viruses described herein comprisea bicistronic or multicistronic nucleic acid sequence, wherein a firstnucleic acid sequence encodes a SIRP1α-CD3 BiTE and a second nucleicacid sequence encodes a therapeutic molecule such as IL-15 (FIG. 7, SEQID NO: 56 and FIG. 8, SEQ ID NO: 57), IL-12 (FIG. 9, SEQ ID NO: 58 andFIG. 10, SEQ ID NO: 59), or CXCL10 (FIG. 11, SEQ ID NO: 60 and FIG. 12,SEQ ID NO: 61). In such embodiments, the SIRP1α-CD3 BiTE (e.g., SEQ IDNO: 46 or SEQ ID NO: 48) is linked to the therapeutic molecule, e.g.,IL-15 (SEQ ID NO: 24), IL-12 p35 (SEQ ID NO: 28), IL-12 p40 (SEQ ID NO:26), and/or CXCL10 (SEQ ID NO: 30), by a T2A self-cleaving peptidelinker (SEQ ID NO: 14).

In some embodiments, the oncolytic viruses described herein comprise abicistronic or multicistronic nucleic acid sequence, wherein a firstnucleic acid sequence encodes a SIRP1α-CD3 BiTE and a second nucleicacid sequence encodes a therapeutic molecule such as MMP9 (FIG. 18A, SEQID NO: 65 and FIG. 18B, SEQ ID NO: 66). In such embodiments, theSIRP1α-CD3 BiTE (e.g., SEQ ID NO: 65 or 66) is linked to the MMP9polypeptide (SEQ ID NO: 34) by a T2A self-cleaving peptide linker (SEQID NO: 14).

In some embodiments, the oncolytic viruses described herein comprise abicistronic or multicistronic nucleic acid sequence, wherein a firstnucleic acid sequence encodes a SIRP1α-CD3 BiTE and a second nucleicacid sequence encodes a therapeutic molecule comprising an anti-PDL1scFv linked to an IgG1 Fc domain (e.g., comprises an IgG1 CH2-CH3-Hinge,SEQ ID NO: 40), such as the SIRP1α-CD3-PDL1-Fc (SL) construct shown inFIG. 37 (SEQ ID NO: 68) or the SIRP1α-CD3-PDL1-Fc (LL) construct show inFIG. 38 (SEQ ID NO: 70).

In some embodiments, the engager molecules comprise an activation domaincomprising an scFv that binds to CD3 and a therapeutic molecule domaincomprising an scFv that binds to PDL1, referred to herein as an PDL1-CD3BiTE or a PDL1 BiTE. Exemplary PDL1-CD3 BiTEs are shown in FIG. 13 (SEQID NO: 50). In some embodiments, the anti-CD3 scFv and the anti-PDL1scFv are linked together by G45 linker (SEQ ID NO: 6). In someembodiments, the oncolytic viruses described herein comprise abicistronic or multicistronic nucleic acid sequence, wherein a firstnucleic acid sequence encodes a PDL1-CD3 BiTE and a second nucleic acidsequence encodes a therapeutic molecule such as IL-15 (FIG. 14, SEQ IDNO: 62), IL-12 (FIG. 15, SEQ ID NO: 63), or CXCL10 (FIG. 16, SEQ ID NO:64). In such embodiments, the SIRP1α-CD3 BiTE (e.g., SEQ ID NO: 50) islinked to the therapeutic molecule, e.g., IL-15 (SEQ ID NO: 24), IL-12p35 (SEQ ID NO: 28), IL-12 p40 (SEQ ID NO: 26), and/or CXCL10 (SEQ IDNO: 30), by a T2A self-cleaving peptide linker (SEQ ID NO: 14).

In some embodiments, the engager molecule is a tripartite engagermolecule and comprises an activation domain comprising an scFv thatbinds to CD3, a therapeutic molecule domain comprising an scFv thatbinds to PDL1, and a third domain comprising an IgG1 Fc domain (e.g.,comprises an IgG1 CH2-CH3-Hinge, SEQ ID NO: 40) and capable of bindingto one or more FcγRs, referred to herein as an PDL1-CD3-Fc tripartite Tcell engager, or TiTE, or a PDL1 TiTE. A schematic of an exemplaryPDL1-CD3-Fc TiTE is shown in FIG. 17 (SEQ ID NO: 52).

The amino acid sequences of exemplary engager molecules and therapeuticmolecules are shown in Table 3.

TABLE 3Amino acid sequences of exemplary engager molecules and therapeutic moleculesSEQ ID BiTE Amino Acid Sequence NO: CD19-CD3MEFGLSWVFLVALFRGVQCDIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNW 44YQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHH H- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 46 CD3-SLWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSASDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 48 CD3-LLWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSASGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH- PDL1-CD3MEFGLSWVFLVALFRGVQCDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQ 50RPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAHHHHHH- PDL1-CD3-MEFGLSWVFLVALFRGVQCDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQ 52 FcRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAVDEAKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGHHHHHH- CD19-CD3-MEFGLSWVFLVALFRGVQCDIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNW 53 IL15YQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSF VHIVQMFINTS-CD19-CD3- MEFGLSWVFLVALFRGVQCDIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNW 54IL12 YQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMWPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASRRKREGRGSLLTCGDVEENPGPPMCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYESLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS- CD19-CD3-MEFGLSWVFLVALFRGVQCDIQLTQSPASLAVSLGQRATISCKASQSVDYDGDSYLNW 55 CXCL10YQQIPGQPPKLLIYDASNLVSGIPPRFSGSGSGTDFTLNIHPVEKVDAATYHCQQSTEDPWTFGGGTKLEIKGGGGSGGGGSGGGGSQVQLQQSGAELVRPGSSVKISCKASGYAFSSYWMNWVKQRPGQGLEWIGQIWPGDGDTNYNGKFKGKATLTADESSSTAYMQLSSLASEDSAVYFCARRETTTVGRYYYAMDYWGQGTTVTVSSGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKER SKRSP-SIRP1α- METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 56CD3-IL15 WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR (SL)KGSPDDVEFKSGAGTELSVRAKPSASDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINTS- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 57 CD3-IL15WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR (LL)KGSPDDVEFKSGAGTELSVRAKPSASGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFINT S- SIRP1α-C3-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 58 IL12(SL)WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSASDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMWPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASRRKREGRGSLLTCGDVEENPGPPMCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 59 CD3-IL12WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR (LL)KGSPDDVEFKSGAGTELSVRAKPSASGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMWPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASRRKREGRGSLLTCGDVEENPGPPMCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYFSLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 60 CD3-WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR CXCL10KGSPDDVEFKSGAGTELSVRAKPSASDIKLQQSGAELARPGASVKMSCKTSGYTFTRY (SL)TMHWVKQRPCQCLEWICYINPSRCYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 61 CD3-WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR CXCL10KGSPDDVEFKSGAGTELSVRAKPSASGGGGSDIKLQQSGAELARPGASVKMSCKTSGY (LL)TFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP- PDL1-CD3-MEFGLSWVFLVALFRGVQCDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQ 62 IL15RPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAHHHHHHRRKREGRGSLLTCGDVEENPGPMRISKPHLRSISIQCYLCLLLNSHFLTEAGIHVFILGCFSAGLPKTEANWVNVISDLKKIEDLIQSMHIDATLYTESDVHPSCKVTAMKCFLLELQVISLESGDASIHDTVENLIILANNSLSSNGNVTESGCKECEELEEKNIKEFLQSFVHIVQMFIN TS- PDL1-CD3-MEFGLSWVFLVALFRGVQCDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQ 63 IL12RPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKGGGGSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGETFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAHHHHHHRRKREGRGSLLTCGDVEENPGPMWPPGSASQPPPSPAAATGLHPAARPVSLQCRLSMCPARSLLLVATLVLLDHLSLARNLPVATPDPGMFPCLHHSQNLLRAVSNMLQKARQTLEFYPCTSEEIDHEDITKDKTSTVEACLPLELTKNESCLNSRETSFITNGSCLASRKTSFMMALCLSSIYEDLKMYQVEFKTMNAKLLMDPKRQIFLDQNMLAVIDELMQALNFNSETVPQKSSLEEPDFYKTKIKLCILLHAFRIRAVTIDRVMSYLNASRRKREGRGSLLTCGDVEENPGPPMCHQQLVISWFSLVFLASPLVAIWELKKDVYVVELDWYPDAPGEMVVLTCDTPEEDGITWTLDQSSEVLGSGKTLTIQVKEFGDAGQYTCHKGGEVLSHSLLLLHKKEDGIWSTDILKDQKEPKNKTFLRCEAKNYSGRFTCWWLTTISTDLTFSVKSSRGSSDPQGVTCGAATLSAERVRGDNKEYEYSVECQEDSACPAAEESLPIEVMVDAVHKLKYENYTSSFFIRDIIKPDPPKNLQLKPLKNSRQVEVSWEYPDTWSTPHSYESLTFCVQVQGKSKREKKDRVFTDKTSATVICRKNASISVRAQDRYYSSSWSEWASVPCS- PDL1-CD3-MEFGLSWVFLVALFRGVQCDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQ 64 CXCL10RPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFCACTKLELKCCCCSDIQMTQSPSSLSASVGDRVTITCRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPEDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGETFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAHHHHHHRRKREGRGSLLTCGDVEENPGPMNQTAILICCLIFLTLSGIQGVPLSRTVRCTCISISNQPVNPRSLEKLEIIPASQFCPRVEIIATMKKKGEKRCLNPESKAIKNLLKAVSKERSKRSP- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 65 CD3-MMP9WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR (SL)KGSPDDVEFKSGAGTELSVRAKPSASDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEEPLSKKLFEESGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED- SIRP1α-METDTLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQ 66 CD3-MMP9WFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFR (LL)KGSPDDVEFKSGAGTELSVRAKPSASGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHHRRKREGRGSLLTCGDVEENPGPMSLWQPLVLVLLVLGCCFAAPRQRQSTLVLFPGDLRTNLTDRQLAEEYLYRYGYTRVAEMRGESKSLGPALLLLQKQLSLPETGELDSATLKAMRTPRCGVPDLGRFQTFEGDLKWHHHNITYWIQNYSEDLPRAVIDDAFARAFALWSAVTPLTFTRVYSRDADIVIQFGVAEHGDGYPFDGKDGLLAHAFPPGPGIQGDAHFDDDELWSLGKGVVVPTRFGNADGAACHFPFIFEGRSYSACTTDGRSDGLPWCSTTANYDTDDRFGFCPSERLYTRDGNADGKPCQFPFIFQGQSYSACTTDGRSDGYRWCATTANYDRDKLFGFCPTRADSTVMGGNSAGELCVFPFTFLGKEYSTCTSEGRGDGRLWCATTSNFDSDKKWGFCPDQGYSLFLVAAHEFGHALGLDHSSVPEALMYPMYRFTEGPPLHKDDVNGIRHLYGPRPEPEPRPPTTTTPQPTAPPTVCPTGPPTVHPSERPTAGPTGPPSAGPTGPPTAGPSTATTVPLSPVDDACNVNIFDAIAEIGNQLYLFKDGKYWRFSEGRGSRPQGPFLIADKWPALPRKLDSVFEEPLSKKLFFFSGRQVWVYTGASVLGPRRLDKLGLGADVAQVTGALRSGRGKMLLFSGRRLWRFDVKAQMVDPRSASEVDRMFPGVPLDTHDVFQYREKAYFCQDRFYWRVSSRSELNQVDQVGYVTYDILQCPED- SIRP1α-METDRLLLWVLLLWVPGSTGDYPYDVPDYAGAQPADDIQMTQSPSSLSASVGDRVTIT 68 CD3-PDL1-CRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQP Fc(SL)EDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAVDEAKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKVDEQKLISEEDLNRRKREGRGSLLTCGDVEENPGPMETDRLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSASDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKL ELKHHHHHH-SIRP1α- METDRLLLWVLLLWVPGSTGDYPYDVPDYAGAQPADDIQMTQSPSSLSASVGDRVTIT 70CD3-PDL1- CRASQDVSTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSGSGTDFTLTISSLQPFc(LL) EDFATYYCQQYLYHPATFGQGTKVEIKRGGGGSGGGGSGGGGSEVQLVESGGGLVQPGGSLRLSCAASGFTFSDSWIHWVRQAPGKGLEWVAWISPYGGSTYYADSVKGRFTISADTSKNTAYLQMNSLRAEDTAVYYCARRHWPGGFDYWGQGTLVTVSAVDEAKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGKVDEQKLISEEDLNRRKREGRGSLLTCGDVEENPGPMETDRLLLWVLLLWVPGSTGDEEELQIIQPDKSVLVAAGETATLRCTITSLFPVGPIQWFRGAGPGRVLIYNQRQGPFPRVTTVSDTTKRNNMDFSIRIGNITPADAGTYYCIKFRKGSPDDVEFKSGAGTELSVRAKPSASGGGGSDIKLQQSGAELARPGASVKMSCKTSGYTFTRYTMHWVKQRPGQGLEWIGYINPSRGYTNYNQKFKDKATLTTDKSSSTAYMQLSSLTSEDSAVYYCARYYDDHYCLDYWGQGTTLTVSSVEGGSGGSGGSGGSGGVDDIQLTQSPAIMSASPGEKVTMTCRASSSVSYMNWYQQKSGTSPKRWIYDTSKVASGVPYRFSGSGSGTSYSLTISSMEAEDAATYYCQQWSSNPLTFGAGTKLELKHHHHHH-

In some embodiments, the present invention provides recombinant nucleicacid sequences encoding an engager molecule and/or a therapeuticmolecule. Exemplary recombinant nucleic acid sequences are shown inTable 4.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule, wherein the therapeutic molecule is IL-15. In someembodiments, the nucleic acid sequences provided herein encode an IL-15therapeutic molecule comprising an amino acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the amino acid sequenceof SEQ ID NO: 24. In some embodiments, the nucleic acid sequencesprovided herein encode an IL-15 therapeutic molecule that is 100%identical to the amino acid sequence of SEQ ID NO: 24. In someembodiments, the nucleic acid sequences provided herein encode an IL-15therapeutic molecule comprising the amino acid sequence of SEQ ID NO:24. In some embodiments, the nucleic acid sequences provided hereinencode an IL-15 therapeutic molecule consisting of the amino acidsequence of SEQ ID NO: 24. In some embodiments, the nucleic acidsequences provided herein encode an IL-15 therapeutic molecule andcomprise a sequence that is at least 80%, at least, 85%, at least 90%,at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the nucleic acid sequence of SEQ ID NO: 23. In someembodiments, the nucleic acid sequences provided herein encode an IL-15therapeutic molecule and comprise the nucleic acid sequence of SEQ IDNO: 23. In some embodiments, the nucleic acid sequences provided hereinencode an IL-15 therapeutic molecule and consist of the nucleic acidsequence of SEQ ID NO: 23.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule, wherein the therapeutic molecule is IL-12 (i.e.,IL-12 p35 and/or IL-12 p40). In some embodiments, the nucleic acidsequences provided herein encode an IL-12 therapeutic moleculecomprising an amino acid sequence that is at least 80%, at least, 85%,at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, orat least 99% identical to the amino acid sequence of SEQ ID NO: 26. Insome embodiments, the nucleic acid sequences provided herein encode anIL-12 therapeutic molecule that is 100% identical to the amino acidsequence of SEQ ID NO: 26. In some embodiments, the nucleic acidsequences provided herein encode an IL-12 therapeutic moleculecomprising the amino acid sequence of SEQ ID NO: 26. In someembodiments, the nucleic acid sequences provided herein encode an IL-12therapeutic molecule consisting of the amino acid sequence of SEQ ID NO:26. In some embodiments, the nucleic acid sequences provided hereinencode an IL-12 therapeutic molecule and comprise a sequence that is atleast 80%, at least, 85%, at least 90%, at least 95%, at least 96%, atleast 97%, at least 98%, or at least 99% identical to the nucleic acidsequence of SEQ ID NO: 25. In some embodiments, the nucleic acidsequences provided herein encode an IL-12 therapeutic molecule andcomprise the nucleic acid sequence of SEQ ID NO: 25. In someembodiments, the nucleic acid sequences provided herein encode an IL-12therapeutic molecule and consist of the nucleic acid sequence of SEQ IDNO: 25.

In some embodiments, the nucleic acid sequences provided herein encodean IL-12 therapeutic molecule comprising an amino acid sequence that isat least 80%, at least, 85%, at least 90%, at least 95%, at least 96%,at least 97%, at least 98%, or at least 99% identical to the amino acidsequence of SEQ ID NO: 28. In some embodiments, the nucleic acidsequences provided herein encode an IL-12 therapeutic molecule that is100% identical to the amino acid sequence of SEQ ID NO: 28. In someembodiments, the nucleic acid sequences provided herein encode an IL-12therapeutic molecule comprising the amino acid sequence of SEQ ID NO:28. In some embodiments, the nucleic acid sequences provided hereinencode an IL-12 therapeutic molecule consisting of the amino acidsequence of SEQ ID NO: 28. In some embodiments, the nucleic acidsequences provided herein encode an IL-12 therapeutic molecule andcomprise a sequence that is at least 80%, at least, 85%, at least 90%,at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the nucleic acid sequence of SEQ ID NO: 27. In someembodiments, the nucleic acid sequences provided herein encode an IL-12therapeutic molecule and comprise the nucleic acid sequence of SEQ IDNO: 27. In some embodiments, the nucleic acid sequences provided hereinencode an IL-12 therapeutic molecule and consist of the nucleic acidsequence of SEQ ID NO: 27.

In some embodiments, the nucleic acid sequences provided herein encodean IL-12 therapeutic molecule comprising an amino acid sequence of SEQID NO: 26 and 28. In some embodiments, the nucleic acid sequencesprovided herein encode an IL-12 therapeutic molecule and comprise thenucleic acid sequences of SEQ ID NO: 25 and 27.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule, wherein the therapeutic molecule is CXCL10. Insome embodiments, the nucleic acid sequences provided herein encode aCXCL10 therapeutic molecule comprising an amino acid sequence that is atleast 80%, at least, 85%, at least 90%, at least 95%, at least 96%, atleast 97%, at least 98%, or at least 99% identical to the amino acidsequence of SEQ ID NO: 30. In some embodiments, the nucleic acidsequences provided herein encode a CXCL10 therapeutic molecule that is100% identical to the amino acid sequence of SEQ ID NO: 30. In someembodiments, the nucleic acid sequences provided herein encode a CXCL10therapeutic molecule comprising the amino acid sequence of SEQ ID NO:30. In some embodiments, the nucleic acid sequences provided hereinencode a CXCL10 therapeutic molecule consisting of the amino acidsequence of SEQ ID NO: 30. In some embodiments, the nucleic acidsequences provided herein encode a CXCL10 therapeutic molecule andcomprise a sequence that is at least 80%, at least, 85%, at least 90%,at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the nucleic acid sequence of SEQ ID NO: 29. In someembodiments, the nucleic acid sequences provided herein encode a CXCL10therapeutic molecule and comprise the nucleic acid sequence of SEQ IDNO: 29. In some embodiments, the nucleic acid sequences provided hereinencode a CXCL10 therapeutic molecule and consist of the nucleic acidsequence of SEQ ID NO: 29.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule, wherein the therapeutic molecule is MMP9. In someembodiments, the nucleic acid sequences provided herein encode an MMP9therapeutic molecule comprising an amino acid sequence that is at least80%, at least, 85%, at least 90%, at least 95%, at least 96%, at least97%, at least 98%, or at least 99% identical to the amino acid sequenceof SEQ ID NO: 34. In some embodiments, the nucleic acid sequencesprovided herein encode an MMP9 therapeutic molecule that is 100%identical to the amino acid sequence of SEQ ID NO: 34. In someembodiments, the nucleic acid sequences provided herein encode an MMP9therapeutic molecule comprising the amino acid sequence of SEQ ID NO:34. In some embodiments, the nucleic acid sequences provided hereinencode an MMP9 therapeutic molecule consisting of the amino acidsequence of SEQ ID NO: 34. In some embodiments, the nucleic acidsequences provided herein encode an MMP9 therapeutic molecule andcomprise a sequence that is at least 80%, at least, 85%, at least 90%,at least 95%, at least 96%, at least 97%, at least 98%, or at least 99%identical to the nucleic acid sequence of SEQ ID NO: 33. In someembodiments, the nucleic acid sequences provided herein encode an MMP9therapeutic molecule and comprise the nucleic acid sequence of SEQ IDNO: 33. In some embodiments, the nucleic acid sequences provided hereinencode an MMP9 therapeutic molecule and consist of the nucleic acidsequence of SEQ ID NO: 33.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule, wherein the therapeutic molecule comprises ananti-PDL1 scFv. In some embodiments, the nucleic acid sequences providedherein encode a therapeutic molecule comprising an anti-PDL1 scFv,wherein the anti-PDL1 scFv comprises a light chain variable fragmentcomprising an amino acid sequence that is at least 80%, at least, 85%,at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, orat least 99% identical to the amino acid sequence of SEQ ID NO: 36 and aheavy chain variable fragment comprising an amino acid sequence that isat least 80%, at least, 85%, at least 90%, at least 95%, at least 96%,at least 97%, at least 98%, or at least 99% identical to the amino acidsequence of SEQ ID NO: 38. In some embodiments, the nucleic acidsequences provided herein encode a therapeutic molecule comprising ananti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chainvariable fragment comprising an amino acid sequence that is 100%identical to the amino acid sequence of SEQ ID NO: 36 and a heavy chainvariable fragment that is 100% identical to the amino acid sequence ofSEQ ID NO: 38. In some embodiments, the nucleic acid sequences providedherein encode a therapeutic molecule comprising an anti-PDL1 scFv,wherein the anti-PDL1 scFv comprises a light chain variable fragmentcomprising the amino acid sequence of SEQ ID NO: 36 and a heavy chainvariable fragment comprising the amino acid sequence of of SEQ ID NO:38. In some embodiments, the nucleic acid sequences provided hereinencode a therapeutic molecule comprising an anti-PDL1 scFv, wherein theanti-PDL1 scFv comprises a light chain variable fragment consisting ofthe amino acid sequence of SEQ ID NO: 36 and a heavy chain variablefragment consisting of the amino acid sequence of of SEQ ID NO: 38.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1scFv comprises a light chain variable fragment nucleic acid sequencethat is at least 80%, at least, 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, or at least 99% identical to thenucleic acid sequence of SEQ ID NO: 35 and a heavy chain variablefragment nucleic acid sequence that is at least 80%, at least, 85%, atleast 90%, at least 95%, at least 96%, at least 97%, at least 98%, or atleast 99% identical to the nucleic acid sequence of SEQ ID NO: 37. Insome embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1scFv comprises a light chain variable fragment nucleic acid sequencethat is 100% identical to the nucleic acid sequence of SEQ ID NO: 35 anda heavy chain variable fragment nucleic acid sequence that is 100%identical to the amino acid sequence of SEQ ID NO: 37. In someembodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv, wherein the anti-PDL1scFv comprises a light chain variable fragment nucleic acid sequencecomprising SEQ ID NO: 35 and a heavy chain variable fragment nucleicacid sequence comprising SEQ ID NO: 37. In some embodiments, the nucleicacid sequences provided herein encode a therapeutic molecule comprisingan anti-PDL1 scFv, wherein the anti-PDL1 scFv comprises a light chainvariable fragment nucleic acid sequence consisting of SEQ ID NO: 35 anda heavy chain variable fragment nucleic acid sequence consisting of SEQID NO: 37.

In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain.In some embodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain,wherein the IgG1 Fc domain comprises an amino acid sequence that is thatis at least 80%, at least, 85%, at least 90%, at least 95%, at least96%, at least 97%, at least 98%, or at least 99% identical to the aminoacid sequence of SEQ ID NO: 40. In some embodiments, the nucleic acidsequences provided herein encode a therapeutic molecule comprising ananti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain is 100%identical to the amino acid sequence of SEQ ID NO: 40. In someembodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain,wherein the IgG1 Fc domain comprises the amino acid sequence of SEQ IDNO: 40. In some embodiments, the nucleic acid sequences provided hereinencode a therapeutic molecule comprising an anti-PDL1 scFv and an IgG1Fc domain, wherein the IgG1 Fc domain consists of the amino acidsequence of SEQ ID NO: 40. In some embodiments, the nucleic acidsequences provided herein encode a therapeutic molecule comprising ananti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fc domain nucleicacid sequence is at least 80%, at least, 85%, at least 90%, at least95%, at least 96%, at least 97%, at least 98%, or at least 99% identicalto the nucleic acid sequence of SEQ ID NO: 39. In some embodiments, thenucleic acid sequences provided herein encode a therapeutic moleculecomprising an anti-PDL1 scFv and an IgG1 Fc domain, wherein the IgG1 Fcdomain nucleic acid sequence comprises SEQ ID NO: 39. In someembodiments, the nucleic acid sequences provided herein encode atherapeutic molecule comprising an anti-PDL1 scFv and an IgG1 Fc domain,wherein the IgG1 Fc domain nucleic acid sequence comprises SEQ ID NO:39.

In some embodiments, the nucleic acid sequences provided herein comprisea nucleic acid sequence selected from SEQ ID NOs: 43, 45, 47, 49, 51,67, and 69. In some embodiments, the nucleic acid sequences providedherein are at least 80%, at least, 85%, at least 90%, at least 95%, atleast 96%, at least 97%, at least 98%, or at least 99% identical to anucleic acid sequence selected from SEQ ID NOs: 43, 45, 47, 49, 51, 67,and 69. In some embodiments, the nucleic acid sequences provided hereinare 100% identical to a nucleic acid sequence selected from SEQ ID NOs:43, 45, 47, 49, 51, 67, and 69. In some embodiments, the nucleic acidsequences provided herein consist of a nucleic acid sequence selectedfrom SEQ ID NOs: 43, 45, 47, 49, 51, 67, and 69.

In some embodiments, the nucleic acid sequences provided herein encodean engager molecule and/or therapeutic molecule that is at least 80%, atleast, 85%, at least 90%, at least 95%, at least 96%, at least 97%, atleast 98%, or at least 99% identical to an amino acid sequence selectedfrom SEQ ID NOs: 44, 46, 48, 50, and 52. In some embodiments, thenucleic acid sequences provided herein encode an engager moleculeprotein that is 100% identical to an amino acid sequence selected fromSEQ ID NOs: 44, 46, 48, 50, and 52. In some embodiments, the nucleicacid sequences provided herein encode an engager molecule proteincomprising an amino acid sequence selected from SEQ ID NOs: 44, 46, 48,50, and 52. In some embodiments, the nucleic acid sequences providedherein encode an engager molecule protein consisting of an amino acidsequence selected from SEQ ID NOs: 44, 46, 48, 50, and 52.

In some embodiments, the recombinant nucleic acid sequences providedherein encode an engager molecule and a therapeutic molecule. In someembodiments, the recombinant nucleic acid sequences encode an amino acidsequence comprising an engager molecule and a therapeutic molecule,wherein the amino acid sequence is at least 80%, at least, 85%, at least90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least99% identical to an amino acid sequence selected from SEQ ID NOs: 53-66,68 and 70. In some embodiments, the nucleic acid sequences encode anamino acid sequence comprising an engager molecule and a therapeuticmolecule, wherein the amino acid sequence is 100% identical to an aminoacid sequences selected from SEQ ID NOs: 53-66, 68 and 70. In someembodiments, the nucleic acid sequences encode an amino acid sequencecomprising an engager molecule and a therapeutic molecule, wherein theamino acid sequence consists of an amino acid sequence selected from SEQID NOs: 53-66, 68 and 70.

TABLE 4 Nucleic sequences of exemplary engager molecules SEQ ID BiTENucleic Acid Sequence NO: CD19-CD3ATGGAGTTCGGCCTGAGCTGGGTGTTCCTGGTGGCCCTGTTCAGGGGCGTGCAGTGCG 43ACATCCAGCTGACCCAGAGCCCCGCCAGCCTGGCCGTGAGCCTGGGCCAGAGGGCCACCATCAGCTGCAAGGCCAGCCAGAGCGTGGACTACGACGGCGACAGCTACCTGAACTGGTACCAGCAGATCCCCGGCCAGCCCCCCAAGCTGCTGATCTACGACGCCAGCAACCTGGTGAGCGGCATCCCCCCCAGGTTCAGCGGCAGCGGCAGCGGCACCGACTTCACCCTGAACATCCACCCCGTGGAGAAGGTGGACGCCGCCACCTACCACTGCCAGCAGAGCACCGAGGACCCCTGGACCTTCGGCGGCGGCACCAAGCTGGAGATCAAGGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCGGCGGCGGCGGCAGCCAGGTGCAGCTGCAGCAGAGCGGCGCCGAGCTGGTGAGGCCCGGCAGCAGCGTGAAGATCAGCTGCAAGGCCAGCGGCTACGCCTTCAGCAGCTACTGGATGAACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCCAGATCTGGCCCGGCGACGGCGACACCAACTACAACGGCAAGTTCAAGGGCAAGGCCACCCTGACCGCCGACGAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGGCCAGCGAGGACAGCGCCGTGTACTTCTGCGCCAGGAGGGAGACCACCACCGTGGGCAGGTACTACTACGCCATGGACTACTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCGGCGGCGGCGGCAGCGACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGCACCACCACCACCAC CACTAGSIRP1α-CD3 ATGGAGACCGATACCCTGCTCTTGTGGGTTTTGCTTCTTTGGGTGCCAGGATCTACAG 45(SL) GTGATGAAGAAGAATTGCAGATCATCCAACCAGACAAATCCGTACTCGTGGCCGCAGGAGAGACCGCTACCCTCAGATGTACCATCACTTCTCTCTTCCCCGTTGGCCCCATCCAGTGGTTTCGAGGCGCAGGACCAGGACGAGTGCTTATTTACAATCAACGACAGGGCCCATTCCCAAGAGTGACAACAGTATCCGATACCACCAAGCGCAATAATATGGACTTTAGCATTAGAATCGGCAACATAACACCCGCTGACGCCGGTACATACTATTGTATTAAATTTCGAAAGGGCTCACCAGACGACGTGGAATTTAAGTCAGGGGCCGGAACCGAACTCTCAGTTAGAGCAAAACCTTCTGCTAGCGACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGCACCACCATCATCACCACTGAG SIRP1α-CD3ATGGAGACCGATACCCTGCTCTTGTGGGTTTTGCTTCTTTGGGTGCCAGGATCTACAG 47 (LL)GTGATGAAGAAGAATTGCAGATCATCCAACCAGACAAATCCGTACTCGTGGCCGCAGGAGAGACCGCTACCCTCAGATGTACCATCACTTCTCTCTTCCCCGTTGGCCCCATCCAGTGGTTTCGAGGCGCAGGACCAGGACGAGTGCTTATTTACAATCAACGACAGGGCCCATTCCCAAGAGTGACAACAGTATCCGATACCACCAAGCGCAATAATATGGACTTTAGCATTAGAATCGGCAACATAACACCCGCTGACGCCGGTACATACTATTGTATTAAATTTCGAAAGGGCTCACCAGACGACGTGGAATTTAAGTCAGGGGCCGGAACCGAACTCTCAGTTAGAGCAAAACCTTCTGCTAGCGGCGGCGGCGGCAGCGACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGCACCACCACCACCACCACTAG PDL1-CD3ATGGAGTTCGGCCTGAGCTGGGTGTTCCTGGTGGCCCTGTTCAGGGGCGTGCAGTGCG 49ACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGGCGGCGGCGGCAGCGATATCCAGATGACACAGAGCCCATCATCTCTGTCTGCAAGCGTAGGAGACCGAGTCACCATTACATGCAGAGCCTCCCAAGACGTTTCCACAGCAGTGGCCTGGTATCAGCAAAAACCTGGTAAGGCGCCCAAGCTTCTCATCTATTCAGCCAGTTTTCTGTATAGCGGCGTTCCCAGCCGATTCTCTGGCTCTGGATCCGGCACGGACTTTACTTTGACAATTTCCTCTCTTCAGCCCGAAGATTTTGCAACCTACTACTGTCAGCAATATCTCTACCATCCAGCCACATTCGGACAGGGCACCAAAGTCGAAATCAAAAGAGGCGGCGGCGGCAGTGGCGGCGGGGGTTCAGGAGGCGGGGGTTCTGAAGTGCAACTCGTTGAAAGCGGAGGAGGGCTTGTCCAACCTGGCGGGTCACTGCGGTTGAGCTGCGCCGCAAGCGGATTCACCTTCTCAGACTCTTGGATCCATTGGGTGCGCCAGGCTCCCGGAAAAGGCTTGGAATGGGTTGCTTGGATTTCACCGTATGGCGGTTCCACATACTACGCTGACAGCGTTAAGGGTCGATTCACCATCTCTGCAGATACTTCAAAAAACACAGCCTACCTTCAGATGAATAGTTTGCGCGCCGAGGACACAGCGGTTTATTATTGTGCCCGAAGACATTGGCCCGGCGGTTTCGACTACTGGGGGCAAGGTACGTTGGTGACTGTGAGCGCCCACCACCATCATCACCACTGA PDL1-CD3-ATGGAGTTCGGCCTGAGCTGGGTGTTCCTGGTGGCCCTGTTCAGGGGCGTGCAGTGCG 51 FcACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGGGCGGCGGCGGCAGCGATATCCAGATGACACAGAGCCCATCATCTCTGTCTGCAAGCGTAGGAGACCGAGTCACCATTACATGCAGAGCCTCCCAAGACGTTTCCACAGCAGTGGCCTGGTATCAGCAAAAACCTGGTAAGGCGCCCAAGCTTCTCATCTATTCAGCCAGTTTTCTGTATAGCGGCGTTCCCAGCCGATTCTCTGGCTCTGGATCCGGCACGGACTTTACTTTGACAATTTCCTCTCTTCAGCCCGAAGATTTTGCAACCTACTACTGTCAGCAATATCTCTACCATCCAGCCACATTCGGACAGGGCACCAAAGTCGAAATCAAAAGAGGCGGCGGCGGCAGTGGCGGCGGGGGTTCAGGAGGCGGGGGTTCTGAAGTGCAACTCGTTGAAAGCGGAGGAGGGCTTGTCCAACCTGGCGGGTCACTGCGGTTGAGCTGCGCCGCAAGCGGATTCACCTTCTCAGACTCTTGGATCCATTGGGTGCGCCAGGCTCCCGGAAAAGGCTTGGAATGGGTTGCTTGGATTTCACCGTATGGCGGTTCCACATACTACGCTGACAGCGTTAAGGGTCGATTCACCATCTCTGCAGATACTTCAAAAAACACAGCCTACCTTCAGATGAATAGTTTGCGCGCCGAGGACACAGCGGTTTATTATTGTGCCCGAAGACATTGGCCCGGCGGTTTCGACTACTGGGGGCAAGGTACGTTGGTGACTGTGAGCGCCGTAGATGAAGCAAAATCTTGTGACAAAACCCATACCTGCCCACCATGCCCAGCCCCAGAACTTCTTGGCGGACCCTCTGTCTTCCTTTTCCCTCCGAAGCCCAAGGATACCCTGATGATCAGCCGAACCCCGGAGGTAACATGTGTGGTGGTCGATGTTAGCCATGAGGATCCTGAAGTCAAATTTAACTGGTATGTAGACGGTGTTGAGGTGCACAACGCTAAAACTAAGCCCAGGGAGGAGCAGTACAACTCAACCTATCGCGTCGTATCTGTGCTTACCGTCCTGCATCAAGACTGGCTCAATGGTAAGGAATATAAATGTAAAGTGAGTAACAAGGCACTGCCAGCACCTATCGAAAAAACCATCTCAAAGGCGAAGGGACAGCCCAGGGAACCCCAGGTCTATACTCTGCCACCTTCTCGGGATGAATTGACCAAGAACCAAGTTAGCCTGACATGTCTGGTGAAAGGTTTCTATCCAAGCGATATAGCTGTCGAGTGGGAGTCCAATGGCCAACCTGAGAACAATTATAAGACCACCCCACCCGTTCTGGACAGCGACGGATCCTTTTTCCTGTACTCAAAACTCACTGTCGATAAATCAAGATGGCAACAAGGCAACGTTTTTAGCTGTAGCGTGATGCACGAAGCACTTCATAATCACTATACACAGAAGTCACTCTCTCTTTCTCCAGGACACCACCATCATCACCACTGA SIRP1α-ATGGAAACCGATACACTTCTGTTGTGGGTGCTGCTGCTGTGGGTCCCTGGTTCAACAG 67 CD3-PDL1-GCGATTATCCCTACGATGTGCCCGACTACGCAGGCGCTCAGCCAGCTGATGATATCCA Fc(SL)GATGACACAGAGCCCATCATCTCTGTCTGCAAGCGTAGGAGACCGAGTCACCATTACATGCAGAGCCTCCCAAGACGTTTCCACAGCAGTGGCCTGGTATCAGCAAAAACCTGGTAAGGCGCCCAAGCTTCTCATCTATTCAGCCAGTTTTCTGTATAGCGGCGTTCCCAGCCGATTCTCTGGCTCTGGATCCGGCACGGACTTTACTTTGACAATTTCCTCTCTTCAGCCCGAAGATTTTGCAACCTACTACTGTCAGCAATATCTCTACCATCCAGCCACATTCGGACAGGGCACCAAAGTCGAAATCAAAAGAGGCGGCGGCGGCAGTGGCGGCGGGGGTTCAGGAGGCGGGGGTTCTGAAGTGCAACTCGTTGAAAGCGTAGGAGGGCTTGTCCAACCTGGCGGGTCACTGCGGTTGAGCTGCGCCGCAAGCGGATTCACCTTCTCAGACTCTTGGATCCATTGGGTGCGCCAGGCTCCCGGAAAAGGCTTGGAATGGGTTGCTTGGATTTCACCGTATGGCGGTTCCACATACTACGCTGACAGCGTTAAGGGTCGATTCACCATCTCTGCAGATACTTCAAAAAACACAGCCTACCTTCAGATGAATAGTTTGCGCGCCGAGGACACAGCGGTTTATTATTGTGCCCTAAGACATTGGCCCGGCGGTTTCGACTACTGGGGGCAAGGTACGTTGGTGACTGTGAGCGCCGTAGATGAAGCAAAATCTTGTGACAAAACCCATACCTGCCCACCATGCCCAGCCCCAGAACTTCTTGGCGTACCCTCTGTCTTCCTTTTCCCTCCGAAGCCCAAGGATACCCTGATGATCAGCCGAACCCCGGAGGTAACATGTGTGGTGGTCGATGTTAGCCATGAGGATCCTGAAGTCAAATTTAACTGGTATGTAGACGGTGTTGAGGTGCACAACGCTAAAACTAAGCCCAGGGAGGAGCAGTACAACTCAACCTATCGCGTCGTATCTGTGCTTACCGTCCTGCATCAAGACTGGCTCAATGGTAAGGAATATAAATGTAAAGTGAGTAACAAGGCACTGCCAGCACCTATCGAAAAAACCATCTCAAAGGCGAAGGGACAGCCCAGGGAACCCCAGGTCTATACTCTGCAACCTTCTCGGGATGAATTGACCAAGAACCAAGTTAGCCTGACATGTCTGGTGAAAGGTTTCTATCCAAGCGATATAGCTGTCGAGTGGGAGTCCAATGGCCAACCTGAGAACAATTATAAGACCACCCCACCCGTTCTGGACAGCGACGGATCCTTTTTCCTGTACTCAAAACTCACTGTCGATAAATCAAGATGGCAACAAGGCAACGTTTTTAGCTGTAGCGTGATGCACGAAGCACTTCATAATCACTATACACAGAAGTCACTCTCTCTTTCTCCAGGAAAGGTTGACGAACAGAAATTGATATCCGAGGAAGATCTCAATAGGAGGAAGAGAGAAGGCAGGGGGAGCCTTCTCACTTGCGGCGATGTCGAGGAAAATCCGGGGCCTATGGAGACCGATACCCTGCTCTTGTGGGTTTTGCTTCTTTGGGTGCCAGGATCTACAGGTGATGAAGAAGAATTGCAGATCATCCAACCAGACAAATCCGTACTCGTGGCCGCAGGAGAGACCGCTACCCTCAGATGTACCATCACTTCTCTCTTCCCCGTTGGCCCCATCCAGTGGTTTCGAGGCGCAGGACCAGGACGAGTGCTTATTTACAATCAACGACAGGGCCCATTCCCAAGAGTGACAACAGTATCCGATACCACCAAGCGCAATAATATGGACTTTAGCATTAGAATCGGCAACATAACACCCGCTGACGCCGGTACATACTATTGTATTAAATTTCGAAAGGGCTCACCAGACGACGTGGAATTTAAGTCAGGGGCCGGAACCGAACTCTCAGTTAGAGCAAAACCTTCTGCTAGCGACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTCCGGCGCCGGCACCAAGCTGGAGCTGAAGCACCACCATCATCACCACTGA SIRP1α-ATGGAAACCGATACACTTCTGTTGTGGGTGCTGCTGCTGTGGGTCCCTGGTTCAACAG 69 CD3-PDL1-GCGATTATCCCTACGATGTGCCCGACTACGCAGGCGCTCAGCCAGCTGATGATATCCA Fc(LL)GATGACACAGAGCCCATCATCTCTGTCTGCAAGCGTAGGAGACCGAGTCACCATTACATGCAGAGCCTCCCAAGACGTTTCCACAGCAGTGGCCTGGTATCAGCAAAAACCTGGTAAGGCGCCCAAGCTTCTCATCTATTCAGCCAGTTTTCTGTATAGCGGCGTTCCCAGCCGATTCTCTGGCTCTGGATCCGGCACGGACTTTACTTTGACAATTTCCTCTCTTCAGCCCGAAGATTTTGCAACCTACTACTGTCAGCAATATCTCTACCATCCAGCCACATTCGGACAGGGCACCAAAGTCGAAATCAAAAGAGGCGGCGGCGGCAGTGGCGGCGGGGGTTCAGGAGGCGGGGGTTCTGAAGTGCAACTCGTTGAAAGCGTAGGAGGGCTTGTCCAACCTGGCGGGTCACTGCGGTTGAGCTGCGCCGCAAGCGGATTCACCTTCTCAGACTCTTGGATCCATTGGGTGCGCCAGGCTCCCGGAAAAGGCTTGGAATGGGTTGCTTGGATTTCACCGTATGGCGGTTCCACATACTACGCTGACAGCGTTAAGGGTCGATTCACCATCTCTGCAGATACTTCAAAAAACACAGCCTACCTTCAGATGAATAGTTTGCGCGCCGAGGACACAGCGGTTTATTATTGTGCCCTAAGACATTGGCCCGGCGGTTTCGACTACTGGGGGCAAGGTACGTTGGTGACTGTGAGCGCCGTAGATGAAGCAAAATCTTGTGACAAAACCCATACCTGCCCACCATGCCCAGCCCCAGAACTTCTTGGCGTACCCTCTGTCTTCCTTTTCCCTCCGAAGCCCAAGGATACCCTGATGATCAGCCGAACCCCGGAGGTAACATGTGTGGTGGTCGATGTTAGCCATGAGGATCCTGAAGTCAAATTTAACTGGTATGTAGACGGTGTTGAGGTGCACAACGCTAAAACTAAGCCCAGGGAGGAGCAGTACAACTCAACCTATCGCGTCGTATCTGTGCTTACCGTCCTGCATCAAGACTGGCTCAATGGTAAGGAATATAAATGTAAAGTGAGTAACAAGGCACTGCCAGCACCTATCGAAAAAACCATCTCAAAGGCGAAGGGACAGCCCAGGGAACCCCAGGTCTATACTCTGCAACCTTCTCGGGATGAATTGACCAAGAACCAAGTTAGCCTGACATGTCTGGTGAAAGGTTTCTATCCAAGCGATATAGCTGTCGAGTGGGAGTCCAATGGCCAACCTGAGAACAATTATAAGACCACCCCACCCGTTCTGGACAGCGACGGATCCTTTTTCCTGTACTCAAAACTCACTGTCGATAAATCAAGATGGCAACAAGGCAACGTTTTTAGCTGTAGCGTGATGCACGAAGCACTTCATAATCACTATACACAGAAGTCACTCTCTCTTTCTCCAGGAAAGGTTGACGAACAGAAATTGATATCCGAGGAAGATCTCAATAGGAGGAAGAGAGAAGGCAGGGGGAGCCTTCTCACTTGCGGCGATGTCGAGGAAAATCCGGGGCCTATGGAGACCGATACCCTGCTCTTGTGGGTTTTGCTTCTTTGGGTGCCAGGATCTACAGGTGATGAAGAAGAATTGCAGATCATCCAACCAGACAAATCCGTACTCGTGGCCGCAGGAGAGACCGCTACCCTCAGATGTACCATCACTTCTCTCTTCCCCGTTGGCCCCATCCAGTGGTTTCGAGGCGCAGGACCAGGACGAGTGCTTATTTACAATCAACGACAGGGCCCATTCCCAAGAGTGACAACAGTATCCGATACCACCAAGCGCAATAATATGGACTTTAGCATTAGAATCGGCAACATAACACCCGCTGACGCCGGTACATACTATTGTATTAAATTTCGAAAGGGCTCACCAGACGACGTGGAATTTAAGTCAGGGGCCGGAACCGAACTCTCAGTTAGAGCAAAACCTTCTGCTAGCGGCGGCGGCGGCAGCGACATCAAGCTGCAGCAGAGCGGCGCCGAGCTGGCCAGGCCCGGCGCCAGCGTGAAGATGAGCTGCAAGACCAGCGGCTACACCTTCACCAGGTACACCATGCACTGGGTGAAGCAGAGGCCCGGCCAGGGCCTGGAGTGGATCGGCTACATCAACCCCAGCAGGGGCTACACCAACTACAACCAGAAGTTCAAGGACAAGGCCACCCTGACCACCGACAAGAGCAGCAGCACCGCCTACATGCAGCTGAGCAGCCTGACCAGCGAGGACAGCGCCGTGTACTACTGCGCCAGGTACTACGACGACCACTACTGCCTGGACTACTGGGGCCAGGGCACCACCCTGACCGTGAGCAGCGTGGAGGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCAGCGGCGGCGTGGACGACATCCAGCTGACCCAGAGCCCCGCCATCATGAGCGCCAGCCCCGGCGAGAAGGTGACCATGACCTGCAGGGCCAGCAGCAGCGTGAGCTACATGAACTGGTACCAGCAGAAGAGCGGCACCAGCCCCAAGAGGTGGATCTACGACACCAGCAAGGTGGCCAGCGGCGTGCCCTACAGGTTCAGCGGCAGCGGCAGCGGCACCAGCTACAGCCTGACCATCAGCAGCATGGAGGCCGAGGACGCCGCCACCTACTACTGCCAGCAGTGGAGCAGCAACCCCCTGACCTTCGGCGCCGGCACCAAGCTGGAGCTGAAGCACCACCACCACCACCACTAG

Additional exemplary embodiments of engager molecules include engagermolecules comprising an activation domain comprising an anti-CD3 scFv(e.g., comprised of SEQ ID NOs: 20 and 22) and a therapeutic domaincomprising an scFv that binds to a cell surface protein such as CTLA4,TIM3, LAG3, BTLA, KIR, TIGIT, OX40, or GITR. In some embodiments, theoncolytic viruses described herein comprise a bicistronic ormulticistronic nucleic acid sequence, wherein a first nucleic acidsequence encodes an engager molecules comprising an activation domaincomprising an anti-CD3 scFv (e.g., comprised of SEQ ID NOs: 20 and 22)and a therapeutic domain comprising an scFv that binds to a cell surfaceprotein such as CTLA4, TIM3, LAG3, BTLA, KIR, TIGIT, OX40, CD47, orGITR, and a second nucleic acid sequence encoding a therapeutic moleculesuch as IL-15 (SEQ ID NO: 24), IL-12 (SEQ ID NOs: 26 and 28), CXCL10(SEQ ID NO: 30), or MMP9 (SEQ ID NO: 34). In such embodiments, theengager molecule is linked to the therapeutic molecule polypeptide by aT2A self-cleaving peptide linker (SEQ ID NO: 14).

Additional exemplary embodiments of engager molecules include engagermolecules comprising an activation domain comprising an anti-CD3 scFv(e.g., comprised of SEQ ID NOs: 20 and 22) and an antigen recognitiondomain comprising an scFv that binds to SLAMF7 (also known as CD319) orCD27 (either the membrane bound form of CD27 or the soluble form ofCD27). In some embodiments, the oncolytic viruses described hereincomprise a bicistronic or multicistronic nucleic acid sequence, whereina first nucleic acid sequence encodes an engager molecules comprising anactivation domain comprising an anti-CD3 scFv (e.g., comprised of SEQ IDNOs: 20 and 22) and an antigen-recognition domain comprising an scFvthat binds to a target cell antigen such as SLAMF7 or CD27, and a secondnucleic acid sequence encoding a therapeutic molecule such as IL-15 (SEQID NO: 24), IL-12 (SEQ ID NOs: 26 and 28), CXCL10 (SEQ ID NO: 30), orMMP9 (SEQ ID NO: 34). In such embodiments, the engager molecule islinked to the therapeutic molecule polypeptide by a T2A self-cleavingpeptide linker (SEQ ID NO: 14).

Additional cell surface proteins that are suitable for target by theengager molecules described herein are shown below in Table 5.Additional proteins that are suitable for use as therapeutic moleculesare show below in Table 6.

TABLE 5 Cell-surface proteins suitable for targeting by engagermolecules NCBI Reference Sequence Cell-surface protein (RefSeq)Identifier human SLAMF7 NP_067004.3 human NKGD2L NP_079494.1 human CTLA4NP_005205.2 human TIM3 NP_116171.3 human LAG3 NP_002277.4 human BTLA(isoform NP_001078826.1; 1 and 2, respectively) NP_861445.3 human KIRhuman TIGIT NP_776160.2 human OX40 NP_003318.1 human GITR (isoformNP_004186.1; 1, 2, 3 respectively) NP_683699.1; NP_683700.1 human CD27NP_001233.1 human CD40 (isoforms NP_001241.1; 1-5, respectively)NP_690593.1; NP_001289682.1; NP_001309350.1; NP_001309351.1 human NKGD2LNP_079494.1 human CD200 NP_005935.4

TABLE 6 Proteins suitable for use as therapeutic molecules NCBIReference Sequence Molecule (RefSeq) Identifier human TNFα NP_000585.2human CX3CL1 NP_002987.1 human CCR4 NP_005499.1 human CSF-1 NP_000748.3human TGFβ NP_000651.3 human IL-7 NP_000871.1 human GM-CSF NP_000749.2Therapeutic Uses of Oncolytic Viruses

In some embodiments, the present invention provides compositions andmethods of use for the prevention, treatment, and/or amelioration of acancerous disease. In some embodiments, the methods described hereincomprise administering an effective amount (e.g., a therapeuticallyeffective amount) of an oncolytic virus described herein to a subject inneed thereof, wherein the virus expresses an engager molecule or anengager molecule and a therapeutic molecule.

In some embodiments, compositions and methods of the present inventionare useful for all stages and types of cancer, including for minimalresidual disease, early solid tumor, advanced solid tumor and/ormetastatic solid tumor. In some embodiments, compositions and methods ofthe present invention are used to treat a variety of solid tumorsassociated with a number of different cancers. The term “solid tumors”refers to relapsed or refractory tumors as well as metastases (whereverlocated), other than metastatses observed in lymphatic cancer.

Exemplary solid tumors include, but are not limited to, brain and othercentral nervous system tumors (e.g. tumors of the meninges, brain,spinal cord, cranial nerves and other parts of central nervous system,e.g. glioblastomas or medulla blastomas); head and/or neck cancer;breast tumors; circulatory system tumors (e.g. heart, mediastinum andpleura, and other intrathoracic organs, vascular tumors andtumor-associated vascular tissue); excretory system tumors (e.g. kidney,renal pelvis, ureter, bladder, other and unspecified urinary organs);gastrointestinal tract tumors (e.g. oesophagus, stomach, smallintestine, colon, colorectal, rectosigmoid junction, rectum, anus andanal canal), tumors involving the liver and intrahepatic bile ducts,gall bladder, other and unspecified parts of biliary tract, pancreas,other and digestive organs); head and neck; oral cavity (lip, tongue,gum, floor of mouth, palate, and other parts of mouth, parotid gland,and other parts of the salivary glands, tonsil, oropharynx, nasopharynx,pyriform sinus, hypopharynx, and other sites in the lip, oral cavity andpharynx); reproductive system tumors (e.g. vulva, vagina, Cervix uteri,Corpus uteri, uterus, ovary, and other sites associated with femalegenital organs, placenta, penis, prostate, testis, and other sitesassociated with male genital organs); respiratory tract tumors (e.g.nasal cavity and middle ear, accessory sinuses, larynx, trachea,bronchus and lung, e.g. small cell lung cancer or non-small cell lungcancer); skeletal system tumors (e.g. bone and articular cartilage oflimbs, bone articular cartilage and other sites); skin tumors (e.g.malignant melanoma of the skin, non-melanoma skin cancer, basal cellcarcinoma of skin, squamous cell carcinoma of skin, mesothelioma,Kaposi's sarcoma); and tumors involving other tissues includingperipheral nerves and autonomic nervous system, connective and softtissue, retroperitoneum and peritoneum, eye and adnexa, thyroid, adrenalgland and other endocrine glands and related structures, secondary andunspecified malignant neoplasm of lymph nodes, secondary malignantneoplasm of respiratory and digestive systems and secondary malignantneoplasm of other sites, oligodendroglioma, oligoastrocytoma,astrocytoma, glioblastoma or medulloblastoma or other solid tumor.

In particular embodiments, the solid tumor is a brain tumor. In someinstances, the brain tumor includes, but is not limited to, a glioma, inparticular ependymoma, oligodendroglioma, oligoastrocytoma, astrocytoma,glioblastoma, or a medulloblastoma.

In some embodiments, compositions and methods of the present inventionare used to treat a hematologic cancer. The term “hematologic cancer”refers herein to a cancer of the blood system and includes relapsed orrefractory hematologic cancer as well as a metastasized hematologiccancer (wherever located). In some instances, the hematologic cancer isa T-cell malignancy or a B-cell malignancy. Exemplary T-cellmalignancies include, but are not limited to, peripheral T-cell lymphomanot otherwise specified (PTCL-NOS), anaplastic large cell lymphoma,angioimmunoblastic lymphoma, cutaneous T-cell lymphoma, adult T-cellleukemia/lymphoma (ATLL), blastic NK-cell lymphoma, enteropathy-typeT-cell lymphoma, hematosplenic gamma-delta T-cell lymphoma,lymphoblastic lymphoma, nasal NK/T-cell lymphomas, or treatment-relatedT-cell lymphomas.

Exemplary B-cell malignancies include, but are not limited to, chroniclymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), high riskCLL, a non-CLL/SLL lymphoma, prolymphocytic leukemia (PLL), follicularlymphoma (FL), diffuse large B-cell lymphoma (DLBCL), mantle celllymphoma (MCL), Waldenström's macroglobulinemia, multiple myeloma,extranodal marginal zone B cell lymphoma, nodal marginal zone B celllymphoma, Burkitt's lymphoma, non-Burkitt high grade B cell lymphoma,primary mediastinal B-cell lymphoma (PMBL), immunoblastic large celllymphoma, precursor B-lymphoblastic lymphoma, B cell prolymphocyticleukemia, lymphoplasmacytic lymphoma, splenic marginal zone lymphoma,plasma cell myeloma, plasmacytoma, mediastinal (thymic) large B celllymphoma, intravascular large B cell lymphoma, primary effusionlymphoma, or lymphomatoid granulomatosis. In some cases, the hematologiccancer is a relapsed or refractory hematologic cancer. In some cases,the hematologic cancer is a metastasized hematologic cancer.

In some embodiments, the oncolytic virus is engineered to produce a highlevel of expression of the engager molecule and/or the therapeuticpolypeptide prior to the death of the virally-infected cell, e.g.,within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18,19, 20, 21, 22, 23 or 24 hours of infection, or within 2, 3, 4, 5, or 6days of infection. Expression of the engager molecule and/or thetherapeutic polypeptide can be determined by methods known in the art,including Western blot, ELISA, immunoprecipitation, or electrophoresis,among others. In general, a “high level of expression” in reference to atherapeutic molecule refers to a level of expression that is greaterthan the basal level of expression of a corresponding polypeptide in acell that is not infected with the oncolytic virus.

Compositions and Routes of Administration

In some embodiments, a therapeutically effective amount of an oncolyticvirus or compositions thereof are administered to a subject. Inaccordance with this disclosure, the term “pharmaceutical composition”relates to a composition for administration to an individual.Administration of the compositions described herein can be local orsystemic and can be effected by different ways, e.g., by intravenous,subcutaneous, intraperitoneal, intramuscular, topical or intradermaladministration. In some embodiments, compositions disclosed herein areadministered by any means known in the art. For example, thecompositions described herein may be administered to a subjectintravenously, intratumorally, intradermally, intraarterially,intraperitoneally, intralesionally, intracranially, intraarticularly,intraprostaticaly, intrapleurally, intratracheally, intranasally,intravitreally, intravaginally, intrarectally, topically,intratumorally, intramuscularly, intrathecally, subcutaneously,subconjunctival, intravesicularlly, mucosally, intrapericardially,intraumbilically, intraocularly, orally, locally, by inhalation, byinjection, by infusion, by continuous infusion, by localized perfusion,via a catheter, via a lavage, in a cream, or in a lipid composition. Inparticular embodiments, the composition is administered to theindividual via infusion or injection. In some embodiments,administration is parenteral, e.g., intravenous. In some embodiments,the oncolytic virus or composition thereof is administered directly tothe target site, e.g., by biolistic delivery to an internal or externaltarget site or by catheter to a site in an artery. In particularembodiments, the compositions described herein are administeredsubcutaneously or intravenously. In some embodiments, the oncolyticviruses or compositions thereof described herein are administeredintravenously or intraarterially.

In a preferred embodiment, the compositions described herein areformulated for a particular route of administration, for parenteral,transdermal, intraluminal, intra-arterial, intrathecal, intravenousadministration, or for direct injection into a cancer. In someembodiments, the compositions further comprise a pharmaceuticallyacceptable carrier. “Pharmaceutically or pharmacologically acceptable”refer herein to molecular entities and compositions that do not producean adverse, allergic or other untoward reaction when administered to ananimal, or a human, as appropriate. In some embodiments, thepharmaceutical compositions of the present disclosure further comprise apharmaceutically acceptable carrier. A “pharmaceutically acceptablecarrier” includes any and all solvents, dispersion media, coatings,buffer, stabilizing formulation, antibacterial and antifungal agents,isotonic and absorption delaying agents and the like. Examples ofsuitable pharmaceutical carriers are well known in the art and includephosphate buffered saline solutions, water, emulsions, such as oil/wateremulsions, various types of wetting agents, sterile solutions, etc.Compositions comprising such carriers are formulated by well-knownconventional methods. In some embodiments, supplementary activeingredients are also incorporated into the compositions. For humanadministration, the compositions described herein are met withsterility, pyrogenicity, and general safety and purity standards asrequired by FDA Office of Biologics standards.

In some embodiments, the compositions described herein comprise acarrier such as a solvent or dispersion medium containing, for example,water, ethanol, polyol (for example, glycerol, propylene glycol, andliquid polyethylene glycol, and the like), suitable mixtures thereof,and vegetable oils. The proper fluidity is maintained, for example, bythe use of a coating, such as lecithin, by the maintenance of therequired particle size in the case of dispersion and by the use ofsurfactants. The prevention of the action of microorganisms is broughtabout by various antibacterial and antifungal agents known in the art.In many cases, it is preferable to include isotonic agents, for example,sugars or sodium chloride. In some embodiments, prolonged absorption ofthe injectable compositions is brought about by the use in thecompositions of agents delaying absorption, for example, aluminummonostearate and gelatin.

In some embodiments, the oncolytic viruses described herein areformulated into a composition in a neutral or salt form.Pharmaceutically acceptable salts, include the acid addition salts(formed with the free amino groups of the protein) and which are formedwith inorganic acids such as, for example, hydrochloric or phosphoricacids, or such organic acids as acetic, oxalic, tartaric, mandelic, andthe like. Salts formed with the free carboxyl groups are derived frominorganic bases such as, for example, sodium, potassium, ammonium,calcium, or ferric hydroxides, and such organic bases as isopropylamine,trimethylamine, histidine, procaine and the like.

Pharmaceutical forms suitable for injectable use include sterile aqueoussolutions or dispersions; formulations including sesame oil, peanut oilor aqueous propylene glycol; and sterile powders for the extemporaneouspreparation of sterile injectable solutions or dispersions. In somecases, the form is sterile and is fluid. In some cases, it is stableunder the conditions of manufacture and certain storage parameters (e.g.refrigeration and freezing) and is preserved against the contaminatingaction of microorganisms, such as bacteria and fungi. Aqueouscompositions of some embodiments herein include an effective amount of avirus, nucleic acid, therapeutic protein, peptide, construct,stimulator, inhibitor, and the like, dissolved or dispersed in apharmaceutically acceptable carrier or aqueous medium. Aqueouscompositions of vectors expressing any of the foregoing are alsocontemplated.

In certain embodiments, biological material is extensively dialyzed toremove undesired small molecular weight molecules and/or lyophilized formore ready formulation into a desired vehicle, where appropriate. Insome embodiments, the active compounds or constructs are formulated forparenteral administration, e.g., formulated for injection via theintravenous, intramuscular, sub-cutaneous, intralesional, intranasal orintraperitoneal routes. Any route used for vaccination or boost of asubject is used. The preparation of an aqueous composition that containsan active component or ingredient is known to those of skill in the artin light of the present disclosure. Typically, such compositions areprepared as injectables, either as liquid solutions or suspensions;solid forms suitable for use in preparing solutions or suspensions uponthe addition of a liquid prior to injection is also prepared; and thepreparations are also emulsified.

In some instances, the oncolytic virus is dispersed in apharmaceutically acceptable formulation for injection. In someembodiments, sterile injectable solutions are prepared by incorporatingthe active compounds or constructs in the required amount in theappropriate solvent with any of the other ingredients enumerated above,as required, followed by filtered sterilization.

Upon formulation, the compositions described herein are administered ina manner compatible with disease to be treated and the dosageformulation and in such amount as is therapeutically effective. Theformulations are easily administered in a variety of dosage forms, suchas the type of injectable solutions described above, but also as slowrelease capsules or microparticles and microspheres and the like.

For parenteral administration in an aqueous solution, for example, thesolution is suitably buffered if necessary and the liquid diluent firstrendered isotonic with sufficient saline or glucose. These particularaqueous solutions are especially suitable for intravenous,intratumorally, intramuscular, subcutaneous and intraperitonealadministration. In this context, sterile aqueous media that is employedis known to those of skill in the art in light of the presentdisclosure. For example, one dosage is dissolved in 1 mL of isotonicNaCl solution and either added to 1000 mL of hypodermolysis fluid orinjected at the proposed site of infusion.

In addition to the compounds formulated for parenteral administration,such as intravenous, intratumorally, intradermal or intramuscularinjection, other pharmaceutically acceptable forms include, e.g.,tablets or other solids for oral administration; liposomal formulations;time release capsules; biodegradable and any other form currently used.

In some embodiments, the viruses are encapsulated to inhibit immunerecognition and placed at the site of a tumor.

In some instances, preparations for parenteral administration includesterile aqueous or non-aqueous solutions, suspensions, and emulsions.Examples of non-aqueous solvents are propylene glycol, polyethyleneglycol, vegetable oils such as olive oil, and injectable organic esterssuch as ethyl oleate. Aqueous carriers include water, alcoholic/aqueoussolutions, emulsions or suspensions, including saline and bufferedmedia. Parenteral vehicles include sodium chloride solution, Ringer'sdextrose, dextrose and sodium chloride, lactated Ringer's, or fixedoils. Intravenous vehicles include fluid and nutrient replenishes,electrolyte replenishers (such as those based on Ringer's dextrose), andthe like. Preservatives and other additives are also present such as,for example, antimicrobials, anti-oxidants, chelating agents, and inertgases and the like. In addition, the pharmaceutical composition of thepresent disclosure might comprise proteinaceous carriers, like, e.g.,serum albumin or immunoglobulin, preferably of human origin. It isenvisaged that the pharmaceutical composition of the disclosure mightcomprise, in addition to the proteinaceous bispecific single chainantibody constructs or nucleic acid molecules or vectors encoding thesame (as described in this disclosure), further biologically activeagents, depending on the intended use of the pharmaceutical composition.

In some embodiments, tumor-infiltrating virus-producing cells whichcontinuously release vectors are formulated for direct implantation intoa tumor in order to increase the viral oncolysis and the transferefficiency of the therapeutic genes.

Intranasal formulations are known in the art and are described in, forexample, U.S. Pat. Nos. 4,476,116; 5,116,817; and 6,391,452.Formulations which are prepared according to these and other techniqueswell-known in the art are prepared as solutions in saline, employingbenzyl alcohol or other suitable preservatives, fluorocarbons, and/orother solubilizing or dispersing agents known in the art. See, forexample, Ansel, H. C. et al., Pharmaceutical Dosage Forms and DrugDelivery Systems, Sixth Ed. (1995). Preferably these compositions andformulations are prepared with suitable nontoxic pharmaceuticallyacceptable ingredients. These ingredients are known to those skilled inthe preparation of nasal dosage forms and some of these are found inRemington: The Science and Practice of Pharmacy, 21st edition, 2005, astandard reference in the field. The choice of suitable carriers ishighly dependent upon the exact nature of the nasal dosage form desired,e.g., solutions, suspensions, ointments, or gels. Nasal dosage formsgenerally contain large amounts of water in addition to the activeingredient. Minor amounts of other ingredients such as pH adjusters,emulsifiers or dispersing agents, preservatives, surfactants, gellingagents, or buffering and other stabilizing and solubilizing agents arealso present. The nasal dosage form is isotonic with nasal secretions.

For administration by inhalation described herein is in a form as anaerosol, a mist or a powder. Pharmaceutical compositions describedherein are conveniently delivered in the form of an aerosol spraypresentation from pressurized packs or a nebulizer, with the use of asuitable propellant, e.g., dichlorodifluoromethane,trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide orother suitable gas. In the case of a pressurized aerosol, the dosageunit is determined by providing a valve to deliver a metered amount.Capsules and cartridges of, such as, by way of example only, gelatin foruse in an inhaler or insufflator is formulated containing a powder mixof the compound described herein and a suitable powder base such aslactose or starch.

Therapeutically Effective Amounts and Therapeutic Regimens

In some embodiments, the oncolytic viruses and compositions thereofdescribed herein are administered to a subject at therapeuticallyeffective amount. The therapeutically effective amount will depend onthe subject to be treated, the state (e.g., general health) of thesubject, the protection desired, the disease to be treated, the route ofadministration, and/or the nature of the virus. In some embodiments, theperson responsible for administration (e.g., an attending physician)will determine the appropriate dose for an individual. As is well knownin the medical arts, dosages for any one patient depend upon manyfactors, including the patient's size, weight, body surface area, age,sex, and general health, the particular compound to be administered, theparticular disease to be treated, timing and route of administration,and other drugs being administered concurrently. Therefore, it isexpected that for each individual patient, even if the viruses that areadministered to the population at large, each patient is monitored forthe proper dosage for the individual, and such practices of monitoring apatient are routine in the art.

In some embodiments, the therapeutically effective amount of anoncolytic virus described herein is administered in a single dose. Insome embodiments of the present invention, the pseudotyped oncolyticviruses or compositions thereof are administered to a subject at a doseranging from about 1×10⁺⁵ pfu to about 1×10⁺¹⁵ pfu (plaque formingunits), about 1×10⁺⁸ pfu to about 1×10⁺¹⁵ pfu, about 1×10⁺¹⁰ pfu toabout 1×10⁺¹⁵ pfu, or about 1×10⁺⁸ pfu to about 1×10⁺¹² pfu. Forexample, in some embodiments, the pseudotyped oncolytic viruses orcompositions thereof are administered to a subject at a dose of about10⁵, 10⁶, 10⁷, 10⁸, 10⁹, 10¹⁰, 10¹¹, 10¹², 10¹³, 10¹⁴, or 10¹⁵ pfu ofvirus. In some embodiments, the dose depends, on the age of the subjectto which a composition is being administered. For example, a lower dosemay be required if the subject is juvenile, and a higher dose may berequired if the subject is an adult human subject. In certainembodiments, for example, a juvenile subject receives about 1×10⁺⁸ pfuand about 1×10⁺¹⁰ pfu, while an adult human subject receives a dosebetween about 1×10⁺¹⁰ pfu and about 1×10⁺¹² pfu. In some embodiments,the therapeutically effective amount of an oncolytic virus describedherein is administered over the course of two or more doses. In someembodiments, the two or more doses are administered simultaneously(e.g., on the same day or over a short period of time) or at appropriateintervals, for example as two, three, four or more sub-doses per day.

In some embodiments, the oncolytic viruses or compositions thereofdescribed herein are administered to a subject once. In someembodiments, the oncolytic viruses or compositions thereof describedherein are administered to a subject more than once. For example, acomposition disclosed herein may be administered multiple times,including 1, 2, 3, 4, 5, 6, or more times. In some embodiments, acomposition disclosed herein may be administered to a subject on a dailyor weekly basis for a time period or on a monthly, bi-yearly, or yearlybasis depending on need or exposure to a pathogenic organism or to acondition in the subject (e.g. cancer). In particular embodiments, theoncolytic viruses and compositions thereof are formulated in such a way,and administered in such and amount and/or frequency, that they areretained by the subject for extended periods of time.

In some embodiments, the pseudotyped oncolytic viruses or compositionsthereof are administered for therapeutic applications or is administeredas a maintenance therapy, such as for example, for a patient inremission. In some embodiments, the pseudotyped oncolytic viruses orcompositions thereof are administered once every month, once every 2months, once every 6 months, once a year, twice a year, three times ayear, once every two years, once every three years, or once every fiveyears.

In some embodiments wherein a patient's status does improve, thepseudotyped oncolytic viruses or compositions thereof may beadministered continuously upon the doctor's discretion. In someembodiments, the dose composition is temporarily reduced and/oradministration of the composition is temporarily suspended for a certainlength of time (i.e., a “drug holiday”). In some embodiments, the lengthof the drug holiday varies between 2 days and 1 year, including by wayof example only, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 10days, 12 days, 15 days, 20 days, 28 days, 35 days, 50 days, 70 days, 100days, 120 days, 150 days, 180 days, 200 days, 250 days, 280 days, 300days, 320 days, 350 days, or 365 days. The dose reduction during a drugholiday is from 10%-100%, including, by way of example only, 10%, 15%,20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%,90%, 95%, or 100%.

In some embodiments, once improvement of a patient's conditions hasoccurred, a maintenance dose may be administered if necessary. In someembodiments, the dosage and/or the frequency of administration of thecomposition is reduced, as a function of the symptoms, to a level atwhich the improved disease, disorder or condition is retained. In someembodiments, patients may require intermittent treatment on a long-termbasis upon any recurrence of symptoms.

In some embodiments, toxicity and therapeutic efficacy of suchtherapeutic regimens are determined by standard pharmaceuticalprocedures in cell cultures or experimental animals, including, but notlimited to, the determination of the LD₅₀ (the dose lethal to 50% of thepopulation) and the ED₅₀ (the dose therapeutically effective in 50% ofthe population). The dose ratio between the toxic and therapeuticeffects is the therapeutic index and it is expressed as the ratiobetween LD₅₀ and ED₅₀. Compounds exhibiting high therapeutic indices arepreferred. The data obtained from cell culture assays and animal studiesare used in formulating a range of dosage for use in human. The dosageof such compounds lies preferably within a range of circulatingconcentrations that include the ED₅₀ with minimal toxicity. The dosagevaries within this range depending upon the dosage form employed and theroute of administration utilized.

In some instances, tumor antigen expression levels are evaluated toassess the progress of treatment in a patient, to stratify a patient,and/or to modulate a therapeutic regimen. In some instances, assessmentof antigen expression levels include the use of immunohistochemistry(IHC) (including semi-quantitative or quantitative IHC) or otherantibody-based assays (Western blot, fluorescent immunoassay (FIA),fluorescence in situ hybridization (FISH), radioimmunoassay (RIA),radioimmunoprecipitation (RIP), enzyme-linked immunosorbent assay(ELISA), immunoassay, immunoradiometric assay, fluoroimmunoassay,chemiluminescent assay, bioluminescent assay, gel electrophoresis), orindirectly by quantitating the transcripts for these genes (e.g. by insitu hybridization, nuclease protection, Northern blot, polymerase chainreaction (PCR) including reverse transcriptase PCR (RT-PCR)). In someinstances, cells, for example, lymphocytes, are analyzed using FACstechnology or paraffin embedded tumor sections using antibodies.

In some instances, antibodies are used to characterize the proteincontent of target cells through techniques such as immunohistochemistry,ELISAs and Western blotting. In some cases, this provides a screen e.g.for the presence or absence of a subject likely to respond favorably tooncolytic virus therapy and/or a need for co-administering an immunestimulating agent with an oncolytic virus.

In some embodiments, immunohistochemistry is performed on a sample oftissue from a biopsy. In some cases, the sample is examined fresh orfrozen. In some instances, antibodies against antigens presented in thecell are added to the sample on a slide and the antibodies bind whereverthe antigens are present. In some embodiments, excess antibody is thenwashed away. In some cases, the antibodies that remain bound to the cellare further labeled by a secondary antibody for visualization under amicroscope.

In some embodiments, test samples are obtained from a subject such asfor example, from tissue (e.g. tumor biopsy), cerebrospinal fluid (CSF),lymph, blood, plasma, serum, peripheral blood mononuclear cells (PBMCs),lymph fluid, lymphocytes, synovial fluid and urine. In particularembodiments, the test sample is obtained from CSF or tumor tissue. Inother particular embodiments, the test sample is obtained from tumortissue and e.g. the relative number of CD4⁺ and/or CD8⁺ cells in thesample is determined and/or the level of one or more Th1 and/or Th2cytokines in the sample is measured e.g. by immunofluorescent stainingof fixed and permeabilized cells from the sample with antibodies againstthe Th1 and/or Th2 cytokines. In other particular embodiments, the testsample is obtained from blood and e.g. the level of one or more Th1and/or Th2 cytokines in the sample is measured by ELISA.

Combination Therapy

In some embodiments, the viruses, expression constructs, nucleic acidmolecules and/or vectors described herein are administered incombination with another therapeutic agent. In some embodiments, theoncolytic viruses and an additional therapeutic agent are formulated inthe same compositions. In such embodiments, the composition may furthercomprise a pharmaceutically acceptable carrier or excipient. In someembodiments, the oncolytic viruses and an additional therapeutic agentare formulated in separate compositions (e.g., two or more compositionssuitable for administration to patient or subject). The disclosurefurther encompasses co-administration protocols with other cancertherapies, e.g. bispecific antibody constructs, targeted toxins or othercompounds, including those which act via immune cells, including T-celltherapy. The clinical regimen for co-administration of the inventivecomposition(s) encompass(es) co-administration at the same time, beforeand/or after the administration of the other component. Particularcombination therapies include chemotherapy, radiation, surgery, hormonetherapy, and/or other types of immunotherapy. In some embodiments, atherapeutically effective amount of a pseudotyped oncolytic virus isadministered to a subject in need thereof in combination with anadditional therapeutic agent. In some instances, the additionaltherapeutic agent is a chemotherapeutic agent, a steroid, animmunotherapeutic agent, a targeted therapy, or a combination thereof.

In some embodiments, pharmaceutical compositions are administered inconjunction with an adjuvant therapy. For examples, activating adjuvanttreatments are administered prior to, contemporaneous with, or after oneor more administrations (e.g., intratumoral injection of the pseudotypedvirus). For example, adjuvant therapy includes modulation of Toll-likereceptor (TLR) ligands, such as TLR9 activation by DNA moleculescomprising CpG sequences, or TLR9 activation (e.g., by RNA ligands).Other adjuvant treatments include agonizing antibodies or otherpolypeptides (e.g., activation of CD40 or GITR by CD40 Ligand (CD40L) orGITR Ligand (GITRL), respectively). Further, provided are cyclicdinucleotides (e.g., c-di-GMP) that modulate STING. Another activatingadjuvant includes interleukins such as IL-33.

In some embodiments, the additional therapeutic agent comprises an agentselected from: bendamustine, bortezomib, lenalidomide, idelalisib(GS-1101), vorinostat, everolimus, panobinostat, temsirolimus,romidepsin, vorinostat, fludarabine, cyclophosphamide, mitoxantrone,pentostatine, prednisone, etopside, procarbazine, and thalidomide.

In some embodiments, the additional therapeutic agent is a multi-agenttherapeutic regimen. In some embodiments the additional therapeuticagent comprises the HyperCVAD regimen (cyclophosphamide, vincristine,doxorubicin, dexamethasone alternating with methotrexate andcytarabine). In some embodiments, the HyperCVAD regimen is administeredin combination with rituximab.

In some embodiments the additional therapeutic agent comprises theR-CHOP regiment (rituximab, cyclophosphamide, doxorubicin, vincristine,and prednisone).

In some embodiments the additional therapeutic agent comprises the FCRregimen (FCR (fludarabine, cyclophosphamide, rituximab).

In some embodiments the additional therapeutic agent comprises the FCMRregimen (fludarabine, cyclophosphamide, mitoxantrone, rituximab).

In some embodiments the additional therapeutic agent comprises the FMRregimen (fludarabine, mitoxantrone, rituximab).

In some embodiments the additional therapeutic agent comprises the PCRregimen (pentostatin, cyclophosphamide, rituximab).

In some embodiments the additional therapeutic agent comprises the PEPCregimen (prednisone, etoposide, procarbazine, cyclophosphamide).

In some embodiments the additional therapeutic agent comprisesradioimmunotherapy with ⁹⁰Y-ibritumomab tiuxetan or ¹³¹I-tositumomab.

In some embodiments, the additional therapeutic agent is an autologousstem cell transplant.

In some embodiments, the additional therapeutic agent is selected from:nitrogen mustards such as for example, bendamustine, chlorambucil,chlormethine, cyclophosphamide, ifosfamide, melphalan, prednimustine,trofosfamide; alkyl sulfonates like busulfan, mannosulfan, treosulfan;ethylene imines like carboquone, thiotepa, triaziquone; nitrosoureaslike carmustine, fotemustine, lomustine, nimustine, ranimustine,semustine, streptozocin; epoxides such as for example, etoglucid; otheralkylating agents such as for example dacarbazine, mitobronitol,pipobroman, temozolomide; folic acid analogues such as for examplemethotrexate, permetrexed, pralatrexate, raltitrexed; purine analogssuch as for example cladribine, clofarabine, fludarabine,mercaptopurine, nelarabine, tioguanine; pyrimidine analogs such as forexample azacitidine, capecitabine, carmofur, cytarabine, decitabine,fluorouracil, gemcitabine, tegafur; vinca alkaloids such as for examplevinblastine, vincristine, vindesine, vinflunine, vinorelbine;podophyllotoxin derivatives such as for example etoposide, teniposide;colchicine derivatives such as for example demecolcine; taxanes such asfor example docetaxel, paclitaxel, paclitaxel poliglumex; other plantalkaloids and natural products such as for example trabectedin;actinomycines such as for example dactinomycin; antracyclines such asfor example aclarubicin, daunorubicin, doxorubicin, epirubicin,idarubicin, mitoxantrone, pirarubicin, valrubicin, zorubincin; othercytotoxic antibiotics such as for example bleomycin, ixabepilone,mitomycin, plicamycin; platinum compounds such as for examplecarboplatin, cisplatin, oxaliplatin, satraplatin; methylhydrazines suchas for example procarbazine; sensitizers such as for exampleaminolevulinic acid, efaproxiral, methyl aminolevulinate, porfimersodium, temoporfin; protein kinase inhibitors such as for exampledasatinib, erlotinib, everolimus, gefitinib, imatinib, lapatinib,nilotinib, pazonanib, sorafenib, sunitinib, temsirolimus; otherantineoplastic agents such as for example alitretinoin, altretamine,amzacrine, anagrelide, arsenic trioxide, asparaginase, bexarotene,bortezomib, celecoxib, denileukin diftitox, estramustine,hydroxycarbamide, irinotecan, lonidamine, masoprocol, miltefosein,mitoguazone, mitotane, oblimersen, pegaspargase, pentostatin,romidepsin, sitimagene ceradenovec, tiazofurine, topotecan, tretinoin,vorinostat; estrogens such as for example diethylstilbenol,ethinylestradiol, fosfestrol, polyestradiol phosphate; progestogens suchas for example gestonorone, medroxyprogesterone, megestrol; gonadotropinreleasing hormone analogs such as for example buserelin, goserelin,leuprorelin, triptorelin; anti-estrogens such as for examplefulvestrant, tamoxifen, toremifene; anti-androgens such as for examplebicalutamide, flutamide, nilutamide, enzyme inhibitors,aminoglutethimide, anastrozole, exemestane, formestane, letrozole,vorozole; other hormone antagonists such as for example abarelix,degarelix; Immunostimulants such as for example histaminedihydrochloride, mifamurtide, pidotimod, plerixafor, roquinimex,thymopentin; immunosuppressants such as for example everolimus,gusperimus, leflunomide, mycophenolic acid, sirolimus; calcineurininhibitors such as for example ciclosporin, tacrolimus; otherimmunosuppressants such as for example azathioprine, lenalidomide,methotrexate, thalidomide; and Radiopharmaceuticals such as for example,iobenguane.

In some embodiments, the additional therapeutic agent is selected from:interferons, interleukins, tumor necrosis factors, growth factors, orthe like.

In some embodiments, the additional therapeutic agent is selected from:ancestim, filgrastim, lenograstim, molgramostim, pegfilgrastim,sargramostim; Interferons such as for example IFNα natural, IFN α-2a,IFN α-2b, IFN alfacon-1, IFN α-n1, IFN βnatural, IFN β-1a, IFN β-1b, IFNγ, peginterferon α-2a, peginterferon α-2b; interleukins such as forexample aldesleukin, oprelvekin; other immunostimulants such as forexample BCG vaccine, glatiramer acetate, histamine dihydrochloride,immunocyanin, lentinan, melanoma vaccine, mifamurtide, pegademase,pidotimod, plerixafor, poly I:C, poly ICLC, roquinimex, tasonermin,thymopentin; Immunosuppressants such as for example abatacept, abetimus,alefacept, antilymphocyte immunoglobulin (horse), antithymocyteimmunoglobulin (rabbit), eculizumab, efalizumab, everolimus, gusperimus,leflunomide, muromab-CD3, mycophenolic acid, natalizumab, sirolimus;TNFα inhibitors such as for example adalimumab, afelimomab, certolizumabpegol, etanercept, golimumab, infliximab; Interleukin Inhibitors such asfor example anakinra, basiliximab, canakinumab, daclizumab, mepolizumab,rilonacept, tocilizumab, ustekinumab; calcineurin inhibitors such as forexample ciclosporin, tacrolimus; other immunosuppressants such as forexample azathioprine, lenalidomide, methotrexate, thalidomide.

In some embodiments, the additional therapeutic agent is selected from:Adalimumab, Alemtuzumab, Basiliximab, Bevacizumab, Cetuximab,Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Gemtuzumab,Ibritumomab tiuxetan, Infliximab, Muromonab-CD3, Natalizumab,Panitumumab, Ranibizumab, Rituximab, Tositumomab, Trastuzumab, or thelike, or a combination thereof.

In some embodiments, the additional therapeutic agent is selected from:monoclonal antibodies such as for example alemtuzumab, bevacizumab,catumaxomab, cetuximab, edrecolomab, gemtuzumab, panitumumab, rituximab,trastuzumab; Immunosuppressants, eculizumab, efalizumab, muromab-CD3,natalizumab; TNF alpha Inhibitors such as for example adalimumab,afelimomab, certolizumab pegol, golimumab, infliximab; InterleukinInhibitors, basiliximab, canakinumab, daclizumab, mepolizumab,tocilizumab, ustekinumab; Radiopharmaceuticals, ibritumomab tiuxetan,tositumomab; additional monoclonal antibodies such as for exampleabagovomab, adecatumumab, alemtuzumab, anti-CD30 monoclonal antibodyXmab2513, anti-MET monoclonal antibody MetMab, apolizumab, apomab,arcitumomab, basiliximab, bispecific antibody 2B1, blinatumomab,brentuximab vedotin, capromab pendetide, cixutumumab, claudiximab,conatumumab, dacetuzumab, denosumab, eculizumab, epratuzumab,epratuzumab, ertumaxomab, etaracizumab, figitumumab, fresolimumab,galiximab, ganitumab, gemtuzumab ozogamicin, glembatumumab, ibritumomab,inotuzumab ozogamicin, ipilimumab, lexatumumab, lintuzumab, lintuzumab,lucatumumab, mapatumumab, matuzumab, milatuzumab, monoclonal antibodyCC49, necitumumab, nimotuzumab, oregovomab, pertuzumab, ramacurimab,ranibizumab, siplizumab, sonepcizumab, tanezumab, tositumomab,trastuzumab, tremelimumab, tucotuzumab celmoleukin, veltuzumab,visilizumab, volociximab, zalutumumab.

In some embodiments, the additional therapeutic agent is selected from:agents that affect the tumor micro-environment such as cellularsignaling network (e.g. phosphatidylinositol 3-kinase (PI3K) signalingpathway, signaling from the B-cell receptor and the IgE receptor). Insome embodiments, the additional therapeutic agent is a PI3K signalinginhibitor or a syc kinase inhibitor. In one embodiment, the sykinhibitor is R788. In another embodiment is a PKCγ inhibitor such as byway of example only, enzastaurin.

Examples of agents that affect the tumor micro-environment include PI3Ksignaling inhibitor, syc kinase inhibitor, protein kinase inhibitorssuch as for example dasatinib, erlotinib, everolimus, gefitinib,imatinib, lapatinib, nilotinib, pazonanib, sorafenib, sunitinib,temsirolimus; other angiogenesis inhibitors such as for example GT-111,JI-101, R1530; other kinase inhibitors such as for example AC220, AC480,ACE-041, AMG 900, AP24534, Arry-614, AT7519, AT9283, AV-951, axitinib,AZD1152, AZD7762, AZD8055, AZD8931, bafetinib, BAY 73-4506, BGJ398,BGT226, BI 811283, B16727, BIM 1120, BIBW 2992, BMS-690154, BMS-777607,BMS-863233, BSK-461364, CAL-101, CEP-11981, CYC116, DCC-2036,dinaciclib, dovitinib lactate, E7050, EMD 1214063, ENMD-2076,fostamatinib disodium, GSK2256098, GSK690693, INCB18424, INNO-406,JNJ-26483327, JX-594, KX2-391, linifanib, LY2603618, MGCD265, MK-0457,MK1496, MLN8054, MLN8237, MP470, NMS-1116354, NMS-1286937, ON 01919.Na,OSI-027, OSI-930, Btk inhibitor, PF-00562271, PF-02341066, PF-03814735,PF-04217903, PF-04554878, PF-04691502, PF-3758309, PHA-739358, PLC3397,progenipoietin, R547, R763, ramucirumab, regorafenib, R05185426,SAR103168, SCH 727965, SGI-1176, SGX523, SNS-314, TAK-593, TAK-901,TKI258, TLN-232, TTP607, XL147, XL228, XL281R05126766, XL418, XL765.

In some embodiments, the additional therapeutic agent is selected from:inhibitors of mitogen-activated protein kinase signaling, e.g., U0126,PD98059, PD184352, PD0325901, ARRY-142886, SB239063, SP600125, BAY43-9006, wortmannin, or LY294002; Syk inhibitors; mTOR inhibitors; andantibodies (e.g., rituxan).

In some embodiments, the additional therapeutic agent is selected from:20-epi-1, 25 dihydroxyvitamin D3; 5-ethynyluracil; abiraterone;aclarubicin; acylfulvene; adecypenol; adozelesin; aldesleukin; ALL-TKantagonists; altretamine; ambamustine; amidox; amifostine;aminolevulinic acid; amrubicin; amsacrine; anagrelide; anastrozole;andrographolide; angiogenesis inhibitors; antagonist D; antagonist G;antarelix; anti-dorsalizing morphogenetic protein-1; antiandrogen,prostatic carcinoma; antiestrogen; antineoplaston; antisenseoligonucleotides; aphidicolin glycinate; apoptosis gene modulators;apoptosis regulators; apurinic acid; ara-CDP-DL-PTBA; argininedeaminase; asulacrine; atamestane; atrimustine; axinastatin 1;axinastatin 2; axinastatin 3; azasetron; azatoxin; azatyrosine; baccatinIII derivatives; balanol; batimastat; BCR/ABL antagonists;benzochlorins; benzoylstaurosporine; beta lactam derivatives;beta-alethine; betaclamycin B; betulinic acid; bFGF inhibitor;bicalutamide; bisantrene; bisaziridinylspermine; bisnafide; bistrateneA; bizelesin; breflate; bropirimine; budotitane; buthionine sulfoximine;calcipotriol; calphostin C; camptothecin derivatives; canarypox IL-2;capecitabine; carboxamide-amino-triazole; carboxyamidotriazole; CaRestM3; CARN 700; cartilage derived inhibitor; carzelesin; casein kinaseinhibitors (ICOS); castanospermine; cecropin B; cetrorelix; chlorins;chloroquinoxaline sulfonamide; cicaprost; cis-porphyrin; cladribine;clomifene analogues; clotrimazole; collismycin A; collismycin B;combretastatin A4; combretastatin analogue; conagenin; crambescidin 816;crisnatol; cryptophycin 8; cryptophycin A derivatives; curacin A;cyclopentanthraquinones; cycloplatam; cypemycin; cytarabine ocfosfate;cytolytic factor; cytostatin; dacliximab; decitabine; dehydrodidemnin B;deslorelin; dexamethasone; dexifosfamide; dexrazoxane; dexverapamil;diaziquone; didemnin B; didox; diethylnorspermine;dihydro-5-azacytidine; 9-dioxamycin; diphenyl spiromustine; docosanol;dolasetron; doxifluridine; droloxifene; dronabinol; duocarmycin SA;ebselen; ecomustine; edelfosine; edrecolomab; eflornithine; elemene;emitefur; epirubicin; epristeride; estramustine analogue; estrogenagonists; estrogen antagonists; etanidazole; etoposide phosphate;exemestane; fadrozole; fazarabine; fenretinide; filgrastim; finasteride;flavopiridol; flezelastine; fluasterone; fludarabine; fluorodaunorunicinhydrochloride; forfenimex; formestane; fostriecin; fotemustine;gadolinium texaphyrin; gallium nitrate; galocitabine; ganirelix;gelatinase inhibitors; gemcitabine; glutathione inhibitors; hepsulfam;heregulin; hexamethylene bisacetamide; hypericin; ibandronic acid;idarubicin; idoxifene; idramantone; ilmofosine; ilomastat;imidazoacridones; imiquimod; immunostimulant peptides; insulin-such asfor example growth factor-1 receptor inhibitor; interferon agonists;interferons; interleukins; iobenguane; iododoxorubicin; ipomeanol, 4-;iroplact; irsogladine; isobengazole; isohomohalicondrin B; itasetron;jasplakinolide; kahalalide F; lamellarin-N triacetate; lanreotide;leinamycin; lenograstim; lentinan sulfate; leptolstatin; letrozole;leukemia inhibiting factor; leukocyte alpha interferon;leuprolide+estrogen+progesterone; leuprorelin; levamisole; liarozole;linear polyamine analogue; lipophilic disaccharide peptide; lipophilicplatinum compounds; lissoclinamide 7; lobaplatin; lombricine;lometrexol; lonidamine; losoxantrone; lovastatin; loxoribine;lurtotecan; lutetium texaphyrin; lysofylline; lytic peptides;maitansine; mannostatin A; marimastat; masoprocol; maspin; matrilysininhibitors; matrix metalloproteinase inhibitors; menogaril; merbarone;meterelin; methioninase; metoclopramide; MIF inhibitor; mifepristone;miltefosine; mirimostim; mismatched double stranded RNA; mitoguazone;mitolactol; mitomycin analogues; mitonafide; mitotoxin fibroblast growthfactor-saporin; mitoxantrone; mofarotene; molgramostim; monoclonalantibody, human chorionic gonadotrophin; monophosphoryl lipidA+myobacterium cell wall sk; mopidamol; multiple drug resistance geneinhibitor; multiple tumor suppressor 1-based therapy; mustard anticanceragent; mycaperoxide B; mycobacterial cell wall extract; myriaporone;N-acetyldinaline; N-substituted benzamides; nafarelin; nagrestip;naloxone+pentazocine; napavin; naphterpin; nartograstim; nedaplatin;nemorubicin; neridronic acid; neutral endopeptidase; nilutamide;nisamycin; nitric oxide modulators; nitroxide antioxidant; nitrullyn;O6-benzylguanine; octreotide; okicenone; oligonucleotides; onapristone;ondansetron; ondansetron; oracin; oral cytokine inducer; ormaplatin;osaterone; oxaliplatin; oxaunomycin; palauamine; palmitoylrhizoxin;pamidronic acid; panaxytriol; panomifene; parabactin; pazelliptine;pegaspargase; peldesine; pentosan polysulfate sodium; pentostatin;pentrozole; perflubron; perfosfamide; perillyl alcohol; phenazinomycin;phenylacetate; phosphatase inhibitors; picibanil; pilocarpinehydrochloride; pirarubicin; piritrexim; placetin A; placetin B;plasminogen activator inhibitor; platinum complex; platinum compounds;platinum-triamine complex; porfimer sodium; porfiromycin; prednisone;propyl bis-acridone; prostaglandin J2; proteasome inhibitors; proteinA-based immune modulator; protein kinase C inhibitor; protein kinase Cinhibitors, microalgal; protein tyrosine phosphatase inhibitors; purinenucleoside phosphorylase inhibitors; purpurins; pyrazoloacridine;pyridoxylated hemoglobin polyoxyethylene conjugate; raf antagonists;raltitrexed; ramosetron; ras farnesyl protein transferase inhibitors;ras inhibitors; ras-GAP inhibitor; retelliptine demethylated; rhenium Re186 etidronate; rhizoxin; ribozymes; RII retinamide; rogletimide;rohitukine; romurtide; roquinimex; rubiginone B1; ruboxyl; safingol;saintopin; SarCNU; sarcophytol A; sargramostim; Sdi 1 mimetics;semustine; senescence derived inhibitor 1; sense oligonucleotides;signal transduction inhibitors; signal transduction modulators; singlechain antigen-binding protein; sizofiran; sobuzoxane; sodiumborocaptate; sodium phenylacetate; solverol; somatomedin bindingprotein; sonermin; sparfosic acid; spicamycin D; spiromustine;splenopentin; spongistatin 1; squalamine; stem cell inhibitor; stem-celldivision inhibitors; stipiamide; stromelysin inhibitors; sulfinosine;superactive vasoactive intestinal peptide antagonist; suradista;suramin; swainsonine; synthetic glycosaminoglycans; tallimustine;tamoxifen methiodide; tauromustine; tazarotene; tecogalan sodium;tegafur; tellurapyrylium; telomerase inhibitors; temoporfin;temozolomide; teniposide; tetrachlorodecaoxide; tetrazomine;thaliblastine; thiocoraline; thrombopoietin; thrombopoietin mimetic;thymalfasin; thymopoietin receptor agonist; thymotrinan; thyroidstimulating hormone; tin ethyl etiopurpurin; tirapazamine; titanocenebichloride; topsentin; toremifene; totipotent stem cell factor;translation inhibitors; tretinoin; triacetyluridine; triciribine;trimetrexate; triptorelin; tropisetron; turosteride; tyrosine kinaseinhibitors; tyrphostins; UBC inhibitors; ubenimex; urogenitalsinus-derived growth inhibitory factor; urokinase receptor antagonists;vapreotide; variolin B; vector system, erythrocyte gene therapy;velaresol; veramine; verdins; verteporfin; vinorelbine; vinxaltine;vitaxin; vorozole; zanoterone; zeniplatin; zilascorb; and zinostatinstimalamer.

In some embodiments, the additional therapeutic agent is selected from:alkylating agents, antimetabolites, natural products, or hormones, e.g.,nitrogen mustards (e.g., mechloroethamine, cyclophosphamide,chlorambucil, etc.), alkyl sulfonates (e.g., busulfan), nitrosoureas(e.g., carmustine, lomusitne, ete.), or triazenes (decarbazine, etc.).Examples of antimetabolites include but are not limited to folic acidanalog (e.g., methotrexate), or pyrimidine analogs (e.g., Cytarabine),purine analogs (e.g., mercaptopurine, thioguanine, pentostatin).

In some embodiments, pharmaceutical compositions are administered inconjuction with an adjuvant therapy. For examples, activating adjuvanttreatments are administered prior to, contemporaneous with, or after oneor more administrations (e.g., intratumoral injection of the pseudotypedvirus). For example, adjuvant therapy includes modulation of Toll-likereceptor (TLR) ligands, such as TLR9 activation by DNA moleculescomprising CpG sequences, or TLR9 activation (e.g., by RNA ligands).Other adjuvant treatments include agonizing antibodies or otherpolypeptides (e.g., activation of CD40 or GITR by CD40 Ligand (CD40L) orGITR Ligand (GITRL), respectively). Further, provided are cyclicdinucleotides (e.g., c-di-GMP) that modulate STING. Another activatingadjuvant includes interleukins such as IL33. In some instances, thepharmaceutical compositions described herein are administered inconjuction with an adjuvant therapy.

Kits

In some embodiments, the present invention provides kits comprising oneor more oncolytic viruses as described herein, a nucleic acid sequenceas described herein, a vector as described herein, and/or a host cell asdescribed herein. In some embodiments, the kits comprise apharmaceutical composition as described herein above, either alone or incombination with further therapeutic agents to be administered to anindividual in need thereof.

In some embodiments, the present invention provides kits for the use ofvectors and virus-producing cells according to the invention as drugs intherapeutic methods. In particular, the vectors and virus producingcells according to some embodiments of the invention are used for thetherapy or treatment of solid tumors in a subject. In some embodiments,the therapeutic effect is caused by the oncolytic properties of therecombinant vectors and viruses as well as by the use of therapeuticgenes.

In some embodiments, the present invention provides kits for use withmethods and compositions. Some embodiments concern kits having vaccinecompositions of use to reduce onset of or treat subjects having one ormore solid tumors. Other embodiments concern kits for making and usingmolecular constructs described herein. In some instances, kits alsoinclude a suitable container, for example, vials, tubes, mini- ormicrofuge tubes, test tube, flask, bottle, syringe or other container.Where an additional component or agent is provided, the kit contains oneor more additional containers into which this agent or component isplaced. Kits herein also include a means for containing the constructs,vaccine compositions and any other reagent containers in closeconfinement for commercial sale. Such containers include injection orblow-molded plastic containers into which the desired vials areretained. Optionally, one or more additional agents such as otheranti-viral agents, anti-fungal or anti-bacterial agents are needed forcompositions described, for example, for compositions of use as avaccine.

All publications, patents, and patent applications mentioned in thisspecification are herein incorporated by reference to the same extent asif each individual publication, patent, or patent application wasspecifically and individually indicated to be incorporated by reference.

EXAMPLES

The examples below further illustrate the described embodiments withoutlimiting the scope of the invention.

Example 1: Preparation of Pseudotyped VSV-G

The following protocol was adopted to prepare an exemplary pseudotypedVSV-G, by combining VSV-Glycoprotein (VSV-GP) with HIV1-gag and revproteins.

Cell Culture and Transfection:

DNA of the following packaging plasmids was mixed and prepared fortransfection into 293T cells: pMDLg/pRRE expressing HIV-1 GAG/POL;pRSV/REV expressing HIV-1 REV; and pMD2.G 5 60 5.8 VSV glycoprotein. TheDNA mix was added to 500 μL of pre-warmed Optimem II medium. A workingstock of polyethyleneimine transfection reagent (PEI) was prepared at 1μg/μL in 1×PBS, pH 4.5, and 88 of the working stock was added to themixture, maintaining a 4:1 v/w ratio of PEI:DNA. The mixture wasvortexed briefly and left for 5-10 min at room temperature to form aPEI:DNA transfection complex. A total of 2.5×10⁶ low passage (less thanP20) 293T cells were seeded per 15 cm dish in 15 mL DMEM supplementedwith 10% serum and 1% Pen/Strep. 2 hours prior to transfection, the cellculture medium was aspirated and replaced with 15 mL of fresh pre-warmedgrowth medium (GM). The transfection complex was then added drop-wise toeach 15 cm plate, swirled briefly to mix and incubated for 8 hrs in 10%CO₂, 35° C. After 8 hours, the medium was replaced with 10 mL of freshgrowth medium containing 25 mM HEPES and 10% serum. The mixture was thenincubated for 48 hrs post-transfection.

Virus Collection:

The medium from each dish was removed, pooled, and filtered through a0.22 μm low protein binding/fast flow filter unit and stored at 4° C. A5 mL volume of fresh growth medium was added to each dish and incubatedovernight at 4° C. (60-72 hours post transfection). The second lot ofmedium from each dish was collected, as in the previous step, and pooledwith previous media harvest. The plasmid carry-over is removed bydigestion with DNASE-I (1 mg/mL stock). A 1 μg/mL solution the viralsupernatant, supplemented with 1 of 1M MgCl₂, was incubated at roomtemperature for 30 min followed by 2-4 hrs at 4° C. The filteredsupernatants can be used directly on cultured cells, or aliquoted andstored at −80° C. The pseduotyped VSV-G viral supernatant can beoptionally concentrated and purified.

Example 2: Construction of Pseudotyped VSV-G Expressing a CD28-CA125Bispecific Antibody Engager Molecule

Pseudotyped VSV-G is prepared as described in Example 1 and furtherprocessed to express a nucleic acid encoding an engager polypeptidecomprising an activation domain comprising an anti-CD28 molecule and anantigen recognition domain comprising an anti-CA125 molecule, and anucleic acid encoding an anti-PD1 immune modulatory peptide. Theresulting oncolytic virus is a pseudotyped onlcolytic VSV-G virusencoding a CD28-CA125 engager molecule and an anti-PD1 therapeuticmolecule (CD28-CA125-PD1 VSV-G).

Example 3: CD28-CA125-PD1 VSV-G Activates Human T Cells and ExhibitsAnti-Tumor Activity

Human T cells are infected with the pseudotyped CD28-CA125-PD1 VSV-Gvirus. 24 hrs to 48 hrs post viral infection, the T cell culture mediumis collected and checked for the presence of proinflammatory cytokines.These results will show that T cells are activated by CD28-CA125-PD1VSV-G, as evidenced by presence of proinflammatory cytokines such asIFN-β and IL-2 in the cell culture supernatant of CD28-CA125-PD1 VSV-Ginfected human T cells.

EphA2-overexpressing gastric cancer cells, from KATO3 cell line, areinfected with pseudotyped CD28-CA125-PD1 VSV-G or non-pseudotypedCD28-CA125-PD1 VSV virus and the cell proliferation is assessed. Theseresults will show that cell proliferation is significantly reduced incells KATO3 cells infected with pseudotyped CD28-CA125-PD1 VSV-Gcompared to KATO3 cells infected with non-pseudotyped CD28-CA125-PD1 VSVvirus.

Example 4: CD19-CD3, SIRP1α-CD3, and PDL1-CD3-Fc Engager MoleculesSpecifically Bind to T-Cells Via CD3

The binding of bipartite (CD19-CD3 and SIRP1α-CD3) and triparte(PDL1-CD3-Fc) engager molecules to T cells was assessed. Briefly, 25,000T cells were stimulated with 200 U/mL IL-2 for 12 days. After 12 days, Tcell were incubated with varying concentrations of engager molecules(500, 1000, or 2000 ng/mL for CD19-CD3 and SIRP1α-CD3; neat supernatantfor PDL1-CD3-Fc) for 20 minutes at room temperature in triplicate. Cellswere then washed twice, followed by staining with an anti-6λHis APCantibody at 500 ng/mL for an additional 20 minutes. Cells were washedagain and treated with propidium iodide (PI) to exclude dead cells fromfurther analysis. Stained cells were analyzed by flow cytometry on a BDLSR Fortesa cytometer and the percentage of the cell population positivefor staining was set at 2% of the secondary only control.

Results for CD19-CD3 (FIG. 19A), SIRP1α-CD3 (FIG. 19B), and PDL1-CD3-Fc(FIG. 19C) show that the CD3 binding moiety of each of these moleculesfunctional binds to CD3-expressing 293F T cells, as indicated by anincrease in the percentage of cells that are positive for the engagermolecules compared to the secondary antibody alone. In particular, adose dependent increase in the % positive cells is observed for CD19-CD3(FIG. 19A), while the SIRP1α-CD3 construct demonstrated maximal bindingat all concentrations. The amount of the neat PDL1-CD3-Fc supernatantused resulted in binding of the construct to the majority of T cells(FIG. 19C).

The results of this experiment are quantified in FIG. 20. In particular,all of the constructs demonstrated a significant increase in the %positive T cells compared to samples where no engager molecule wasadded.

Additional experiments demonstrated that the binding of the CD19-CD3,SIRP1α-CD3, and PDL1-CD3-Fc was mediated by interactions of the anti-CD3domain of the engager molecules with CD3 expressed by the T cells. Priorto exposure of T cells to the engager molecules, the T cells wereincubated with an anti-CD3 monoclonal antibody (OKT3). Preincubationwith the OKT3 inhibited binding of the CD19-CD3 engager, andsubstantially reduced binding of the PDL1-CD3-Fc engager. The lack ofinhibition of binding of the SIRP1α-CD3 engager by preincubation withOKT3 (FIG. 21C) is likely due to an incomplete inhibition of CD3 by OKT3in these samples.

Example 5: SIRP1α-CD3 Constructs Specifically Bind to CD47

Experiments were performed to determine the binding specificity of theSIRP1α-CD3 engager constructs. Raji cells were preincubated withSIRP1α-CD3 engagers for 20 min at RT. Cells were then washed andincubated with a fluorescently labelled anti-CD47 monoclonal antibodyfor 20 min at RT, after which cells were washed and analyzed by flowcytometry. Raji cells that were not preincubated with the SIRP1α-CD3engager showed significant binding of the anti-CD47 monoclonal antibody(FIG. 22, IgG control histogram vs. the anti-CD47 histogram).Preincubation of Raji cells with the SIRP1α-CD3 engager blocked bindingof the anti-CD47 monoclonal antibody (FIG. 22, anti-CD47 histogram vs.anti-CD47+SIRP1α-CD3 histograph).

Example 6: Binding of SIRP1α-CD3 and CD19-CD3 Engager Molecules toTarget Cells

Experiments were performed to determine the ability of SIRP1α-CD3 andCD19-CD3 BiTEs to bind to Raji (CD19⁺CD47⁺, FIG. 23), U2OS (CD19⁻CD47⁺,FIG. 24), GBM30-luc (CD19⁻CD47⁺, FIG. 25), and U251 (CD19⁻CD47⁺, FIG.26) target cell types. For each target cell type, cells were treatedwith 500 or 1000 ng/mL of either (i) His-tagged soluble SIRP1α; (ii)SIRP1α-CD3 BiTE; or (iii) or CD19-CD3 BiTE. Cells were then stained witha fluorescently labelled anti-His antibody and analyzed by flowcytometry.

The results of SIRP1α-CD3 and CD19-CD3 binding to CD19⁺CD47⁺ Raji cellsare shown in FIG. 23. Relative to the negative control Ig (2° only),soluble SIRP1α, SIRP1α-CD3 BiTE, and CD19-CD3 BiTE were able to bind toRaji cells, as indicated by a shift towards the right of the engagerhistograms compared to the IgG control histogram (FIG. 23A).Quantitation of the binding data showing percentage of BiTE positivecells is show in FIG. 23B.

The results of SIRP1α-CD3 and CD19-CD3 binding to CD19⁻CD47⁺ U2OS cellsare shown in FIG. 24. Relative to the negative control Ig (2° only),soluble SIRP1α, SIRP1α-CD3 BiTE were able to bind to U2OS cells at allconcentrations used, as indicated by a shift towards the right of theengager histograms compared to the IgG control histogram (FIG. 24A).CD19-CD3 BiTEs were unable to bind to U2OS cells, which was expectedbased on the lack of CD19 expression by U2OS cells. Quantitation ofthese binding data showing percentage of BiTE positive cells is show inFIG. 24B.

The results of SIRP1α-CD3 and CD19-CD3 binding to CD19⁻CD47⁺GBM30-luccells are shown in FIG. 25. Relative to the negative control Ig (2°only), SIRP1α-CD3 BiTE were able to bind to GBM30-luc cells at allconcentrations used, as indicated by a shift towards the right of theengager histograms compared to the IgG control histogram (FIG. 25A). Inconstant, CD19-CD3 BiTEs were unable to bind to GBM30-luc cells, whichwas expected based on the lack of CD19 expression by GBM30-luc cells.Quantitation of these binding data showing percentage of BiTE positivecells is show in FIG. 25B.

The results of SIRP1α-CD3 and CD19-CD3 binding to CD19⁻CD47⁺ U251 cellsare shown in FIG. 26. Relative to the negative control Ig (2° only),SIRP1α-CD3 BiTE were able to bind to U251 cells at all concentrationsused, as indicated by a shift towards the right of the engagerhistograms compared to the IgG control histogram (FIG. 26A). Inconstant, CD19-CD3 BiTEs were unable to bind to U251 cells, which wasexpected based on the lack of CD19 expression by U251 cells.Quantitation of these binding data showing percentage of BiTE positivecells is show in FIG. 26B.

Example 7: Binding of PDL1-CD3-Fc TiTEs to U251 Cells is Mediated byCD47, not FcγRs

As the PDL1-CD3-Fc TiTE construct comprises 2 domains that are capableof binding to target cells (the anti-PDL1 and the Fc domain) experimentswere performed to assess the binding specificity of these constructs.CD19⁻CD47⁺U251 cells were treated with 2 μg/mL of a fluorescentlylabeled anti-PDL1 antibody, an isotype control, or PDL1-CD3-Fctransfection supernant. Relative to negative control Ig, the PDL1-CD3-FcTiTE bound to U251 cells (FIG. 27B). To assess whether this observedbinding was due to interactions with CD47 or FcγRs expressed by U251cells, the FcγR expression on U251 cells was determined. Cells wereincubated with 2 μg/mL of fluorophore-conjugated anti-CD16/32(recognizing FcγRIII/FcγRII) or anti-CD64 (recognizing FcγRI) mAbs for20 min at RT. Cells were then washed and analyzed by flow cytometryusing a BD LSR Fortessa cytometer. As shown in FIG. 27C, U251 cells donot express FcγRI, FcγRII, or FcγRIII, indicating the binding of thePDL1-CD3-Fc construct was mediated by interactions with CD47 and notFcγRs.

Example 8: CD19-CD3, SIRP1α-CD3, and PDL1-CD3-Fc Constructs StimulateCD8+ T Cell-Mediated Killing of Target Cells

Experiments were performed to determine the ability of CD19-CD3,SIRP1α-CD3, and PDL1-CD3-Fc constructs to mediate killing of targetcells. Briefly, CD8⁺ T cells were stimulated for 8-12 days in thepresence of 200 U/mL IL-2 and Dynabeads. Prior to co-culture with targetcells, all Dynabeads were removed by magnet and cells were washed toremove IL-2. Raji (FIG. 28), THP1 (FIG. 29), U251 (FIG. 30), and 293F(FIG. 31) target cells were labeled with the fluorescent membrane dyePKH67 green before plating. CD8⁺ effector T cells were then co-culturedwith target cells at an effector to target ratio of 1:1 along with 1000ng/mL CD19-CD3 BiTE, SIRP1α-CD3 BiTEs, or a 1:3 dilution of PDL1-CD3-Fctransfection supernatant. Co-cultures of target and effector cells wereincubated for 18 hours, after which they were stained with 7-AAD andlive/dead analysis was performed by flow cytometry on a BD LSR Fortesacytometer.

The results of these experiments indicate that the CD19-CD3, SIRP1α-CD3and PDL1-CD3-Fc engager constructs were all capable of inducing effectorcell-mediated death of Raji target cells (FIG. 28), The EC₅₀ for each ofthe CD19-CD3, SIRP1α-CD3 and PDL1-CD3-Fc engager molecules on Raji cellsare shown below in Table 7.

TABLE 7 EC50 of engager molecules on Raji cells Engager Molecule EC₅₀(ng/mL) CD19-CD3 0.6997 SIRP1α-CD3 0.0137 PDL1-CD3-Fc 0.8907

The results of these experiments further indicate that the PDL1-CD3-Fcengager constructs, but not the CD19-CD3 constructs, were capable ofinducing effector cell-mediated death of THP1 target cells (FIG. 29).This is likely due to the lack of/relatively low expression of CD19 byTHP1 cells.

Further, the PDL1-CD3-Fc engager constructs were capable of inducingeffector cell-mediated death of U251 target cells (FIG. 30), while theCD19-CD3 constructs did not induce effector cell-mediated death of U251cells due to a lack of CD19 expression by U251 cells. The EC₅₀ for eachof the CD19-CD3 and PDL1-CD3-Fc constructs on U251 cells are shown belowin Table 8.

TABLE 8 EC50 of engager molecules on U251 cells Engager Molecule EC₅₀(ng/mL) CD19-CD3 2.247 PDL1-CD3-Fc 2.611

Further, the SIRP1α-CD3 engager constructs were capable of inducingeffector cell-mediated death of 293F target cells (FIG. 31), indicatedby the increase in cell death in SIRP1α-CD3 containing cultures comparedto a control osteopontin-fusion protein (OPN 1). The EC₅₀ for SIRP1α-CD3engager molecules on 293F cells is shown below in Table 9.

TABLE 9 EC50 of SIRP1α-CD3 on 293F cells Engager Molecule EC₅₀ (ng/mL)SIRP1α-CD3 0.0184

Example 9: PDL1-CD3-Fc BiTE Enhances Primary NK Cell Killing of U251Cells

Experiments are performed to assess the ability of PDL1-CD3-Fcconstructs to induce NK cell-mediated killing of target cells. Briefly,U251 cells are labeled with cell membrane dye PKH67 green, and thenseeded and allowed to adhere to wells over night (FIG. 32). Primary NKcells (StemCell Technologies, Inc.) are then added to each well at aneffector to target ratio of 1:1, along with varying amounts of virallyproduced PDL1-CD3-Fc protein. Effector/target cell co-culture areincubated at 37° C. for 6 hours prior to live/dead analysis by 7-AADstaining. Stained cells are analyzed by flow cytometry on a BD LSRFortesa cytometer.

These results will demonstrate that virally produced PDL1-CD3-Fccompounds are able to stimulate NK cell-mediated death of target cellssuch as U251.

Example 10: oHSV-Infected Vero Cells Express SIRP-1α-CD3 BiTEs

To demonstrate that the oncolytic viruses described here are capable orproducing the engager molecules, Vero cells were infected with oHSVexpressing SIRP1α-CD3 BiTEs (FIG. 32) with either a short linker (SL)(ONCR-085; 2A5B SIRP1α-CD3 (SL) BiTE) or long linker (LL) (ONCR-087;2A5B SIRP1α-CD3 (LL) BiTE), or with oHSV expressing PDL1-CD3-Fc TiTEs(ONCR-089, FIG. 33). Cells were infected for 3 days, after whichsupernatants from infected cells were passed through a 100K MWCOultrafiltration membrane to remove any viral particles. The flowthroughwas concentrated with a 10K MWCO ultrafiltration membrane. Concentratedviral supernatants and 100 ng, 50 ng, 25 ng, or 12.5 ng of purifiedSIRP1α-CD3 or PDL1-CD3-Fc protein were then analyzed by PAGE followed byWestern blotting with an anti-6×His detection antibody in order todetermine the amount of engager protein present in the viralsupernatants.

The results demonstrate that cells infected with either ONCR-085 orONCR-087 produced the SIRP1α-CD3 (SL) and SIRP1α-CD3 (LL) protein,respectively (FIG. 32). Further, cells infected with ONCR-089 producedthe PDL1-CD3-Fc protein (FIG. 33). The ability of the 100K and 10KAmicon filtration and concentration steps to remove remaining virus wasassessed by Western blot. The workflow for clarifying viral supernatantscomprises low-speed centrifugation of the supernatants followed byfiltration through a 0.8 μm filter membrane. Supernatant filtrates arethen passaged through an Amicon 100 kDa filter to entrain the virus,followed by passage of the filtrate through an Amicon 10 kDa filter toentrain remaining protein. Aliquots of supernatants fromvirally-infected cells were taken before and after processing with theAmicon filters and the presence of HSV was determined by blotting withan anti-HSV polyclonal antibody. These results show that theultrafiltration steps used to purify the engager constructs effectivelyremoved virus (FIG. 35). Therefore, any target cell killing observed inthe presence of these engager constructs is due to the engager constructitself, and not a result of viral infection of the target cells.

Example 11: Virally-Produced SIRP1α-CD3 and PDL1-CD3-Fc EngagerConstructs Induced Effector-Cell Mediated Killing of Target Cells

Experiments were performed to assess the ability of virally-producedengager molecules (SIRP1α-CD3 and PDL1-CD3-Fc constructs) to mediatetarget cell killing. Briefly, SIRP1α-CD3 (SL), SIRP1α-CD3 (LL) andPDL1-CD3-Fc proteins were prepared from Vero cells as described inExample 10. 50 μL of the resulting SIRP1α-CD3 (SL), SIRP1α-CD3 (LL), andPDL1-CD3-Fc engager proteins protein samples were diluted 1:1 in tissueculture media containing 20% FBS. The diluted engager proteins were thenincubated with activated CD8⁺ effector T cells co-cultured withfluorescently labelled U251 target cells at a target to effector ratioof 1:1 for 18 hours. Cell death of U251 cells was assessed by flowcytometry on a BD LSR Fortesa cytometer.

The results of this experiment demonstrate that virally-produced engagerconstructs direct T-cell mediated killing of U251 target cells (FIG.34A). These results are quantified in FIG. 34B.

Example 12: Expression of SIRP1α-CD3/PDL1-Fc Compounds from 293 T Cells

Two expression plasmids encoding a SIRP1α-CD3 engager molecule and aPDL1-Fc therapeutic molecule were generated. One construct comprised afirst gene encoding an HA-tagged PDL1-Fc linked to a second geneencoding a His-tagged SIRP1α-CD3 BiTE. The SIRP1α amino acid sequencewas linked to the anti-CD3 scFv by a single amino acid linker (i.e., ashort linker) (SIRP1α-CD3/PDL1-Fc (SL), FIG. 37). The other constructcomprised a first gene encoding a PDL1-Fc linked to a second geneencoding a SIRP1α-CD3 BiTE. The SIRP1α amino acid sequence was linked tothe anti-CD3 scFv by a G4S linker (i.e., a long linker)(SIRP1α-CD3/PDL1-Fc (LL), FIG. 38). The constructs were inserted into aplasmid (FIG. 39) and the resultant SIRP1α-CD3/PDL1-Fc expressionplasmids were transfected into 293 Free Style T cells. Four days afterplasmid transfection, culture supernatants were collected.

Anti-PDL1-Fc compounds were purified from the culture supernatants usinga HiTrap MabSelect SuRe Protein A column HiTrap column (GE Healthcare).Briefly, supernatants from 293 T cells transfected with either theSIRP1α-CD3/PDL1-Fc (LL) or the SIRP1α-CD3/PDL1-Fc (LL) expressionplasmids were loaded onto the column to purify the anti-PDL1-Fccompounds by binding of the HA-tag to the column. Flow through wascollected for SIRP1α-CD3 BiTE detection by Western Blot using ananti-His antibody (FIG. 40B). Columns were washed with wash buffer (20mM sodium phosphate, 150 mM NaCl, pH 7.4). Bound anti-PDL1-Fc proteinwas eluted with IgG elution buffer (pH 2.8, Pierce) and was immediatelyneutralized with a 1 M Tris-HCl buffer, pH 8.

The anti-PDL1-Fc protein content of different elution fractions thenwere visualized by Coomassie staining. Briefly, elution fractions wererun on a 4%-12% Bis-Tris NuPAGE gel in MOPS buffer at 180 volts for 1hour. Gels were stained for 1 hour in Simply Blue SafeStain followed bydestaining with water. Anti-PDL1-Fc protein content for each elutionfraction is show in FIG. 40A. After Coomassie analysis, elutionfractions were combined and dialyzed against PBS at 4° C. Totalanti-PDL1-Fc protein concentration was then determined by a BCA assay.

Example 13: Isolated PDL1-Fc Proteins Stimulate T Cell-Mediated Death ofTarget Cells

The ability of the anti-PDL1-Fc proteins to induce effectorcell-mediated death of target cells was assessed by a PD1/PDL1 blockadeassay. A general schematic of the assay is show in FIG. 41A-41B.Briefly, CD8⁺ T cells were co-cultured with PDL1-expressing target cells(CHO-K1 cells). Varying concentrations of the anti-PDL1-Fc proteinisolated as described in Example 12 were then added to the culture. Thehighest concentration of anti-PDL1-Fc used was 50 μg/mL. 8, 2.5 foldserial dilutions were then performed to generate the remainder of theanti-PDL1-Fc concentrations. Cell death was analyzed by a CytoTox-Glo™cytotoxicity assay in the presence (FIG. 41B) and absence (FIG. 41A) ofthe anti-PDL1-Fc. Results are quantified in FIG. 41C. The EC₅₀ of theanti-PDL1-Fc is shown in Table 10. These results demonstrate that theanti-PDL1-Fc therapeutic molecules produced from the expressionconstructs described herein are capable of mediating effectorcell-mediated death of target cells.

TABLE 10 EC50 of anti-PDL1-Fc compounds Compound EC₅₀ anti-PDL1-Fc 0.45μg/mL

Example 13: oHSV-Infected Vero Cells Express MMP9 and Anti-PDL1-FcTherapeutic Molecules

In addition to producing the engager molecules as described in Example10, experiments are performed to demonstrate that the oncolytic virusesdescribed here are capable or producing the MMP9 and anti-PDL1-Fctherapeutic molecules. Vero cells are infected with oHSV expressingSIRP1α-CD3/PDL1-Fc constructs BiTEs (FIG. 37 and FIG. 38) or with oHSVexpressing SIRP1α-CD3/MMP9 constructs (FIG. 18A and FIG. 18B). Cells areinfected for 3 days, after which supernatants from infected cells arepassed through a 100K MWCO ultrafiltration membrane to remove any viralparticles. The flowthrough is concentrated with a 10K MWCOultrafiltration membrane. MMP9 and anti-PDL1-Fc are purified fromfiltered, concentrated supernatants according to the protocol outlinedin Example 11. Protein A-isolated MMP9 and anti-PDL1 fractions areanalyzed by PAGE followed by Coomassie staining. SIRP1α-CD3 BiTEspresent in the Protein A flowthrough are analyzed by Western blottingwith an anti-6× His detection antibody.

The results will demonstrate that cells infected with oHSV vectorsencoding either SIRP1α-CD3/PDL1-Fc constructs or SIRP1α-CD3/MMP9constructs produce the SIRP1α-CD3 (SL) and SIRP1α-CD3 (LL) BiTE protein,MMP9, and anti-PDL1-Fc.

Example 14: Virally-Produced SIRP1α-CD3/MMP9 and SIRP1α-CD3/PDL1-FcEngager Constructs Induce Effector-Cell Mediated Killing of Target Cells

Experiments are performed to assess the ability of virally-producedengager molecules (SIRP1α-CD3) and therapeutic molecules (MMP9 andanti-PDL1-Fc) to mediate target cell killing. Briefly, SIRP1α-CD3 (SL),SIRP1α-CD3 (LL), MMP9, and anti-PDL1-Fc proteins are prepared from Verocells as described in Example 13. 50 μL of the resulting protein samplesare diluted in tissue culture media containing 20% FBS. The dilutedproteins are then incubated with activated CD8⁺ effector T cells or NKeffector cells and are co-cultured with fluorescently labelled targetcells at a target to effector ratio of 1:1 for 18 hours. Cell death oftarget cells is assessed by flow cytometry on a BD LSR Fortesacytometer.

The results of this experiment will demonstrate that virally-producedSIRP1α-CD3 engager constructs and therapeutic molecules MMP9 andanti-PDL1-Fc are able to direct T-cell and/or NK cell mediated killingof target cells.

While preferred embodiments of the present invention have been shown anddescribed herein, it will be obvious to those skilled in the art thatsuch embodiments are provided by way of example only. Numerousvariations, changes, and substitutions will now occur to those skilledin the art without departing from the invention. It should be understoodthat various alternatives to the embodiments of the invention describedherein may be employed in practicing the invention. It is intended thatthe following claims define the scope of the invention and that methodsand structures within the scope of these claims and their equivalents becovered thereby.

The invention claimed is:
 1. An oncolytic herpes simplex virus (HSV)comprising a recombinant nucleic acid comprising: i) a first nucleicacid sequence encoding a polypeptide comprising a first domain specificfor an antigen expressed on an effector cell and a second domain thathinds to an antigen expressed on a target cell, wherein the antigenexpressed on the target cell is FAP, PDL1 or CD47, and wherein theantigen expressed on the effector cell is CD3, CD16 or NKp46, and ii) asecond nucleic acid sequence encoding an immune modulator polypeptideselected from the group consisting of a cytokine, a costimulatorymolecule, an immune checkpoint polypeptide, an anti-angiogenesis factor,and a matrix metalloprotease (MMP).
 2. The oncolytic HSV of claim 1,wherein the antigen expressed on the target cell is FAP.
 3. Theoncolytic HSV of claim 1, wherein the antigen expressed on the targetcell is PDL1.
 4. The oncolytic HSV of claim 1, wherein the antigenexpressed on the target cell is CD47.
 5. The oncolytic HSV of claim 1,wherein the antigen expressed on the effector cell is CD3.
 6. Theoncolytic HSV of claim 1, wherein the first and second nucleic acidsequences are expressed from a single promoter sequence present in therecombinant nucleic acid.
 7. The oncolytic HSV of claim 1, wherein thefirst and second nucleic acids have a size of 7.2-38 kb.
 8. Theoncolytic HSV of claim 1, wherein the HSV is HSV-1.
 9. The oncolytic HSVof claim 1, wherein the immune modulator polypeptide is a cytokineselected from IL-15, IL-12, and CXCL10.
 10. The oncolytic HSV of claim1, wherein one or more HSV glycoproteins are modified to alter thetropism of the oncolytic HSV.
 11. The oncolytic HSV of claim 1, whereinthe immune modulator polypeptide comprises (i) an inhibitor of any oneof PD-1, CTLA-4, LAG3, TIM 3, neuropilin, or CCR4; (ii) an agonist ofany one of GITR, OX-40, or CD28; or (iii) a combination of (i) and (ii).12. A pharmaceutical composition comprising the oncolytic HSV ofclaim
 1. 13. The pharmaceutical composition of claim 12, furthercomprising a pharmaceutically acceptable carrier.